白血病临床试验导航 | 海外癌症临床试验导航

正在招募 Phase 3

NCI NCT03959085 / NCI-2019-02845

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients with High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

AI 简述这是一项III期试验，研究奥加伊妥珠单抗联合化疗用于高危B细胞急性淋巴细胞白血病等，在美国、加拿大、澳大利亚、新西兰开展。

?

适用疾病: Central Nervous System Leukemia；Mixed Phenotype Acute Leukemia；B Acute Lymphoblastic Leukemia
干预: 未列出
地点: United States，Canada，Australia，New Zealand
申办方: Children's Oncology Group

正在招募 Phase 3

NCI NCT04293562 / NCI-2020-00546

A Study to Compare Standard Chemotherapy to Therapy with CPX-351 and/or Gilteritinib for Patients with Newly Diagnosed AML with or without FLT3 Mutations

AI 简述这是一项III期试验，比较标准化疗与CPX-351或吉瑞替尼用于新诊断AML。在美国、加拿大、澳大利亚等地开展。

?

适用疾病: Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States，Canada，Australia
申办方: Children's Oncology Group

正在招募 Phase 3

NCI NCT04269902 / NCI-2020-00752

Testing Early Treatment for Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

AI 简述这是一项III期试验，研究高危慢性淋巴细胞白血病或小淋巴细胞淋巴瘤的早期治疗。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States，Canada
申办方: SWOG

正在招募 Phase 3

NCI NCT06580314 / NCI-2024-04335

Testing Olaparib for One or Two Years, with or without Bevacizumab, to Treat Ovarian Cancer

AI 简述这是一项III期试验，比较奥拉帕利联合或不联合贝伐珠单抗用于卵巢癌。

?

适用疾病: High Grade Ovarian Serous Adenocarcinoma；Primary Peritoneal High Grade Serous Adenocarcinoma；High Grade Fallopian Tube Serous Adenocarcinoma
干预: 未列出
地点: United States，Japan
申办方: NRG Oncology

正在招募 Phase 3

NCI NCT06615050 / NCI-2025-01040

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

AI 简述这是一项III期试验，比较他克莫司/甲氨蝶呤/芦可替尼与环磷酰胺/他克莫司/霉酚酸酯用于异基因造血干细胞移植后的移植物抗宿主病预防。

?

适用疾病: Chronic Myelogenous Leukemia (CML)；Chronic Myelomonocytic Leukemia (CMML)；Follicular Lymphoma
干预: 未列出
地点: United States
申办方: Incyte Corporation

正在招募 Phase 3

NCI NCT07220187 / NCI-2025-06717

Adding Pirtobrutinib to the Usual Treatment for People with Newly Diagnosed Richter Transformation, The PIRAMID Trial

AI 简述这是一项III期试验，在里氏转化患者中加用Pirtobrutinib至常规治疗。

?

适用疾病: Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma；Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma；Richter Syndrome
干预: 未列出
地点: United States
申办方: SWOG

正在招募 Phase 3

NCI NCT07321652 / NCI-2025-08923

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

AI 简述这是一项III期试验，研究Sonrotoclax联合Zanubrutinib用于未经治疗的CLL/SLL。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: Alliance for Clinical Trials in Oncology

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT02416388

Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

AI 简述这是一项II/III期试验，比较柔红霉素与高剂量去甲氧柔红霉素诱导方案，在法国用于18-60岁急性髓系白血病患者。

?

适用疾病: Acute Myeloid Leukemia (AML)
干预: Idarubicin，Daunorubicin，HD Cytarabine，Cyclosporine
地点: France
申办方: University Hospital, Angers

正在招募 Phase 3 生物制剂药物其他

ClinicalTrials.gov / NCI NCT03150693 / NCI-2016-01981

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

AI 简述这是一项III期试验，研究Inotuzumab Ozogamicin联合前线化疗用于新诊断的B急性淋巴细胞白血病年轻患者，在美国和加拿大开展。

?

适用疾病: B Acute Lymphoblastic Leukemia
干预: Allopurinol，Cytarabine，Daunorubicin Hydrochloride，Vincristine Sulfate
地点: United States，Canada
申办方: Alliance for Clinical Trials in Oncology

正在招募 Phase 3 药物

ClinicalTrials.gov NCT03643276

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

AI 简述这是一项III期试验，研究多种药物用于儿童急性淋巴细胞白血病，在澳大利亚、奥地利、捷克、德国等地开展。

?

适用疾病: Acute Lymphoblastic Leukemia, Pediatric
干预: Blinatumomab，Bortezomib，Cyclophosphamide，Cytarabine
地点: Australia，Austria，Czechia，Germany 等 4 个
申办方: Martin Schrappe

正在招募 Phase 3 生物制剂

ClinicalTrials.gov NCT04094311

Study of Out of Specification for Tisagenlecleucel

AI 简述这是一项III期试验，研究CTL019用于B细胞急性淋巴细胞白血病和弥漫大B细胞淋巴瘤。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia；Diffuse Large B-cell Lymphoma
干预: CTL019
地点: Canada，Japan
申办方: Novartis Pharmaceuticals

正在招募 Phase 3 药物

ClinicalTrials.gov NCT04168502

Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

AI 简述这是一项III期试验，在意大利研究Gemtuzumab Ozogamicin化疗用于初治中危急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia
干预: Gemtuzumab Ozogamicin
地点: Italy
申办方: Gruppo Italiano Malattie EMatologiche dell'Adulto

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov / NCI NCT04256317 / NCI-2020-03248

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

AI 简述这是一项II/III期试验，研究ASTX030（cedazuridine+阿扎胞苷）联合维奈托克用于髓系肿瘤。

?

适用疾病: Myelodysplastic Syndromes；Acute Myeloid Leukemia；Myelodysplastic Syndrome/Neoplasm
干预: Azacitidine，ASTX030 (cedazuridine + azacitidine)，Cedazuridine，Venetoclax
地点: United States，Canada，Czechia，France 等 6 个
申办方: Taiho Oncology, Inc.

正在招募 Phase 3 药物

ClinicalTrials.gov NCT04307576

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

AI 简述这是一项III期试验，针对0-45岁急性淋巴细胞白血病患者，研究多种治疗调整方案。

?

适用疾病: Leukemia, Acute Lymphoblastic
干预: Omitted Doxorubicin，Omitted Vincristine+Dexamethasone pulses，Inotuzumab Ozogamicin+Standard Maintenance Therapy，Imatinib
地点: Belgium，Denmark，Estonia，Finland 等 11 个
申办方: Mats Heyman

正在招募 Phase 3 联合产品药物其他

ClinicalTrials.gov NCT04628026

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

AI 简述这是一项III期试验，研究Venetoclax联合标准化疗诱导和巩固治疗用于新诊断急性髓系白血病，在多个欧洲国家开展。

?

适用疾病: Acute Myeloid Leukemia
干预: Venetoclax，Placebo，Standard chemotherapy，Allogeneic stem cell transplantation
地点: Austria，Belgium，Estonia，Finland 等 4 个
申办方: University of Ulm

正在招募 Phase 2, Phase 3 药物手术/操作

ClinicalTrials.gov / NCI NCT04708054 / NCI-2020-13919

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

AI 简述这是一项II/III期试验，研究Venetoclax联合白消安方案用于高危急性髓系白血病和骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia；Chronic Myelomonocytic Leukemia；Myelodysplastic Syndrome
干预: Busulfan，Cladribine，Fludarabine Phosphate，Hematopoietic Cell Transplantation
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 3 联合产品

ClinicalTrials.gov NCT05029531

Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)

AI 简述这是一项III期试验，研究免疫化疗联合风险适应策略用于0-365天婴儿B系急性淋巴细胞白血病，在俄罗斯开展。

?

适用疾病: Acute Lymphoblastic Leukemia, Pediatric；ALL, Infants
干预: the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.
地点: Russia
申办方: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT05183035 / NCI-2022-07200

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

AI 简述这是一项III期试验，研究Venetoclax联合化疗用于儿童复发急性髓系白血病，在美国、澳大利亚、奥地利、比利时等地开展。

?

适用疾病: Acute Myeloid Leukemia；Recurrent Acute Myeloid Leukemia (AML)
干预: Fludarabine，Cytarabine，Gemtuzumab Ozogamicin，Azacitidine
地点: United States，Australia，Austria，Belgium 等 16 个
申办方: PedAL BCU, LLC

正在招募 Phase 3 药物

ClinicalTrials.gov NCT05197192

A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

AI 简述这是一项III期试验，比较阿卡替尼、奥比妥珠单抗和维奈克拉与奥比妥珠单抗和维奈克拉用于高危CLL。在德国开展。

?

适用疾病: Chronic Lymphocytic Leukemia
干预: Obinutuzumab，Venetoclax，Acalabrutinib
地点: Germany
申办方: German CLL Study Group

正在招募 Phase 3 药物

ClinicalTrials.gov NCT05327894

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

AI 简述这是一项3期试验，研究Blinatumomab用于1岁以下KMT2A重排急性淋巴细胞白血病或混合表型急性白血病。

?

适用疾病: Acute Lymphoblastic Leukemia；Mixed Phenotype Acute Leukemia
干预: Blinatumomab，Blinatumomab
地点: Argentina，Australia，Austria，Belgium 等 20 个
申办方: Princess Maxima Center for Pediatric Oncology

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT05429632 / NCI-2022-10700

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

AI 简述这是一项III期试验，研究Mocravimod用于接受异基因造血干细胞移植的急性髓系白血病。

?

适用疾病: Adult Acute Myeloid Leukemia；Acute Myeloid Leukemia (AML)；Acute Myeloid Leukemia with Myelodysplasia-Related Gene Mutations
干预: mocravimod
地点: United States，Argentina，Brazil，France 等 10 个
申办方: Priothera SAS

正在招募 Phase 3 药物

ClinicalTrials.gov NCT05477589

Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML

AI 简述这是一项3期试验，研究BuCyMel与CloFluBu预处理方案用于儿童急性髓系白血病移植，在比利时、丹麦等地开展。

?

适用疾病: Acute Myeloid Leukemia (AML) in Remission；Stem Cell Transplantation
干预: busulfan, cyclophosphamide and melphalan, BuCyMel，clofarabine, fludarabine and busulfan, CloFluBu
地点: Belgium，Denmark，Finland，Hong Kong 等 6 个
申办方: Vastra Gotaland Region

正在招募 Phase 3 药物

ClinicalTrials.gov NCT05645107

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

AI 简述这是一项III期试验，研究XEMBIFY联合标准医疗与安慰剂联合标准医疗，用于预防低丙种球蛋白血症和反复感染患者的感染，涉及B细胞慢性淋巴细胞白血病、多发性骨髓瘤和非霍奇金淋巴瘤等。

?

适用疾病: Hypogammaglobulinemia；Bacterial Infections；B-cell Chronic Lymphocytic Leukemia
干预: Xembify，Placebo
地点: United States，Bosnia and Herzegovina，Bulgaria，Croatia 等 4 个
申办方: Grifols Therapeutics LLC

正在招募 Phase 3 药物

ClinicalTrials.gov NCT05907057

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

AI 简述这是一项III期试验，在多个欧洲国家研究Ivosidenib联合Azacitidine用于新诊断IDH1突变AML。

?

适用疾病: Acute Myeloid Leukemia (AML)
干预: Ivosidenib 500mg Oral Tablet，Azacitidine
地点: Austria，France，Italy，Netherlands
申办方: Servier Affaires Médicales

正在招募 Phase 3 生物制剂药物

ClinicalTrials.gov / NCI NCT05947851 / NCI-2023-09679

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

AI 简述这是一项3期试验，比较Nemtabrutinib联合Venetoclax与VR用于复发难治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤。

?

适用疾病: Leukemia, Lymphocytic, Chronic, B-Cell；Leukemia, Chronic Lymphocytic；Small-Cell Lymphoma
干预: Nemtabrutinib，Venetoclax，Rituximab
地点: United States，Argentina，Australia，Belgium 等 14 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 3 药物

ClinicalTrials.gov NCT05994690

CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients

AI 简述这是一项III期试验，研究标准或研究性方案用于新诊断儿童急性髓系白血病，在荷兰开展。

?

适用疾病: Acute Myeloid Leukemia in Children
干预: Standard Intervention Rc，Investigational Intervention Rc，Standard Intervention Ri，Investigational Intervention Ri
地点: Netherlands
申办方: Princess Maxima Center for Pediatric Oncology

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT06428019 / NCI-2024-09053

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

AI 简述这是一项III期试验，评估Venetoclax联合Obinutuzumab或Acalabrutinib用于初治慢性淋巴细胞白血病患者的肿瘤溶解综合征风险，在美国、澳大利亚、法国、希腊等地开展。

?

适用疾病: Chronic Lymphocytic Leukemia；Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma
干预: Venetoclax，Acalabrutinib，Obinutuzumab
地点: United States，Australia，France，Greece 等 5 个
申办方: AbbVie

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT06652438 / NCI-2026-04136

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

AI 简述这是一项III期试验，比较Revumenib与安慰剂联合阿扎胞苷和Venetoclax用于NPM1突变或KMT2A重排的急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia, Adult；Acute Myeloid Leukemia with MLL Rearrangement；Acute Myeloid Leukemia with NPM1 Mutation
干预: Revumenib，Placebo
地点: Germany，Netherlands，United Kingdom，United States
申办方: Stichting Hemato-Oncologie voor Volwassenen Nederland

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06713837

IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

AI 简述这是一项III期试验，比较高低强度疗法用于复发性/难治性急性髓系白血病，在捷克、德国、意大利、立陶宛等地开展。

?

适用疾病: Acute Myeloid Leukemia；Relapse/Recurrence
干预: High intensity therapies，Low intensity therapies
地点: Czechia，Germany，Italy，Lithuania 等 3 个
申办方: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT06756152

Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis

AI 简述这是一项II/III期试验，研究环磷酰胺、阿巴西普等预防儿童和青年血液肿瘤移植后GVHD。

?

适用疾病: Biphenotypic Acute Leukemia；Acute Lymphoblastic Leukemia；Myeloblastic Leukemia
干预: Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150
地点: Russia
申办方: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov / NCI NCT06788756 / NCI-2025-02906

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

AI 简述这是一项II/III期试验，研究L-Annamycin联合阿糖胞苷用于难治或复发急性髓系白血病的挽救治疗。

?

适用疾病: Acute Myeloid Leukaemia (AML)；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)
干预: Placebo in combination with Cytarabine Injection，Liposomal Annamycin Injection in combination with Cytarabine Injection，Liposomal Annamycin for Injection in combination with Cytarabine Injection.
地点: United States，Georgia，Italy，Lithuania 等 4 个
申办方: Moleculin Biotech, Inc.

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT06846671 / NCI-2025-07449

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

AI 简述这是一项III期试验，比较BGB-16673与研究者选择的治疗方案用于既往经BTK和BCL2抑制剂治疗的CLL/SLL。

?

适用疾病: CLL；Chronic Lymphocytic Leukemia；Refractory Chronic Lymphocytic Leukemia (CLL)
干预: BGB-16673，Bendamustine，Idelalisib，Rituximab
地点: United States，Argentina，Australia，Brazil 等 10 个
申办方: BeOne Medicines

正在招募 Phase 2, Phase 3 药物其他

ClinicalTrials.gov NCT06860269

A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia

AI 简述这是一项II/III期试验，研究新免疫治疗药物和异基因造血干细胞移植用于急性淋巴细胞白血病。

?

适用疾病: Acute Lymphoblastic Leukemia
干预: Randomization + Blinatumomab + chemotherapy，Randomization + Standard frontline T-ALL chemotherapy backbone，Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone，Randomization + Blinatumomab + Ponatinib + chemotherapy
地点: France
申办方: Assistance Publique - Hôpitaux de Paris

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT07007312 / NCI-2025-04758

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

AI 简述这是一项III期试验，比较Ziftomenib联合Ven+Aza或7+3方案用于初治NPM1突变或KMT2A重排AML。

?

适用疾病: Acute Myeloid Leukemia (AML)
干预: Ziftomenib，Placebo，Venetoclax，Azacitidine (AZA)
地点: United States，Australia，Czechia，France 等 8 个
申办方: Kura Oncology, Inc.

正在招募 Phase 3 药物

ClinicalTrials.gov NCT07075016

Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

AI 简述这是一项III期试验，比较Ivosidenib联合Azacitidine加或不加Venetoclax用于新诊断IDH1突变AML，在奥地利等国开展。

?

适用疾病: Acute Myeloid Leukemia
干预: Venetoclax 400，Placebo
地点: Austria，Belgium，Denmark，Estonia 等 12 个
申办方: Stichting Hemato-Oncologie voor Volwassenen Nederland

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT07211958 / NCI-2026-04767

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

AI 简述这是一项III期试验，研究Revumenib联合强化化疗用于新诊断NPM1突变急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemias；Acute Myeloid Leukemia (AML)
干预: Revumenib，Placebo，Intensive Chemotherapy Regimen
地点: Australia，Austria，Belgium，Brazil 等 11 个
申办方: Syndax Pharmaceuticals

正在招募 Phase 3 生物制剂药物

ClinicalTrials.gov / NCI NCT07223021 / NCI-2025-08156

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

AI 简述这是一项III期试验，研究氟达拉滨剂量用于儿童和青年B细胞急性淋巴细胞白血病。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia；B Acute Lymphoblastic Leukemia
干预: Fludarabine，Cyclophosphamide，CAR-T
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT07223814 / NCI-2026-03507

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

AI 简述这是一项III期试验，研究Bleximenib联合标准化疗用于急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia (AML)
干预: Bleximenib，Cytarabine，Daunorubicin or Idarubicin，Placebo
地点: United States，Germany，Netherlands
申办方: Stichting Hemato-Oncologie voor Volwassenen Nederland

正在招募 Phase 3 药物

ClinicalTrials.gov NCT07232134

The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia

AI 简述这是一项III期试验，评价化疗方案用于急性髓系白血病伴唐氏综合征患者。在俄罗斯开展。

?

适用疾病: AML (Acute Myelogenous Leukemia)；Down Syndrome (DS)
干预: 4 chemotherapy blocks: Course 1 AIE (cytarabine/idarubicin/etoposide), Course 2 AI (cytarabine/idarubicin), Course 3 HAD (high-dose cytarabine (1g)/daunorubicin), Course 4 HA (high-dose cytarabine).
地点: Russia
申办方: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

正在招募 Phase 3 药物

ClinicalTrials.gov NCT07342478

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

AI 简述这是一项3期试验，比较rocbrutinib与pirtobrutinib用于既往经共价BTK抑制剂治疗的复发/难治CLL/SLL。在美国开展。

?

适用疾病: CLL / SLL；CLL (Chronic Lymphocytic Leukemia)；CLL, Refractory
干预: Rocbrutinib，Pirtobrutinib
地点: United States
申办方: Newave Pharmaceutical Inc

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT07366801

Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies

AI 简述这是一项II/III期试验，研究Treg富集供体淋巴细胞与CD3去除造血干细胞共输注预防儿童血液恶性肿瘤异基因移植后移植物抗宿主病。在俄罗斯开展。

?

适用疾病: Acute Myeloid Leukemia, Relapsed；Acute Lymphoblastic Leukemia, High Risk；Acute Myeloid Leukemia, High Risk
干预: Cyclosporine A (CsA)，Sirolimus，Ruxolitinib (JAKAVI®)，Abatacept
地点: Russia
申办方: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

正在招募 Phase 2, Phase 3 生物制剂

ClinicalTrials.gov NCT07502118

NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)

AI 简述这是一项II/III期试验，研究Talikabtagene Autoleucel用于复发/难治性B细胞恶性肿瘤。

?

适用疾病: Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)；Relapsed/Refractory Non-Hodgkin Lymphoma；Diffuse Large B-Cell Lymphoma (DLBCL)
干预: Talikabtagene Autoleucel
地点: Turkey (Türkiye)
申办方: Health Institutes of Turkey

正在招募 Phase 3 药物

ClinicalTrials.gov NCT07504458

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

AI 简述这是一项III期试验，比较QTX-2101联合ATRA与静脉用三氧化二砷联合ATRA用于急性早幼粒细胞白血病。

?

适用疾病: Acute Promyelocytic Leukemia (APL)；Acute Promyelocytic Leukaemia；Acute Promyelocytic Leukemia With PML-RARA
干预: QTX-2101 + ATRA，IV arsenic trioxide (ATO) + ATRA
地点: United States
申办方: Quetzal Therapeutics

正在招募 Phase 3 药物

ClinicalTrials.gov NCT07509151

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

AI 简述这是一项III期试验，研究Surovatamig用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤。

?

适用疾病: Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
干预: Surovatamig
地点: Australia，Canada，Turkey (Türkiye)，United Kingdom
申办方: AstraZeneca

正在招募 Phase 2, Phase 3 生物制剂药物

ClinicalTrials.gov / NCI NCT07570173 / NCI-2026-04344

A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

AI 简述这是一项II/III期试验，研究MK-1045与Blinatumomab用于复发/难治B细胞急性淋巴细胞白血病，在以色列、日本、西班牙等地开展。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia；Recurrent B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative；Refractory B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
干预: MK-1045，Blinatumomab，Acetaminophen，Diphenhydramine
地点: Israel，Japan，Spain
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 3 药物

ClinicalTrials.gov NCT07582432

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

AI 简述这是一项III期试验，研究Gamunex-C用于慢性淋巴细胞白血病、多发性骨髓瘤或非霍奇金淋巴瘤。

?

适用疾病: Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
干预: Gamunex-C, 10% Injectable Solution
地点: United States
申办方: Grifols Biologicals, LLC

正在招募 Phase 2

NCI NCT00628238 / NCI-2009-01510

Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

AI 简述这是一项II期试验，研究来那度胺联合利妥昔单抗用于初治慢性淋巴细胞白血病。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Stage I Chronic Lymphocytic Leukemia (CLL)；Stage II Chronic Lymphocytic Leukemia (CLL)
干预: 未列出
地点: United States
申办方: Chronic Lymphocytic Leukemia Research Consortium (CRC)

正在招募 Phase 1, Phase 2

NCI NCT00709215 / NCI-2010-00051

Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia

AI 简述这是一项I/II期试验，研究虫草素联合喷司他丁用于难治性TdT阳性白血病。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Refractory Acute Lymphoblastic Leukemia (ALL)；TDT Positive
干预: 未列出
地点: United States
申办方: OncoVista, Inc.

正在招募 Phase 1, Phase 2

NCI NCT00271063 / NCI-2010-02297

Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia

AI 简述这是一项I/II期试验，研究脂质体安那霉素用于复发或难治性急性淋巴细胞白血病。

?

适用疾病: Recurrent Acute Lymphoblastic Leukemia (ALL)
干预: 未列出
地点: United States
申办方: Callisto Pharmaceuticals

正在招募 Phase 1, Phase 2

NCI NCT01211457 / NCI-2011-01175

Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

AI 简述这是一项I/II期试验，研究Sapacitabine用于急性髓系白血病或骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia (AML)；Myelodysplastic Syndrome
干预: 未列出
地点: United States
申办方: Cyclacel Pharmaceuticals, Inc.

正在招募 Phase 2

NCI NCT00412594 / NCI-2012-01394

Cladribine and Rituximab in Treating Patients with Hairy Cell Leukemia

AI 简述这是一项II期试验，研究克拉屈滨联合利妥昔单抗用于毛细胞白血病。

?

适用疾病: Recurrent Hairy Cell Leukemia；Hairy Cell Leukemia
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT02576301 / NCI-2016-00143

Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS

AI 简述这是一项I/II期试验，研究OXi4503联合阿糖胞苷用于复发急性髓系白血病和骨髓增生异常综合征。

?

适用疾病: Myelodysplastic Syndrome；Recurrent Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: Mateon Therapeutics

正在招募 Phase 2

NCI NCT02646839 / NCI-2016-00518

KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children

AI 简述这是一项II期试验，研究KIR相合单倍体移植用于儿童急性白血病和骨髓增生异常综合征。

?

适用疾病: FLT3 Internal Tandem Duplication Positive；Acute Lymphoblastic Leukemia (ALL)；Acute Megakaryoblastic Leukemia
干预: 未列出
地点: United States
申办方: Michael Pulsipher

正在招募 Phase 2

NCI NCT02802267 / NCI-2016-01186

Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy

AI 简述这是一项II期试验，研究Inecalcitol联合Decitabine用于不适合标准化疗的急性髓系白血病。

?

适用疾病: Secondary Acute Myeloid Leukemia (AML)；Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: Hybrigenics Corporation

正在招募 Phase 1, Phase 2

NCI NCT03018405 / NCI-2017-00722

A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications

AI 简述这是一项I/II期试验，研究多种肿瘤适应症的药物。

?

适用疾病: Metastatic Urothelial Cancer；Advanced Malignant Solid Tumor；Refractory Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: Celyad Oncology SA

正在招募 Phase 2

NCI NCT03125642 / NCI-2017-01037

Chemotherapy with or without Total Body Irradiation before Stem Cell Transplant in Treating Patients with Hodgkin or Non-Hodgkin Lymphoma

AI 简述这是一项II期试验，研究自体干细胞移植用于淋巴瘤，使用Etoposide等预处理方案。

?

适用疾病: Refractory Central Nervous System Lymphoma；Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma；Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma
干预: 未列出
地点: United States
申办方: University of Minnesota/Masonic Cancer Center

正在招募 Phase 2

NCI NCT03418038 / NCI-2018-00057

Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, Clonal Cytopenia of Undetermined Significance and Chronic Myelomonocytic Leukemia

AI 简述这是一项II期试验，研究抗坏血酸联合化疗用于复发难治性淋巴瘤、意义未明克隆性血细胞减少和慢性粒单核细胞白血病。

?

适用疾病: Double-Hit Lymphoma；Refractory Lymphoma；Recurrent Lymphoma
干预: 未列出
地点: United States
申办方: Mayo Clinic in Rochester

正在招募 Phase 1, Phase 2

NCI NCT03867682 / NCI-2019-02582

Venetoclax and Lintuzumab-Ac225 in AML Patients

AI 简述这是一项I/II期试验，研究Venetoclax联合Lintuzumab-Ac225用于复发/难治性急性髓系白血病。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)；Recurrent Chronic Myelomonocytic Leukemia
干预: 未列出
地点: United States
申办方: Actinium Pharmaceuticals Inc

正在招募 Phase 2

NCI NCT03579875 / NCI-2019-02906

Alpha/Beta T Cell Depleted Stem Cell Transplant in Treating Patients with Fanconi Anemia or Telomere Biology Disorder

AI 简述这是一项II期试验，研究去除α/βT细胞的干细胞移植用于范可尼贫血或端粒生物学疾病。

?

适用疾病: Telomere Biology Disorders；Myelodysplastic Syndrome；Fanconi Anemia
干预: 未列出
地点: United States
申办方: University of Minnesota/Masonic Cancer Center

正在招募 Phase 2

NCI NCT02393157 / NCI-2019-05721

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

AI 简述这是一项II期试验，研究Obinutuzumab联合ICE化疗用于复发/难治性CD20+成熟非霍奇金淋巴瘤。

?

适用疾病: Refractory High-Grade B-Cell Lymphoma；Chronic Lymphocytic Leukemia (CLL)；B-Cell Prolymphocytic Leukemia
干预: 未列出
地点: United States
申办方: New York Medical College

正在招募 Phase 2

NCI NCT04093570 / NCI-2019-07634

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

AI 简述这是一项II期试验，研究ASTX727用于血液肿瘤。

?

适用疾病: Acute Myeloid Leukemia (AML)；Chronic Myelomonocytic Leukemia (CMML)；Myelodysplastic Syndrome
干预: 未列出
地点: United States
申办方: Taiho Pharmaceutical Company Limited

正在招募 Phase 1, Phase 2

NCI NCT04195347 / NCI-2019-08205

CM4620 for the Reduction of the Severity of Acute Pancreatitis Due to Treatment with Asparaginase in Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, the CRSPA Study

AI 简述这是一项I/II期试验，研究CM4620用于减轻门冬酰胺酶所致急性胰腺炎，针对急性淋巴细胞白血病或淋巴母细胞淋巴瘤。

?

适用疾病: Acute Lymphoblastic Leukemia (ALL)；Lymphoblastic Lymphoma；Acute Pancreatitis
干预: 未列出
地点: United States
申办方: Saint Jude Children's Research Hospital

正在招募 Phase 2

NCI NCT04282187 / NCI-2020-00749

Decitabine with Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

AI 简述这是一项II期试验，研究地西他滨联合鲁索利替尼等用于加速期/急变期骨髓增殖性肿瘤。

?

适用疾病: Myelodysplastic/Myeloproliferative Disease；Myeloproliferative Neoplasm, Unclassifiable；Secondary Myelofibrosis
干预: 未列出
地点: United States
申办方: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium

正在招募 Phase 1, Phase 2

NCI NCT04329728 / NCI-2020-04547

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

AI 简述这是一项I/II期试验，在美国开展，研究AVM0703用于淋巴系统恶性肿瘤。

?

适用疾病: Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma；Refractory Acute Lymphoblastic Leukemia (ALL)；Recurrent Acute Lymphoblastic Leukemia
干预: 未列出
地点: United States
申办方: AVM Biotechnology Inc

正在招募 Phase 1, Phase 2

NCI NCT04358393 / NCI-2020-05317

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

AI 简述这是一项I/II期试验，研究APG-115单用或联合阿扎胞苷用于复发难治AML、CMML或MDS。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Refractory Myelodysplastic Syndrome；Recurrent Myelodysplastic Syndrome
干预: 未列出
地点: United States
申办方: Ascentage Pharma

正在招募 Phase 2

NCI NCT04249830 / NCI-2020-05892

Donor Stem Cell Transplant after TCR Alpha-Beta+ T Cells/CD19+ B Cell Depletion for the Treatment of Children and Young Adults with Malignant or Non-malignant Hematological Disorders

AI 简述这是一项II期试验，在美国研究TCRαβ+ T细胞/CD19+ B细胞去除后供体干细胞移植用于儿童恶性或非恶性血液疾病。

?

适用疾病: Childhood Myelodysplastic Syndrome with Excess Blasts；Childhood Myelodysplastic Syndrome with Low Blasts；Hematopoietic and Lymphoid Cell Neoplasm
干预: 未列出
地点: United States
申办方: Stanford Cancer Institute Palo Alto

正在招募 Phase 1, Phase 2

NCI NCT04502394 / NCI-2021-00895

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

AI 简述这是一项I/II期试验，研究KRT-232联合Acalabrutinib用于复发/难治性DLBCL或CLL。在美国开展。

?

适用疾病: Refractory Chronic Lymphocytic Leukemia (CLL)；Recurrent Chronic Lymphocytic Leukemia (CLL)；Recurrent Diffuse Large B-Cell Lymphoma
干预: 未列出
地点: United States
申办方: Kartos Therapeutics, Inc.

正在招募 Phase 1, Phase 2

NCI NCT04811560 / NCI-2021-05696

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

AI 简述这是一项1/2期试验，研究Bleximenib用于急性白血病。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)；Recurrent Acute Leukemia
干预: 未列出
地点: United States
申办方: Janssen Research & Development, LLC

正在招募 Phase 1, Phase 2

NCI NCT04959175 / NCI-2021-07758

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

AI 简述这是一项I/II期试验，研究移植后环磷酰胺减量用于血液肿瘤老年或体弱患者，在美国开展。

?

适用疾病: Hematopoietic and Lymphoid Cell Neoplasm；Mature T-Cell and NK-Cell Neoplasm；Primary Myelofibrosis
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 1, Phase 2

NCI NCT04964518 / NCI-2021-09673

A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

AI 简述这是一项I/II期试验，研究APG-2575联合阿扎胞苷用于急性髓系白血病，在美国开展。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Biphenotypic Leukemia；Recurrent Acute Undifferentiated Leukemia
干预: 未列出
地点: United States
申办方: Ascentage Pharma

正在招募 Phase 2

NCI NCT04728893 / NCI-2021-09870

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

AI 简述这是一项II期试验，研究Nemtabrutinib用于血液系统恶性肿瘤，在多个国家开展。

?

适用疾病: Recurrent Waldenstrom Macroglobulinemia；Refractory Waldenstrom Macroglobulinemia；Refractory Marginal Zone Lymphoma
干预: 未列出
地点: United States
申办方: Merck Sharp and Dohme LLC

正在招募 Phase 2

NCI NCT04836390 / NCI-2021-10562

Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant

AI 简述这是一项II期试验，研究供者来源NK细胞输注用于高危急性髓系白血病儿童和年轻成人。

?

适用疾病: Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: Michael Pulsipher

正在招募 Phase 1, Phase 2

NCI NCT05110742 / NCI-2021-10898

iC9 CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells and Lymphodepleting Chemotherapy for the Treatment of Relapsed or Refractory T-cell Leukemia or Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma

AI 简述这是一项I/II期试验，研究iC9 CD5 CAR NK细胞用于复发或难治T细胞白血病或淋巴瘤。

?

适用疾病: Recurrent Mycosis Fungoides and Sezary Syndrome；Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma；Recurrent T Acute Lymphoblastic Leukemia
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05256641 / NCI-2021-12421

Acalabrutinib Maintenance for the Treatment of Patients with Large B-cell Lymphoma

AI 简述这是一项I/II期试验，研究Acalabrutinib维持治疗用于大B细胞淋巴瘤。

?

适用疾病: High Grade B-Cell Lymphoma；Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma；Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
干预: 未列出
地点: United States
申办方: UCLA / Jonsson Comprehensive Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT04835584 / NCI-2021-12575

KRT-232 and TKI Study in Chronic Myeloid Leukemia

AI 简述这是一项I/II期试验，研究KRT-232联合TKI用于BCR-ABL1阳性慢性髓系白血病。

?

适用疾病: Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive；Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive；Refractory Chronic Myelogenous Leukemia (CML)
干预: 未列出
地点: United States
申办方: Kartos Therapeutics, Inc.

正在招募 Phase 1, Phase 2

NCI NCT04959903 / NCI-2022-02250

Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT

AI 简述这是一项I/II期试验，研究SMART101用于儿童和成人血液肿瘤患者T细胞去除移植后，在美国开展。

?

适用疾病: Refractory Acute Lymphoblastic Leukemia (ALL)；Refractory Acute Myeloid Leukemia (AML)；Recurrent Ph-Like Acute Lymphoblastic Leukemia
干预: 未列出
地点: United States
申办方: Smart Immune

正在招募 Phase 2

NCI NCT05592015 / NCI-2022-02385

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

AI 简述这是一项II期试验，研究Ruxolitinib用于治疗T细胞大颗粒淋巴细胞白血病，在美国开展。

?

适用疾病: T-Cell Large Granular Lymphocyte Leukemia
干预: 未列出
地点: United States
申办方: Ohio State University Comprehensive Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05327023 / NCI-2022-03436

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

AI 简述这是一项1/2期试验，研究供体淋巴细胞输注用于高危血液恶性肿瘤，在美国开展。

?

适用疾病: Aggressive B-Cell Non-Hodgkin Lymphoma；Acute Lymphoblastic Leukemia (ALL)；Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 1, Phase 2

NCI NCT05351593 / NCI-2022-03704

Lenalidomide with Tafasitamab for the Treatment of Relapsed Central Nervous System Diffuse Large B-cell Lymphoma

AI 简述这是一项I/II期试验，研究Lenalidomide联合Tafasitamab用于复发中枢神经系统弥漫大B细胞淋巴瘤。

?

适用疾病: Recurrent Central Nervous System Lymphoma；Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma；Recurrent Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
干预: 未列出
地点: United States
申办方: University of California San Francisco

正在招募 Phase 2

NCI NCT05355051 / NCI-2022-03778

Azacitidine and Pembrolizumab for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Acute Myeloid Leukemia

AI 简述这是一项II期试验，研究Azacytidine联合Pembrolizumab用于复发/难治霍奇金淋巴瘤。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)；Recurrent Hodgkin Lymphoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05436418 / NCI-2022-05514

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

AI 简述这是一项1/2期试验，在United States开展，研究环磷酰胺联合西罗莫司和他克莫司用于预防移植物抗宿主病。

?

适用疾病: Refractory Chronic Myelomonocytic Leukemia (CMML)；Mature T-Cell and NK-Cell Neoplasm；Primary Myelofibrosis
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 1, Phase 2

NCI NCT05320198 / NCI-2022-05581

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

AI 简述这是一项I/II期试验，研究DISC-0974用于骨髓纤维化或骨髓增生异常综合征伴贫血。

?

适用疾病: Myelofibrosis Transformation in Essential Thrombocythemia；Myelodysplastic/Myeloproliferative Disease；Primary Myelofibrosis
干预: 未列出
地点: United States
申办方: Disc Medicine, Inc

正在招募 Phase 1, Phase 2

NCI NCT05470491 / NCI-2022-06140

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

AI 简述这是一项I/II期试验，研究减低强度单倍体相合造血干细胞移植后环磷酰胺、硼替佐米等预防移植物抗宿主病用于血液恶性肿瘤。

?

适用疾病: Recurrent T-Cell Prolymphocytic Leukemia；Recurrent B-Cell Prolymphocytic Leukemia；Recurrent Plasma Cell Neoplasm
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 1, Phase 2

NCI NCT05503355 / NCI-2022-07595

A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML

AI 简述这是一项I/II期试验，研究BST-236联合Venetoclax用于不适合强化化疗的新诊断急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: BioSight Ltd.

正在招募 Phase 1, Phase 2

NCI NCT05475925 / NCI-2022-07922

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

AI 简述这是一项1/2期试验，研究DR-01用于大颗粒淋巴细胞白血病或细胞毒性淋巴瘤，在美国、澳大利亚、法国、德国等地开展。

?

适用疾病: Peripheral T-Cell Lymphoma, Not Otherwise Specified with Cytotoxic Phenotype；Lymphoma；Peripheral T-Cell Lymphoma, Unclassifiable
干预: 未列出
地点: United States
申办方: Dren Bio

正在招募 Phase 2

NCI NCT05672355 / NCI-2022-10303

A Vaccine Booster (GEO-CM04S1 or Pfizer-BioNTech) for the Prevention of COVID-19 in Patients with Chronic Lymphocytic Leukemia

AI 简述这是一项II期试验，研究GEO-CM04S1或Pfizer-BioNTech疫苗加强针用于慢性淋巴细胞白血病患者预防COVID-19。

?

适用疾病: COVID-19；Chronic Lymphocytic Leukemia (CLL)
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 2

NCI NCT05672251 / NCI-2022-10312

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

AI 简述这是一项II期试验，研究Loncastuximab Tesirine和Mosunetuzumab用于复发/难治性弥漫大B细胞淋巴瘤。

?

适用疾病: Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma；Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma；Recurrent Transformed Chronic Lymphocytic Leukemia
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 4

NCI NCT04877522 / NCI-2023-00401

Asciminib Roll-over Study

AI 简述这是一项IV期试验，评估Asciminib长期用于CML和ALL。

?

适用疾病: Acute Lymphoblastic Leukemia (ALL)；Chronic Myelogenous Leukemia (CML)；Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
干预: 未列出
地点: United States
申办方: Novartis Pharmaceuticals Corporation

正在招募 Phase 2

NCI NCT04419649 / NCI-2023-02457

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

AI 简述这是一项II期试验，研究Elritercept用于极低、低或中危骨髓增生异常综合征的贫血。

?

适用疾病: Anemia；Chronic Myelomonocytic Leukemia (CMML)；Myelodysplastic Syndrome
干预: 未列出
地点: United States
申办方: Takeda

正在招募 Phase 2

NCI NCT06013423 / NCI-2023-05598

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients with High-Risk Hematologic Diseases

AI 简述这是一项II期试验，研究脐血移植联合环磷酰胺、氟达拉滨和全身照射用于高危血液疾病。

?

适用疾病: Acute Lymphoblastic Leukemia (ALL)；Acute Myeloid Leukemia (AML)；Chronic Myelogenous Leukemia (CML)
干预: 未列出
地点: United States
申办方: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium

正在招募 Phase 1, Phase 2

NCI NCT06066359 / NCI-2023-08318

Genetically Engineered Cells (NY-ESO-1 TCR/IL-15 NK cells) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

AI 简述这是一项I/II期试验，研究NY-ESO-1 TCR/IL-15 NK细胞用于复发难治多发性骨髓瘤或浆细胞白血病。在美国开展。

?

适用疾病: Recurrent Plasma Cell Leukemia；Refractory Plasma Cell Leukemia；Refractory Multiple Myeloma/Plasma Cell Myeloma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05589896 / NCI-2023-08596

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

AI 简述这是一项I/II期试验，首次人体研究HLA部分或完全匹配的异体冻干死供者骨髓移植用于血液恶性肿瘤。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Acute Lymphoblastic Leukemia (ALL)；Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: Ossium Health, Inc.

正在招募 Phase 2

NCI NCT06028828 / NCI-2023-08957

Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

AI 简述这是一项II期试验，调整预处理方案用于异基因造血干细胞移植治疗白血病和淋巴瘤。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Acute Lymphoblastic Leukemia (ALL)；Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: UC Irvine Health/Chao Family Comprehensive Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05322850 / NCI-2023-09341

Orca Q Stem Cells for the Treatment of Pediatric Patients with Leukemia

AI 简述这是一项I/II期试验，研究Orca Q干细胞用于儿童白血病。

?

适用疾病: Acute Lymphoblastic Leukemia (ALL)；Acute Myeloid Leukemia (AML)；Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
干预: 未列出
地点: United States
申办方: UF Health Cancer Institute - Gainesville

正在招募 Phase 2

NCI NCT06176989 / NCI-2023-11058

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

AI 简述这是一项II期试验，研究Enasidenib用于IDH2突变恶性鼻窦和颅底肿瘤。

?

适用疾病: Sinonasal Adenocarcinoma；Metastatic Sinonasal Carcinoma；Paranasal Sinus Large Cell Neuroendocrine Carcinoma
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 2

NCI NCT06229912 / NCI-2024-00534

Revumenib in Treating Patients with Relapsed or Refractory Leukemia Associated with Upregulation of HOX Genes

AI 简述这是一项II期试验，研究Revumenib用于复发性或难治性白血病。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Refractory Acute Lymphoblastic Leukemia (ALL)；Recurrent Acute Lymphoblastic Leukemia
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT06311227 / NCI-2024-01904

Venetoclax for the Treatment of Patients with Relapsed Hairy Cell Leukemia

AI 简述这是一项II期试验，在美国开展，研究Venetoclax用于复发毛细胞白血病。

?

适用疾病: Recurrent Hairy Cell Leukemia；Recurrent Hairy Cell Leukemia Variant
干预: 未列出
地点: United States
申办方: National Cancer Institute LAO

正在招募 Phase 1, Phase 2

NCI NCT06383572 / NCI-2024-03505

PRAME-TCR-NK Cells with Lymphodepleting Chemotherapy for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia

AI 简述这是一项I/II期试验，在美国研究PRAME-TCR-NK细胞用于复发/难治性急性髓系白血病和骨髓增生异常综合征。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)；Myelodysplastic Syndrome Post Cytotoxic Therapy
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT06445959 / NCI-2024-04807

Decitabine and Venetoclax in Combination with Olutasidenib for the Treatment of Patients with Newly Diagnosed, Recurrent or Refractory Acute Myeloid Leukemia

AI 简述这是一项I/II期试验，研究地西他滨、维奈克拉联合Olutasidenib用于急性髓系白血病。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)；Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT06504459 / NCI-2024-05084

Venetoclax in Combination with Cladribine and Cytarabine Alternating with Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

AI 简述这是一项II期试验，研究维奈克拉联合克拉屈滨和阿糖胞苷交替阿扎胞苷加维奈克拉用于新诊断单核细胞AML。

?

适用疾病: Acute Myeloid Leukemia (AML)；Acute Monocytic Leukemia
干预: 未列出
地点: United States
申办方: OHSU Knight Cancer Institute

正在招募 Phase 1, Phase 2

NCI NCT06082947 / NCI-2024-05357

αβT Cell/CD19+ B Cell Depletion for Alternative Donor Stem Cell Transplant for Children and Young Adults with Hematologic Malignancies

AI 简述这是一项I/II期试验，研究αβT/CD19+B细胞清除异基因移植用于儿童和年轻成人血液恶性肿瘤，在美国开展。

?

适用疾病: Refractory Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive；Secondary Acute Myeloid Leukemia (AML)；Acute Lymphoblastic Leukemia (ALL)
干预: 未列出
地点: United States
申办方: Nationwide Children's Hospital

正在招募 Phase 2

NCI NCT05800210 / NCI-2024-06014

Specialized Stem Cell Transplant Product (Hematopoietic Progenitor Blood Cell Graft Cells) for the Treatment of Children, Adolescent and Young Adult Patients with Hematologic Cancers

AI 简述这是一项II期试验，研究造血祖细胞血细胞移植物用于儿童和年轻成人血液癌症，在美国开展。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Recurrent Juvenile Myelomonocytic Leukemia；Acute Lymphoblastic Leukemia (ALL)
干预: 未列出
地点: United States
申办方: UF Health Cancer Institute - Gainesville

正在招募 Phase 1, Phase 2

NCI NCT06542250 / NCI-2024-07237

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

AI 简述这是一项I/II期试验，研究AZD5492用于复发/难治性B细胞恶性肿瘤，在美国开展。

?

适用疾病: Recurrent Follicular Lymphoma；Refractory Chronic Lymphocytic Leukemia (CLL)；Recurrent Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: AstraZeneca Pharmaceuticals LP

正在招募 Phase 2

NCI NCT06668584 / NCI-2025-00104

Olutasidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, or Chronic Myelomonocytic Leukemia after Transplant

AI 简述这是一项II期试验，研究Olutasidenib用于IDH1突变的急性髓系白血病等移植后治疗，在美国开展。

?

适用疾病: Acute Myeloid Leukemia (AML)；Chronic Myelomonocytic Leukemia (CMML)；Myelodysplastic Syndrome
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT06815003 / NCI-2025-00341

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

AI 简述这是一项II期试验，研究Vedolizumab联合移植后环磷酰胺用于预防异基因造血干细胞移植后的移植物抗宿主病，在美国开展。

?

适用疾病: Graft Versus Host Disease；Acute Lymphoblastic Leukemia (ALL)；Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 2

NCI NCT06807606 / NCI-2025-00794

Optimized Cord Blood Transplant with Intermediate Intensity Conditioning Regimen for the Treatment of Relapsed High-Risk Hematologic Cancers after First Donor Stem Cell Transplant

AI 简述这是一项II期试验，研究优化脐带血移植联合中等强度预处理用于首次造血干细胞移植后复发的血液肿瘤。

?

适用疾病: Acute Lymphoblastic Leukemia (ALL)；Acute Myeloid Leukemia (AML)；Chronic Myelogenous Leukemia (CML)
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT06863402 / NCI-2025-01256

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

AI 简述这是一项II期试验，研究Nemtabrutinib和Pembrolizumab用于Richter转化（弥漫大B细胞淋巴瘤亚型）。

?

适用疾病: Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma；Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma；Richter Syndrome
干预: 未列出
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 1, Phase 2

NCI NCT05756322 / NCI-2025-01499

The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias

AI 简述这是一项1/2期试验，研究LBS-007用于复发或难治性急性白血病。

?

适用疾病: Recurrent Acute Lymphoblastic Leukemia；Recurrent Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: Lin BioScience, Inc

正在招募 Phase 2

NCI NCT06630221 / NCI-2025-02053

Eltrombopag for the Treatment of Relapsed or Refractory Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia-0 with TET2 Mutations

AI 简述这是一项II期试验，研究Eltrombopag用于复发难治低危骨髓增生异常综合征和慢性粒单核细胞白血病-0伴TET2突变。

?

适用疾病: Chronic Myelomonocytic Leukemia-0；Refractory Myelodysplastic Syndrome；Recurrent Myelodysplastic Syndrome
干预: 未列出
地点: United States
申办方: Case Comprehensive Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT06930651 / NCI-2025-02697

Genetically Engineered Cells (TGFBR2 KO CAR27/IL-15 NK cells) for the Treatment of Relapsed or Refractory Myeloid Malignancies

AI 简述这是一项I/II期试验，研究基因工程NK细胞用于复发难治性髓系恶性肿瘤，在美国开展。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Refractory Myelodysplastic Syndrome；Recurrent Myelodysplastic Syndrome
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT06315309 / NCI-2025-02755

2 Step ATG with Preparative Chemotherapy and Methotrexate for the Prevention of Acute GVHD for Patients Undergoing Myeloablative Allogeneic Stem Cell Transplant for Hematopoietic Disorders

AI 简述一项II期试验，研究2步ATG联合化疗和甲氨蝶呤预防造血干细胞移植后急性GVHD，在美国开展。

?

适用疾病: Acute Myeloid Leukemia (AML)；Chronic Myelomonocytic Leukemia (CMML)；T cell acute lymphoblastic leukemia
干预: 未列出
地点: United States
申办方: University of Alabama at Birmingham Cancer Center

正在招募 Phase 2

NCI NCT07046078 / NCI-2025-02981

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older with Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

AI 简述这是一项II期试验，研究FLAG-Ida化疗后立即进行低强度全身放疗和供体造血细胞移植，用于60岁以上新诊断高危急性髓系白血病或其他高级别髓系癌症。

?

适用疾病: Acute Myeloid Leukemia (AML)；Chronic Myelomonocytic Leukemia (CMML)；Myelodysplastic Syndrome
干预: 未列出
地点: United States
申办方: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium

正在招募 Phase 2

NCI NCT06973668 / NCI-2025-03239

Comparing Cyclophosphamide, Sirolimus, Ruxolitinib to Cyclophosphamide, Sirolimus, Mycophenolate Mofetil after Allogeneic Stem Cell Transplantation for the Prevention of Graft versus Host Disease in Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

AI 简述这是一项II期试验，在美国开展，比较环磷酰胺、西罗莫司、芦可替尼与环磷酰胺、西罗莫司、吗替麦考酚酯用于AML、MDS或CMML患者异基因移植后预防移植物抗宿主病。

?

适用疾病: Acute Myeloid Leukemia (AML)；Chronic Myelomonocytic Leukemia (CMML)；Myelodysplastic Syndrome
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT06768905 / NCI-2025-03900

131I-Apamistamab Followed by Axicabtagene Ciloleucel for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma, The IOMAB-ACT Trial

AI 简述这是一项I/II期试验，研究Iomab-B序贯CAR-T细胞治疗复发/难治性弥漫大B细胞淋巴瘤。在美国开展。

?

适用疾病: Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma；Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma；Recurrent High-Grade B-Cell Lymphoma
干预: 未列出
地点: United States
申办方: UT Southwestern/Simmons Cancer Center-Dallas

正在招募 Phase 1, Phase 2

NCI NCT05768035 / NCI-2025-03939

Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide

AI 简述这是一项I/II期试验，研究SMART101用于血液恶性肿瘤单倍体移植后。在美国开展。

?

适用疾病: Acute Lymphoblastic Leukemia (ALL)；Acute Myeloid Leukemia (AML)；Myelodysplastic Syndrome
干预: 未列出
地点: United States
申办方: Smart Immune

正在招募 Phase 2

NCI NCT07228273 / NCI-2025-04104

Induction and Consolidation with Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia

AI 简述这是一项II期试验，研究氟达拉滨、阿糖胞苷、伊达比星和Venetoclax用于急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia (AML)；Myelodysplastic Syndrome
干预: 未列出
地点: United States
申办方: OHSU Knight Cancer Institute

正在招募 Phase 2

NCI NCT07032727 / NCI-2025-04331

Olutasidenib Combined with Co-targeted Therapy for the Treatment of Myeloid Cell Cancers in Patients with IDH1 and Co-signaling Gene Mutations

AI 简述这是一项II期试验，研究Olutasidenib联合靶向治疗用于IDH1突变复发难治性髓系肿瘤，在美国开展。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Biphenotypic Leukemia；Recurrent Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT06773936 / NCI-2025-06044

Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

AI 简述这是一项II期试验，研究Asciminib联合常规治疗用于新诊断Ph+急性淋巴细胞白血病。

?

适用疾病: B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1
干预: 未列出
地点: United States
申办方: SWOG Cancer Research Network

正在招募 Phase 2

NCI NCT06265584 / NCI-2025-07477

Anti-Thymocyte Globulin added to Tacrolimus and Methotrexate for Reducing Graft Versus Host Disease after Hematopoietic Stem Cell Transplant for Hematologic Cancers

AI 简述这是一项II期试验，研究抗胸腺细胞球蛋白联合他克莫司和甲氨蝶呤用于预防移植物抗宿主病。

?

适用疾病: Acute Myeloid Leukemia (AML)；Chronic Myelomonocytic Leukemia (CMML)；T cell acute lymphoblastic leukemia
干预: 未列出
地点: United States
申办方: University of Alabama at Birmingham Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT07155226 / NCI-2025-09716

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

AI 简述这是一项I/II期试验，研究AZD3632单药或联合抗癌药物用于伴KMT2Ar等基因改变的血液恶性肿瘤。

?

适用疾病: Refractory Myelodysplastic Syndrome；Recurrent Myelodysplastic Syndrome；Recurrent Acute Leukemia
干预: 未列出
地点: United States
申办方: AstraZeneca Pharmaceuticals LP

正在招募 Phase 1, Phase 2

NCI NCT07294677 / NCI-2026-01627

Capivasertib, Venetoclax, and Low-Intensity Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma, CAVALRY Trial

AI 简述这是一项I/II期试验，在美国开展，研究Capivasertib、Venetoclax和低强度化疗用于急性淋巴细胞白血病/淋巴母细胞淋巴瘤。

?

适用疾病: Early T Precursor Acute Lymphoblastic Leukemia；Recurrent B Acute Lymphoblastic Leukemia；Refractory B Acute Lymphoblastic Leukemia
干预: 未列出
地点: United States
申办方: University of Chicago Comprehensive Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT07508982 / NCI-2026-02429

APG1252 in Combination with Azacitidine for the Treatment of High-Risk, Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia

AI 简述这是一项I/II期试验，在United States研究APG1252联合阿扎胞苷用于高危初治或复发难治急性髓系白血病。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)；Acute Myeloid Leukemia with MECOM Rearrangement
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT07214688 / NCI-2026-04426

Fludarabine and Intermediate-dose Total Body Irradiation Conditioning plus Post-Transplant Cyclophosphamide for the Treatment of Patients Undergoing Allogeneic Stem Cell Transplant for Hematologic Cancers

AI 简述这是一项2期试验，研究氟达拉滨联合中等剂量全身照射及移植后环磷酰胺用于血液肿瘤。

?

适用疾病: Acute Lymphoblastic Leukemia (ALL)；Acute Myeloid Leukemia (AML)；Chronic Myelogenous Leukemia (CML)
干预: 未列出
地点: United States
申办方: Hackensack University Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT00501826 / NCI-2012-01518

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

AI 简述这是一项II期试验，研究联合化疗联合奈拉滨用于T细胞急性淋巴细胞白血病或淋巴母细胞淋巴瘤。

?

适用疾病: T Acute Lymphoblastic Leukemia；T Lymphoblastic Lymphoma；T cell acute lymphoblastic leukemia
干预: Cyclophosphamide，Cytarabine，Dexamethasone，Doxorubicin Hydrochloride
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 生物制剂药物其他

ClinicalTrials.gov / NCI NCT00801489 / NCI-2012-01659

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

AI 简述这是一项II期试验，研究Fludarabine Phosphate、Cytarabine、Filgrastim-sndz、Gemtuzumab Ozogamicin和Idarubicin Hydrochloride用于新诊断急性髓系白血病或高危骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11；Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11；Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
干预: Cytarabine，Decitabine，Filgrastim-sndz，Fludarabine Phosphate
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 生物制剂药物其他

ClinicalTrials.gov / NCI NCT01371630 / NCI-2011-01123

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

AI 简述这是一项I/II期试验，研究Inotuzumab Ozogamicin联合化疗用于急性淋巴细胞白血病。

?

适用疾病: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1；B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative；Burkitt-Like Lymphoma With 11q Aberration
干预: Blinatumomab，Cyclophosphamide，Cytarabine，Dexamethasone
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物其他

ClinicalTrials.gov / NCI NCT01409161 / NCI-2011-02767

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

AI 简述这是一项II期试验，研究Tretinoin和Arsenic Trioxide联用或不联用Gemtuzumab Ozogamicin用于初治急性早幼粒细胞白血病。

?

适用疾病: Acute Promyelocytic Leukemia With PML-RARA；Acute Promyelocytic Leukemia with PML-RARA
干预: Arsenic Trioxide，Gemtuzumab Ozogamicin，Laboratory Biomarker Analysis，Tretinoin
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT01515527 / NCI-2012-00145

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

AI 简述这是一项II期试验，研究Cladribine加低剂量Cytarabine交替Decitabine用于急性髓系白血病或高危骨髓增生异常综合征。

?

适用疾病: Leukemia；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)
干预: Cladribine，Cytarabine，Decitabine
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物其他

ClinicalTrials.gov / NCI NCT02115295 / NCI-2014-01103

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

AI 简述这是一项2期试验，研究克拉屈滨、伊达比星、阿糖胞苷和维奈克拉用于急性髓系白血病、高风险骨髓增生异常综合征或急变期慢性粒细胞白血病。

?

适用疾病: Acute Biphenotypic Leukemia；Acute Myeloid Leukemia；Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
干预: Cladribine，Cytarabine，Gilteritinib，Idarubicin
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT02143830 / NCI-2018-01873

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

AI 简述这是一项II期试验，研究风险调整的化疗方案用于范可尼贫血患者的造血干细胞移植。

?

适用疾病: Fanconi Anemia；Severe Marrow Failure；Myelodysplastic Syndrome (MDS)
干预: Busulfan，Cyclophosphamide，Fludarabine，rabbit ATG
地点: United States
申办方: Children's Hospital Medical Center, Cincinnati

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT02392572 / NCI-2015-00504

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

AI 简述这是一项I/II期试验，研究ONC201联合Venetoclax用于复发或难治性急性白血病或高危骨髓增生异常综合征。

?

适用疾病: Recurrent Acute Lymphoblastic Leukemia；Recurrent Acute Myeloid Leukemia；Recurrent Myelodysplastic Syndrome
干预: Akt/ERK Inhibitor ONC201，Venetoclax
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 生物制剂药物其他

ClinicalTrials.gov / NCI NCT02727803 / NCI-2016-00584

Personalized NK Cell Therapy in CBT

AI 简述这是一项II期试验，研究NK-92细胞联合化疗用于急性白血病、慢性粒细胞白血病等。

?

适用疾病: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive；Acute Biphenotypic Leukemia；Acute Lymphoblastic Leukemia
干预: Allogeneic Natural Killer Cell Line NK-92，Anti-Thymocyte Globulin，Busulfan，Clofarabine
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT02781883 / NCI-2016-00884

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

AI 简述这是一项II期试验，研究BP1001联合Venetoclax和Decitabine用于急性髓系白血病和骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia (AML)；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)
干预: BP1001 in combination with Ventoclax plus decitabine，BP1001 plus decitabine
地点: United States
申办方: Bio-Path Holdings, Inc.

正在招募 Phase 2 生物制剂药物其他

ClinicalTrials.gov / NCI NCT02877303 / NCI-2017-00596

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

AI 简述这是一项II期试验，在美国开展，研究Blinatumomab、Inotuzumab Ozogamicin联合化疗用于B急性淋巴细胞白血病、B淋巴母细胞淋巴瘤等。

?

适用疾病: B Acute Lymphoblastic Leukemia；B Lymphoblastic Lymphoma；Double-Hit Lymphoma
干预: Blinatumomab，Cyclophosphamide，Cytarabine，Dexamethasone
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT02981628 / NCI-2016-01494

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

AI 简述这是一项II期试验，研究Inotuzumab Ozogamicin用于复发难治CD22阳性B急性淋巴细胞白血病或B淋巴母细胞淋巴瘤年轻患者。

?

适用疾病: Recurrent B Acute Lymphoblastic Leukemia；Recurrent B Lymphoblastic Lymphoma；Refractory B Acute Lymphoblastic Leukemia
干预: Asparaginase Erwinia chrysanthemi，Biospecimen Collection，Bone Marrow Aspiration and Biopsy，Calaspargase Pegol
地点: United States，Puerto Rico
申办方: Children's Oncology Group

正在招募 Phase 1, Phase 2 生物制剂药物其他

ClinicalTrials.gov / NCI NCT03013998 / NCI-2017-00278

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

AI 简述这是一项I/II期试验，基于生物标志物选择治疗用于急性髓系白血病或骨髓增生异常综合征。

?

适用疾病: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)
干预: Samalizumab (BAML-16-001-S1)，BI 836858 (BAML-16-001-S2)，Laboratory Biomarker Analysis，Daunorubicin (BAML-16-001-S1)
地点: United States
申办方: Beat AML, LLC

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT03104491 / NCI-2017-00826

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

AI 简述这是一项I/II期试验，研究Inotuzumab Ozogamicin用于移植后急性淋巴细胞白血病。

?

适用疾病: Acute Lymphocytic Leukemia；Recurrent Ph-Like Acute Lymphoblastic Leukemia；Refractory Ph-Like Acute Lymphoblastic Leukemia
干预: Inotuzumab Ozogamicin
地点: United States
申办方: Leland Metheny

正在招募 Phase 1, Phase 2 药物手术/操作放疗

ClinicalTrials.gov / NCI NCT03128034 / NCI-2017-00452

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

AI 简述这是一项I/II期试验，研究211^At-BC8-B10前后供体干细胞移植用于高危急性白血病或骨髓增生异常综合征，在美国开展。

?

适用疾病: Acute Lymphoblastic Leukemia；Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome；Acute Myeloid Leukemia
干预: Cyclosporine，Fludarabine Phosphate，Mycophenolate Mofetil，Peripheral Blood Stem Cell Transplantation
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT03128879

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

AI 简述这是一项II期试验，研究Venetoclax联合Ibrutinib或Acalabrutinib用于高危慢性淋巴细胞白血病，在美国开展。

?

适用疾病: Chronic Lymphocytic Leukemia
干预: Ibrutinib，Venetoclax，Acalabrutinib
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT03136146 / NCI-2018-01198

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

AI 简述这是一项II期试验，研究联合化疗用于复发难治性急性淋巴细胞白血病、淋巴母细胞淋巴瘤、伯基特淋巴瘤/白血病，在美国开展。

?

适用疾病: Recurrent Acute Lymphoblastic Leukemia；Recurrent Adult Lymphoblastic Lymphoma；Recurrent Burkitt Leukemia
干预: Bortezomib，Clofarabine，Cyclophosphamide，Dexamethasone
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT03214562 / NCI-2018-01119

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

AI 简述这是一项I/II期试验，研究维奈托克联合化疗用于新诊断或复发难治性急性髓系白血病。

?

适用疾病: High Risk Myelodysplastic Syndrome；Recurrent Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia
干预: Cytarabine，Filgrastim，Fludarabine，Idarubicin
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT03263572 / NCI-2018-01078

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

AI 简述这是一项II期试验，研究Blinatumomab、甲氨蝶呤、阿糖胞苷、Ponatinib用于费城染色体阳性急性淋巴细胞白血病。

?

适用疾病: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive；Acute Lymphoblastic Leukemia；BCR-ABL1 Fusion Protein Expression
干预: Blinatumomab，Cytarabine，Methotrexate，Ponatinib
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT03314974 / NCI-2017-02310

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

AI 简述一项II期试验，研究清髓性异基因造血干细胞移植用于急性白血病、淋巴瘤等血液疾病。

?

适用疾病: Acute Leukemia；Acute Myeloid Leukemia；Acute Lymphoblastic Leukemia
干预: HSCT with TBI Regimen，HSCT with Non-TBI Regimen
地点: United States
申办方: Masonic Cancer Center, University of Minnesota

正在招募 Phase 2 药物其他

ClinicalTrials.gov / NCI NCT03383575 / NCI-2018-00987

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

AI 简述一项II期试验，研究Azacitidine联合Enasidenib用于IDH2突变骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia；Blasts 20-30 Percent of Bone Marrow Nucleated Cells；Chronic Myelomonocytic Leukemia
干预: Azacitidine，Enasidenib，Quality-of-Life Assessment
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT03471260 / NCI-2018-00921

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

AI 简述这是一项I/II期试验，研究Ivosidenib和Venetoclax联合或不联合阿扎胞苷用于IDH1突变血液恶性肿瘤。

?

适用疾病: Acute Myeloid Leukemia；Hematopoietic and Lymphoid System Neoplasm；Myelodysplastic Syndrome
干预: Azacitidine，Ivosidenib，Venetoclax
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 诊断检测药物

ClinicalTrials.gov / NCI NCT03509961 / NCI-2020-06314

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

AI 简述这是一项II期试验，研究NGS-MRD阴性B-ALL儿童及青年中消除全身照射的清髓性异基因移植。在美国开展。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia；T cell acute lymphoblastic leukemia；Mixed Phenotype Acute Leukemia
干预: NGS-MRD，Myeloablative allogeneic HCT with a non-TBI conditioning regimen
地点: United States
申办方: Pediatric Transplantation & Cellular Therapy Consortium

正在招募 Phase 2 生物制剂药物其他

ClinicalTrials.gov / NCI NCT03516617 / NCI-2018-00591

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

AI 简述这是一项II期试验，研究Acalabrutinib联合或不联合Obinutuzumab用于早期慢性淋巴细胞白血病。在美国开展。

?

适用疾病: Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma；Chronic Lymphocytic Leukemia (CLL)
干预: Acalabrutinib，Laboratory Biomarker Analysis，Obinutuzumab，Patient Observation
地点: United States
申办方: Mayo Clinic

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT03586609 / NCI-2018-01318

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

AI 简述这是一项II期试验，研究Venetoclax、Cladribine、低剂量阿糖胞苷和Azacitidine用于初治急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia (AML)
干预: Azacitidine，Cladribine，Cytarabine，Venetoclax
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT03590171

International Study for Treatment of High Risk Childhood Relapsed ALL 2010

AI 简述这是一项II期试验，研究Bortezomib联合化疗用于高危复发儿童急性淋巴细胞白血病。

?

适用疾病: Acute Lymphoblastic Leukemia (ALL)
干预: Bortezomib
地点: Australia，Austria，Belgium，Czechia 等 11 个
申办方: Charite University, Berlin, Germany

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT03629171 / NCI-2018-01589

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

AI 简述这是一项II期试验，研究脂质体柔红霉素-阿糖胞苷联合venetoclax用于复发、难治或初治急性髓系白血病。

?

适用疾病: Recurrent Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia (AML)
干预: Liposome-encapsulated Daunorubicin-Cytarabine，Venetoclax
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT03661307 / NCI-2018-01789

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

AI 简述这是一项I/II期试验，研究Quizartinib、地西他滨和Venetoclax用于急性髓系白血病或高危骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndrome；Recurrent Acute Myeloid Leukemia
干预: Decitabine，Quizartinib，Venetoclax
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT03670966 / NCI-2018-01788

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

AI 简述这是一项I/II期试验，研究211At-BC8-B10联合干细胞移植用于复发或难治性高危急性白血病或骨髓增生异常综合征。

?

适用疾病: Acute Lymphoblastic Leukemia in Remission；Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome；Acute Myeloid Leukemia in Remission
干预: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10，Cyclophosphamide，Total-Body Irradiation，Peripheral Blood Stem Cell Transplantation
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov NCT03676504

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

AI 简述这是一项I/II期试验，研究CD19.CAR T细胞用于复发或难治性CD19+淋巴系统疾病。

?

适用疾病: Acute Lymphoblastic Leukemia, Adult；Acute Lymphoblastic Leukemia, Pediatric；Chronic Lymphocytic Leukemia
干预: CD19.CAR T Cells，Fludarabine，Cyclophosphamide
地点: Germany
申办方: University Hospital Heidelberg

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT03683433 / NCI-2018-01919

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

AI 简述这是一项II期试验，研究Enasidenib和阿扎胞苷用于IDH2突变复发或难治性急性髓系白血病。

?

适用疾病: Acute Bilineal Leukemia；Acute Biphenotypic Leukemia；Chronic Myelomonocytic Leukemia
干预: Azacitidine，Enasidenib Mesylate
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT03728335 / NCI-2018-02371

Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

AI 简述一项II期试验，研究Enasidenib维持治疗用于IDH2突变急性髓系白血病移植后，在美国开展。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia (AML)
干预: Enasidenib Mesylate
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 2 药物其他

ClinicalTrials.gov / NCI NCT03737955 / NCI-2018-01613

Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia

AI 简述一项II期试验，研究分次Gemtuzumab Ozogamicin用于急性髓系白血病微小残留病变，在美国开展。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia (AML)
干预: Gemtuzumab Ozogamicin，Quality-of-Life Assessment
地点: United States
申办方: University of Washington

正在招募 Phase 2 药物

ClinicalTrials.gov NCT03739502

A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

AI 简述一项II期随机试验，研究高压氧改善脐血干细胞移植植入用于白血病等，在美国开展。

?

适用疾病: AML；NHL；Hodgkin Disease
干预: Hyperbaric oxygen
地点: United States
申办方: University of Rochester

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT03739814 / NCI-2018-02484

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

AI 简述一项II期试验，研究Inotuzumab Ozogamicin和Blinatumomab用于新诊断或复发/难治CD22阳性B急淋，在美国、波多黎各开展。

?

适用疾病: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative；Recurrent B Acute Lymphoblastic Leukemia；Refractory B Acute Lymphoblastic Leukemia
干预: Biospecimen Collection，Blinatumomab，Bone Marrow Aspiration，Bone Marrow Biopsy
地点: United States，Puerto Rico
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT03765177

CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies

AI 简述这是一项I/II期试验，研究CLIC-1901用于复发/难治CD19阳性血液肿瘤，在加拿大开展。

?

适用疾病: Acute Lymphoblastic Leukemia；Non-Hodgkin's Lymphoma；Chronic Lymphocytic Leukemia
干预: CLIC-1901
地点: Canada
申办方: Ottawa Hospital Research Institute

正在招募 Phase 2 药物手术/操作放疗

ClinicalTrials.gov / NCI NCT03779854 / NCI-2018-01752

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

AI 简述这是一项II期试验，研究去除初始T细胞预防儿童和年轻成人血液肿瘤移植后慢性移植物抗宿主病。

?

适用疾病: Acute Biphenotypic Leukemia；Acute Leukemia；Acute Leukemia of Ambiguous Lineage
干预: Total-Body Irradiation，Thiotepa，Fludarabine，Cyclophosphamide
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT03824483 / NCI-2019-01323

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

AI 简述这是一项II期试验，研究Zanubrutinib、Obinutuzumab和Venetoclax用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Leukemia (SLL)；Mantle Cell Lymphoma
干预: Zanubrutinib，Obinutuzumab，Venetoclax
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT03850574 / NCI-2019-06837

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

AI 简述这是一项I/II期试验，研究Tuspetinib用于复发或难治性急性髓系白血病。

?

适用疾病: Leukemia, Myeloid, Acute；Refractory AML；Relapsed Adult AML
干预: Tuspetinib，Venetoclax Oral Tablet，Azacitidine for Intravenous Infusion
地点: United States，Australia，Germany，New Zealand 等 2 个
申办方: Aptose Biosciences Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT03852407

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

AI 简述这是一项II期试验，在比利时开展，比较Flu-Mel-PTCy与Flu-Mel-ATG预处理方案用于异基因造血干细胞移植。

?

适用疾病: Acute Myeloid Leukemia in Remission；Myelodysplastic Syndromes；Chronic Myeloid Leukemia in Remission
干预: Thymoglobulin，Melphalan，Fludarabine，Cyclophosphamid
地点: Belgium
申办方: University of Liege

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT03934372

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

AI 简述这是一项I/II期试验，研究Ponatinib用于儿童复发难治性白血病、淋巴瘤或实体瘤。

?

适用疾病: Acute Myeloid Leukemia；Accelerated Phase Chronic Myeloid Leukemia；Blast Phase Chronic Myeloid Leukemia
干预: Ponatinib
地点: Belgium，France，Italy，Netherlands 等 3 个
申办方: Incyte Biosciences International Sàrl

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT03938987

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

AI 简述这是一项I/II期试验，研究自体CD19 CAR-T细胞用于复发难治侵袭性淋巴瘤或急性淋巴细胞白血病，在加拿大开展。

?

适用疾病: Relapsed Non Hodgkin Lymphoma；Relapsed Adult ALL；Relapsed Pediatric ALL
干预: autologous CD19-directed chimeric antigen receptor (CAR) T-cells
地点: Canada
申办方: University of Alberta

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT03970096 / NCI-2019-03188

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

AI 简述这是一项II期试验，研究减低移植物抗宿主病的方案用于急性白血病或骨髓增生异常综合征的移植。在美国开展。

?

适用疾病: Acute Leukemia；Acute Lymphoblastic Leukemia；Acute Myeloid Leukemia
干预: Total-Body Irradiation，Thiotepa，Fludarabine，Tacrolimus
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04047641 / NCI-2019-04730

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

AI 简述这是一项I/II期试验，研究Cladribine、Idarubicin、Cytarabine联合Quizartinib用于初诊、复发或难治性急性髓系白血病，在美国开展。

?

适用疾病: Acute Myeloid Leukemia；Blasts 20 Percent or More of Bone Marrow Nucleated Cells；High Risk Myelodysplastic Syndrome
干预: Cladribine，Cytarabine，Idarubicin，Quizartinib
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04049539 / NCI-2019-04724

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

AI 简述这是一项I/II期试验，研究脂质体柔红霉素-阿糖胞苷（Vyxeos）用于诱导后持续疾病的急性髓系白血病，在美国开展。

?

适用疾病: Blasts More Than 5 Percent of Bone Marrow Nucleated Cells；Persistent Disease；Refractory Acute Myeloid Leukemia
干预: Liposome-encapsulated Daunorubicin-Cytarabine
地点: United States
申办方: Ohio State University Comprehensive Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04050280 / NCI-2020-01434

CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

AI 简述这是一项II期试验，研究CLAG-GO（Cladribine、Cytarabine、G-CSF联合Gemtuzumab Ozogamicin）用于持续、复发或难治性急性髓系白血病，在美国开展。

?

适用疾病: Acute Myeloid Leukemia, Adult；Acute Myeloid Leukemia Recurrent；Acute Myeloid Leukemia, Relapsed, Adult
干预: Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO)
地点: United States
申办方: University of Maryland, Baltimore

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04065399 / NCI-2019-07963

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

AI 简述这是一项I/II期试验，研究revumenib用于MLL重排或NPM1突变的白血病。

?

适用疾病: Acute Myeloid Leukemia；Acute Lymphoblastic Leukemia；Mixed Lineage Acute Leukemia
干预: revumenib，cobicistat
地点: United States，Australia，Canada，France 等 7 个
申办方: Syndax Pharmaceuticals

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04068597 / NCI-2022-05781

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

AI 简述这是一项I/II期试验，研究CCS1477用于血液恶性肿瘤，如急性髓系白血病。

?

适用疾病: Haematological Malignancy；Acute Myeloid Leukemia；Non Hodgkin Lymphoma
干预: CCS1477，Pomalidomide，Dexamethasone，Azacitidine
地点: United States，France，Spain，Sweden 等 1 个
申办方: CellCentric Ltd.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04140487 / NCI-2019-04959

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

AI 简述这是一项I/II期试验，研究Azacitidine、Venetoclax和Gilteritinib用于复发/难治FLT3突变急性髓系白血病等，在美国开展。

?

适用疾病: Recurrent Acute Myeloid Leukemia；Recurrent Chronic Myelomonocytic Leukemia；Recurrent Myelodysplastic/Myeloproliferative Neoplasm
干预: Azacitidine，Gilteritinib，Venetoclax
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT04150497 / NCI-2019-07707

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

AI 简述这是一项I/II期试验，研究UCART22用于复发或难治性CD22阳性B细胞急性淋巴细胞白血病。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia；Recurrent B Acute Lymphoblastic Leukemia；Refractory B Acute Lymphoblastic Leukemia
干预: UCART22，CLLS52
地点: United States，France
申办方: Cellectis S.A.

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT04169737 / NCI-2019-06675

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

AI 简述这是一项II期试验，在美国研究Acalabrutinib和Venetoclax联合或不联合Obinutuzumab用于高危复发/难治性慢性淋巴细胞白血病。

?

适用疾病: Recurrent Chronic Lymphocytic Leukemia；Recurrent Small Lymphocytic Lymphoma；Refractory Chronic Lymphocytic Leukemia
干预: Acalabrutinib，Obinutuzumab，Venetoclax
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT04186520

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

AI 简述这是一项I/II期试验，研究CAR-20/19-T细胞用于复发难治B细胞恶性肿瘤。

?

适用疾病: Non Hodgkin Lymphoma (NHL)；Mantle Cell Lymphoma (MCL)；Chronic Lymphocytic Leukemia (CLL)
干预: 8/12-Day Production of Car-T Cells，8/12-Day Production of Cryopreserved Car-T Cells，12-Day Production of Car-T Cells
地点: United States
申办方: Medical College of Wisconsin

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT04195633 / NCI-2019-07697

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

AI 简述这是一项II期试验，研究供体干细胞移植联合Treosulfan、氟达拉滨和全身照射用于血液恶性肿瘤。

?

适用疾病: Acute Leukemia；Acute Lymphoblastic Leukemia；Acute Myeloid Leukemia
干预: Allogeneic Hematopoietic Stem Cell Transplantation，Cyclophosphamide，Cyclosporine，Filgrastim
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT04276870 / NCI-2020-02051

Orphan Indications for CD19 Redirected Autologous T Cells

AI 简述这是一项II期试验，研究CD19靶向自体T细胞用于儿童和年轻成人B细胞急性淋巴细胞白血病。

?

适用疾病: Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL；Infants With Very High Risk KMT2A B-ALL；Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation
干预: Murine CART19
地点: United States
申办方: Stephan Grupp MD PhD

正在招募 Phase 1, Phase 2 药物手术/操作

ClinicalTrials.gov NCT04315324

Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

AI 简述这是一项I/II期试验，研究OBI-3424用于复发性或难治性T细胞急性淋巴细胞白血病或淋巴瘤。

?

适用疾病: Recurrent T Acute Lymphoblastic Leukemia；Refractory T Acute Lymphoblastic Leukemia；Refractory T Lymphoblastic Lymphoma
干预: AKR1C3-activated Prodrug AST-3424，Biopsy Procedure，Biospecimen Collection，Bone Marrow Aspiration
地点: United States
申办方: SWOG Cancer Research Network

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04322383 / NCI-2020-02217

Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

AI 简述这是一项II期试验，研究Binimetinib用于复发/难治性BRAF野生型毛细胞白血病。

?

适用疾病: Hairy Cell Leukemia；Recurrent Hairy Cell Leukemia；Refractory Hairy Cell Leukemia Variant
干预: binimetinib
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT04385290

Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)

AI 简述这是一项I/II期试验，研究Midostaurin联合Gemtuzumab Ozogamicin用于急性髓系白血病，在德国开展。

?

适用疾病: Acute Myeloid Leukemia
干预: MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO，MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO，MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO，MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin
地点: Germany
申办方: Technische Universität Dresden

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04493164 / NCI-2020-05258

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

AI 简述这是一项II期试验，研究CPX-351联合Ivosidenib用于IDH1突变急性髓系白血病或高危骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia With Gene Mutations；Myelodysplastic Syndrome；Myeloproliferative Neoplasm
干预: Ivosidenib，Liposome-encapsulated Daunorubicin-Cytarabine
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04496349 / NCI-2021-07729

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

AI 简述这是一项II期试验，研究APG-115单药或联合APG-2575用于复发/难治性T-PLL和NHL。在美国开展。

?

适用疾病: T-Prolymphocytic Leukemia；Non-Hodgkins Lymphoma；Recurrent T-Cell Prolymphocytic Leukemia
干预: APG-115，APG-2575
地点: United States
申办方: Ascentage Pharma Group Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04523428

REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

AI 简述这是一项2期试验，在比利时、丹麦、荷兰等地研究Venetoclax/Acalabrutinib用于CLL/SLL。

?

适用疾病: CLL/SLL
干预: Venetoclax/Acalabrutinib
地点: Belgium，Denmark，Netherlands
申办方: Stichting Hemato-Oncologie voor Volwassenen Nederland

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04544592 / NCI-2020-08490

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

AI 简述这是一项1/2期试验，在美国研究CD19CAR-T细胞用于儿童B-ALL和B-NHL。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia；B-cell Non Hodgkin Lymphoma；Refractory Transformed Non-Hodgkin Lymphoma
干预: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
地点: United States
申办方: University of Colorado, Denver

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT04546399 / NCI-2020-06813

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

AI 简述这是一项II期试验，研究Blinatumomab联合Nivolumab用于首次复发的B细胞急性淋巴细胞白血病。

?

适用疾病: Down Syndrome；Recurrent B Acute Lymphoblastic Leukemia
干预: 3-Dimensional Conformal Radiation Therapy，Asparaginase Erwinia chrysanthemi，Biospecimen Collection，Blinatumomab
地点: United States，Australia，Canada，Puerto Rico
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04560322

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

AI 简述这是一项II期试验，研究Venetoclax联合Obinutuzumab加或不加Acalabrutinib用于复发/难治性慢性淋巴细胞白血病。

?

适用疾病: Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma
干预: Venetoclax，Obinutuzumab，Acalabrutinib
地点: United States
申办方: Massachusetts General Hospital

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT04581512

Study to Evaluate the Safety and Tolerability of EP0042

AI 简述这是一项I/II期试验，研究EP0042用于急性髓系白血病、慢性粒单核细胞白血病和骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia；Chronic Myelomonocytic Leukemia；Myelodysplastic Syndromes
干预: EP0042，Venetoclax，Azacitidine (AZA)
地点: Australia，Netherlands，United Kingdom
申办方: Ellipses Pharma

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT04644016 / NCI-2020-11789

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

AI 简述这是一项II期试验，研究克拉屈滨、氟达拉滨、白消安、环孢素-A用于儿童和年轻成人血液肿瘤的脐带血移植。

?

适用疾病: AML；ALL；MDS
干预: Clofarabine，Fludarabine，Busulfan，Cyclosporine-A
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04679012 / NCI-2022-05396

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

AI 简述这是一项II期试验，研究Polatuzumab Vedotin联合化疗用于Richter转化。

?

适用疾病: Richter Syndrome；Chronic Lymphocytic Leukemia；Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma
干预: Polatuzumab Vedotin，Rituximab，Etoposide，Prednisone
地点: United States
申办方: Weill Medical College of Cornell University

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04687176

Frontline Oral Arsenic Trioxide for APL

AI 简述这是一项II期试验，研究口服三氧化二砷用于急性早幼粒细胞白血病，在香港、新加坡开展。

?

适用疾病: Acute Promyelocytic Leukemia
干预: Oral Arsenic Trioxide Formulation
地点: Hong Kong，Singapore
申办方: The University of Hong Kong

正在招募 Phase 2 器械药物

ClinicalTrials.gov NCT04746209

Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT

AI 简述这是一项2期试验，研究αβT/B细胞耗竭移植后Blinatumomab用于B细胞急性淋巴细胞白血病。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia；B-cell Childhood Acute Lymphoblastic Leukemia；B-Cell ALL, Childhood
干预: Alpha/Beta T-cell and B-cell depleted HCT，Blinatumomab
地点: United States
申办方: Medical College of Wisconsin

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04747912 / NCI-2021-02767

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

AI 简述这是一项2期试验，研究无化疗方案（Inotuzumab ozogamicin、Dasatinib、地塞米松、甲氨蝶呤）用于Ph+急性淋巴细胞白血病。

?

适用疾病: Lymphoblastic Leukemia；Acute Lymphoblastic Leukemia；ph+ Acute Lymphoblastic Leukemia
干预: Inotuzumab ozogamicin，Dasatinib，Dexamethasone，Methotrexate
地点: United States
申办方: University of Chicago

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04758975

Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)

AI 简述这是一项II期试验，研究Venetoclax、Rituximab与Ibrutinib用于慢性淋巴细胞白血病(CLL)。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)
干预: Venetoclax，Rituximab，Ibrutinib
地点: Italy
申办方: Paolo Ghia

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT04771507

A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)

AI 简述这是一项I/II期试验，在挪威、瑞典开展，研究间歇性Ibrutinib用于慢性淋巴细胞白血病。

?

适用疾病: Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma
干预: Ibrutinib
地点: Norway，Sweden
申办方: Jeanette Lundin

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04774393 / NCI-2021-00893

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

AI 简述这是一项I/II期试验，在地西他滨/西达尿苷联合维奈克拉基础上加用ivosidenib或enasidenib治疗复发或难治性急性髓系白血病，在美国开展。

?

适用疾病: Acute Myeloid Leukemia；Recurrent Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia
干预: Decitabine and Cedazuridine，Enasidenib，Ivosidenib，Venetoclax
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04793919

Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

AI 简述这是一项II期试验，研究Mylotarg、三氧化二砷和全反式维甲酸用于儿童和青少年急性早幼粒细胞白血病。

?

适用疾病: Acute Promyelocytic Leukemia
干预: Mylotarg，Arsenic Trioxide，All-trans retinoic acid
地点: Belgium，Czechia，Denmark，France 等 8 个
申办方: Associazione Italiana Ematologia Oncologia Pediatrica

正在招募 Phase 1, Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT04797767 / NCI-2021-01379

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

AI 简述这是一项I/II期试验，研究Venetoclax联合CLAG-M用于急性髓系白血病和高级别髓系肿瘤。

?

适用疾病: Acute Biphenotypic Leukemia；Acute Myeloid Leukemia；Mixed Phenotype Acute Leukemia
干预: Cladribine，Cytarabine，Mitoxantrone，Recombinant Granulocyte Colony-Stimulating Factor
地点: United States
申办方: University of Washington

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov NCT04836507

Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients

AI 简述这是一项I/II期试验，研究CRC01用于复发难治性大B细胞淋巴瘤和B细胞急性淋巴细胞白血病。

?

适用疾病: Relapsed Large B-cell Lymphoma；Refractory Large B-cell Lymphoma；Diffuse Large B-cell Lymphoma (DLBCL)
干预: CRC01，Fludarabine，Cyclophosphamide
地点: South Korea
申办方: Curocell Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04844528 / NCI-2021-08252

Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers

AI 简述这是一项II期试验，研究烟酰胺用于有非黑色素瘤皮肤癌史的慢性淋巴细胞白血病患者。

?

适用疾病: Chronic Lymphocytic Leukemia；Non-melanoma Skin Cancer (NMSC)；Chronic Lymphocytic Leukemia (CLL)
干预: Nicotinamide，Placebo
地点: United States
申办方: University of Utah

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04895436 / NCI-2022-07602

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

AI 简述这是一项II期试验，研究口服Venetoclax联合静脉Obinutuzumab用于复发性慢性淋巴细胞白血病，在美国、澳大利亚等地开展。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Recurrent Chronic Lymphocytic Leukemia (CLL)
干预: Venetoclax，Obinutuzumab
地点: United States，Australia，Austria，Brazil 等 7 个
申办方: AbbVie

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04905810

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

AI 简述这是一项II期试验，研究Azacitidine或Decitabine联合Venetoclax用于既往去甲基化治疗失败的急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Recurrent Acute Myeloid Leukemia
干预: Azacitidine，Decitabine，Venetoclax
地点: United States
申办方: Brian Jonas

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04908228

Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL

AI 简述这是一项II期试验，研究固定疗程的Ibrutinib联合Obinutuzumab用于初治慢性淋巴细胞白血病。

?

适用疾病: Chronic Lymphocytic Leukemia
干预: Ibrutinib and obinutuzumab
地点: Italy
申办方: Paolo Ghia

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04920968

Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"

AI 简述这是一项II期试验，比较Obinutuzumab与Rituximab用于CD20阳性急性淋巴细胞白血病，在波兰开展。

?

适用疾病: CD20-positive Acute Lymphoblastic Leukemia
干预: Obinutuzumab，Rituximab
地点: Poland
申办方: Maria Sklodowska-Curie National Research Institute of Oncology

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04935684

Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation

AI 简述这是一项II期试验，研究粪便微生物群移植用于异基因干细胞移植后的血液肿瘤。

?

适用疾病: Acute Leukemia in Remission；Myelodysplastic Syndromes；Myeloproliferative Syndrome
干预: Fecal Microbiota Transplantation
地点: France
申办方: University Hospital, Clermont-Ferrand

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT04941716 / NCI-2021-05947

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

AI 简述这是一项II期试验，研究Acalabrutinib联合Venetoclax用于复发难治性慢性淋巴细胞白血病。

?

适用疾病: Recurrent Chronic Lymphocytic Leukemia；Recurrent Small Lymphocytic Lymphoma；Refractory Chronic Lymphocytic Leukemia
干预: Acalabrutinib，Venetoclax，Biospecimen Collection，Bone Marrow Aspiration
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04988555 / NCI-2021-11325

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

AI 简述这是一项I/II期试验，研究Enzomenib用于急性白血病。

?

适用疾病: Leukemia, Myeloid, Acute；Leukemia, Lymphocytic, Acute；Multiple Myeloma
干预: Enzomenib，azoles，Venetoclax，Gilteritinib
地点: United States，Belgium，Canada，France 等 8 个
申办方: Sumitomo Pharma America, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04990102 / NCI-2022-08032

Phase IB/II of CPX-351 for Relapse Prevention in AML

AI 简述这是一项I/II期试验，研究CPX-351用于预防急性髓系白血病复发。

?

适用疾病: Acute Myeloid Leukemia (AML) in Remission；Acute Myeloid Leukemia (AML)
干预: CPX-351
地点: United States
申办方: Georgetown University

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04996875

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

AI 简述这是一项II期试验，研究Bezuclastinib用于晚期系统性肥大细胞增多症，在美国、澳大利亚、奥地利、比利时等地开展。

?

适用疾病: Advanced Systemic Mastocytosis (AdvSM)；SM With an Associated Hematologic Neoplasm (SM-AHN)；Mast Cell Leukemia (MCL)
干预: bezuclastinib
地点: United States，Australia，Austria，Belgium 等 10 个
申办方: Cogent Biosciences, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05010122 / NCI-2021-06095

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

AI 简述这是一项I/II期试验，研究ASTX727、Venetoclax和Gilteritinib用于FLT3突变急性髓系白血病或高危骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndrome；Recurrent Acute Myeloid Leukemia
干预: Decitabine and Cedazuridine，Gilteritinib，Venetoclax
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05025098

Precision Therapy Versus Standard Therapy in AML and MDS in Elderly

AI 简述这是一项II期试验，比较精准治疗与标准治疗用于老年急性髓系白血病和骨髓增生异常综合征，在挪威开展。

?

适用疾病: AML, Adult；MDS
干预: Standard therapy，Precision therapy
地点: Norway
申办方: University Hospital, Akershus

正在招募 Phase 2 药物手术/操作放疗

ClinicalTrials.gov / NCI NCT05031897 / NCI-2021-08882

Two Step Haplo With Radiation Conditioning

AI 简述这是一项II期试验，研究两步半相合移植联合全身照射用于多种血液肿瘤。

?

适用疾病: Acute Lymphoblastic Leukemia；Acute Myeloid Leukemia；Adult T-Cell Leukemia/Lymphoma
干预: Fludarabine，Total-Body Irradiation，Donor Lymphocyte Infusion，Cyclophosphamide
地点: United States
申办方: Thomas Jefferson University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05092451 / NCI-2021-12093

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

AI 简述这是一项I/II期试验，研究CAR.70工程化脐血NK细胞联合化疗用于复发/难治性血液肿瘤。

?

适用疾病: B-Cell Lymphoma；Myelodysplastic Syndromes (MDS)；Acute Myeloid Leukemia (AML)
干预: Cyclophosphamide，CAR.70/IL15-transduced CB-NK cells，Fludarabine phosphate
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05168930 / NCI-2022-02035

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

AI 简述这是一项II期试验，研究Zanubrutinib联合Venetoclax用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤，在美国开展。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma (SLL)；Small Lymphocytic Lymphoma
干预: Venetoclax，Zanubrutinib
地点: United States
申办方: Dana-Farber Cancer Institute

正在招募 Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT05183854 / NCI-2021-13373

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

AI 简述这是一项II期试验，研究肺炎球菌疫苗（PCV20和PPSV23）用于慢性淋巴细胞白血病相关免疫缺陷患者，在美国开展。

?

适用疾病: Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma；Chronic Lymphocytic Leukemia (CLL)
干预: Pneumococcal 20-valent Conjugate Vaccine，Pneumococcal Polyvalent Vaccine
地点: United States
申办方: University of Utah

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05184842 / NCI-2022-08681

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

AI 简述这是一项II期试验，研究低剂量地西他滨和Venetoclax用于骨髓增生异常综合征和急性髓系白血病。

?

适用疾病: Myelodysplastic Syndromes；Acute Myeloid Leukemia；Chronic Myelomonocytic Leukemia
干预: Venetoclax，Decitabine
地点: United States
申办方: Montefiore Medical Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05211570 / NCI-2022-04295

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

AI 简述这是一项I/II期试验，研究AB8939联合维奈克拉用于复发/难治性急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia Refractory；Acute Myeloid Leukemia, in Relapse；Myelodysplastic Syndrome Acute Myeloid Leukemia
干预: AB8939，Venetoclax
地点: United States，France，Greece，Spain
申办方: AB Science

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05260528

CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

AI 简述这是一项II期试验，比较CPX-351与强化化疗用于初治中危或高危急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia
干预: Cytarabine and Idarubicin，CPX-315
地点: France
申办方: Centre Hospitalier Universitaire de Nice

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT05272293

Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML

AI 简述这是一项I/II期试验，研究体外扩增半相合自然杀伤细胞用于儿童和年轻成人急性髓系白血病，在白俄罗斯开展。

?

适用疾病: Acute Myeloid Leukemia
干预: NK cell infusions
地点: Belarus
申办方: Belarusian Research Center for Pediatric Oncology, Hematology and Immunology

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05281809

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

AI 简述这是一项II期试验，研究本地生产的CAR-T细胞用于B细胞淋巴瘤和B急性淋巴细胞白血病，在美国开展。

?

适用疾病: B-Cell Lymphoma；B Acute Lymphoblastic Leukemia；Diffuse Large B Cell Lymphoma
干预: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
地点: United States
申办方: John Lister

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05289687 / NCI-2021-13973

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

AI 简述这是一项II期试验，研究Daratumumab用于化疗难治性微小残留病灶阳性的T细胞急性淋巴细胞白血病。

?

适用疾病: T-cell Acute Lymphoblastic Leukemia；Recurrent T Acute Lymphoblastic Leukemia；Refractory T Acute Lymphoblastic Leukemia
干预: Daratumumab / Hyaluronidase Injection
地点: United States
申办方: Eastern Cooperative Oncology Group

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05310591

Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence

AI 简述这是一项1/2期试验，在法国研究Nivolumab联合Tisagenlecleucel用于急性淋巴细胞白血病儿童和青少年。

?

适用疾病: B Acute Lymphoblastic Leukemia；Acute Lymphoblastic Leukemia, in Relapse
干预: Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) )，Nivolumab starting at day -1
地点: France
申办方: Assistance Publique - Hôpitaux de Paris

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT05334693

Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML

AI 简述这是一项I/II期试验，研究扩增单倍体NK细胞作为儿童/年轻成人AML的巩固治疗。在白俄罗斯开展。

?

适用疾病: Acute Myeloid Leukemia
干预: Expanded haploidentical NK cells
地点: Belarus
申办方: Belarusian Research Center for Pediatric Oncology, Hematology and Immunology

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT05336812 / NCI-2022-01752

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

AI 简述这是一项II期试验，研究Acalabrutinib联合Venetoclax或Obinutuzumab用于初治慢性淋巴细胞白血病。在美国开展。

?

适用疾病: Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma；Chronic Lymphocytic Leukemia (CLL)
干预: Acalabrutinib，Obinutuzumab，Venetoclax
地点: United States
申办方: Ohio State University Comprehensive Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05360160 / NCI-2022-03312

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

AI 简述这是一项I/II期试验，研究SNDX-5613联合ASTX727和Venetoclax用于急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia (AML)；Recurrent Mixed Phenotype Acute Leukemia
干预: SNDX-5613，Venetoclax，ASTX727
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT05366218

Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia

AI 简述这是一项I/II期试验，研究Tafasitamab用于复发或难治性儿童B系急性淋巴细胞白血病，在德国开展。

?

适用疾病: ALL, Childhood B-Cell；Acute Lymphoid Leukemia Relapse；Acute Lymphocytic Leukemia Refractory
干预: Tafasitamab
地点: Germany
申办方: University Hospital Tuebingen

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05388006 / NCI-2022-02068

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

AI 简述这是一项II期试验，研究Acalabrutinib、Venetoclax和Durvalumab用于Richter转化。

?

适用疾病: Chronic Lymphocytic Leukemia；Richter Syndrome；Small Lymphocytic Lymphoma
干预: Acalabrutinib，Durvalumab，Venetoclax，Biospecimen Collection
地点: United States
申办方: Mayo Clinic

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT05401097 / NCI-2022-01324

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

AI 简述这是一项II期试验，比较IDH靶向与非靶向方案用于初治IDH突变型AML且不耐受强化诱导治疗的患者。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia (AML)
干预: Azacitidine，Biopsy，Enasidenib，Ivosidenib
地点: United States
申办方: Alice Mims

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05431257

Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling

AI 简述这是一项II期试验，研究阿扎胞苷联合低剂量Venetoclax用于急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia
干预: Venetoclax
地点: Denmark
申办方: Rigshospitalet, Denmark

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05442216 / NCI-2022-07526

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

AI 简述这是一项II期试验，研究Tagraxofusp联合阿扎胞苷与维奈克拉用于新诊断的继发性急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Secondary Acute Myeloid Leukemia (AML)
干预: Tagraxofusp，Azacitidine，Venetoclax
地点: United States
申办方: Joshua Zeidner

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT05442515 / NCI-2022-05683

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

AI 简述这是一项I/II期试验，研究CD19/CD22双顺反子CAR-T细胞用于儿童和年轻成人复发/难治性B细胞恶性肿瘤。

?

适用疾病: B-NHL；B-Non Hodgkin Lymphoma；Acute Lymphocytic Leukemia
干预: CD19/CD22-CAR-transduced T cells，cyclophosphamide，fludarabine
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT05480449 / NCI-2023-06713

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

AI 简述这是一项1/2期试验，研究自体huCART19 T细胞用于儿童B细胞急性淋巴细胞白血病，在美国开展。

?

适用疾病: B Cell Acute Lymphoblastic Leukemia (B-ALL)；B Lineage Lymphoblastic Lymphoma；B Acute Lymphoblastic Leukemia
干预: Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)
地点: United States
申办方: Stephan Grupp MD PhD

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT05503134 / NCI-2024-05356

Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML

AI 简述这是一项I/II期试验，研究通用供体自然杀伤细胞用于复发/难治性急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)
干预: Universal Donor Natural Killer Cells
地点: United States
申办方: Nationwide Children's Hospital

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05536349 / NCI-2022-07625

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

AI 简述这是一项II期试验，研究Pirtobrutinib、Venetoclax和Obinutuzumab三药联合用于初治慢性淋巴细胞白血病或Richter转化。

?

适用疾病: Leukemia；Recurrent Transformed Chronic Lymphocytic Leukemia；Refractory Transformed Chronic Lymphocytic Leukemia
干预: Pirtobrutinib，Obinutuzumab，Venetoclax，Valacyclovir
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT05554393 / NCI-2022-07534

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

AI 简述这是一项II期试验，比较三种化疗方案用于中危急性髓系白血病年轻患者，在美加等地开展。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia (AML)
干预: Azacitidine，Biospecimen Collection，Bone Marrow Aspiration，Cytarabine
地点: United States，Canada，Puerto Rico
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT05554406 / NCI-2022-07535

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

AI 简述这是一项II期试验，研究新药用于新诊断高危急性髓系白血病，在美加等地开展。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm；Acute Myeloid Leukemia Post Cytotoxic Therapy
干预: Azacitidine，Biospecimen Collection，Bone Marrow Aspiration，Cytarabine
地点: United States，Canada，Puerto Rico
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05580601

Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)

AI 简述这是一项1/2期试验，研究CIML-NK细胞用于复发难治性急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia
干预: CIML-NK Cells
地点: United States
申办方: Children's Hospital Medical Center, Cincinnati

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05580861

Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment

AI 简述这是一项1/2期试验，研究柳氮磺吡啶用于接受强化疗的老年急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia
干预: Sulfasalazine
地点: France
申办方: Assistance Publique - Hôpitaux de Paris

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05601726

First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients

AI 简述这是一项I/II期试验，首次研究ABD-3001用于复发难治急性髓系白血病和高风险骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia, Adult；Myelodysplastic Syndromes
干预: ABD-3001，ABD-3001
地点: France
申办方: Advanced BioDesign

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT05643742

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

AI 简述这是一项I/II期试验，研究CTX112用于复发或难治性B细胞恶性肿瘤，在美国和澳大利亚开展。

?

适用疾病: B-cell Lymphoma；Non-Hodgkin Lymphoma；B-cell Malignancy
干预: CTX112
地点: United States，Australia
申办方: CRISPR Therapeutics AG

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05645718 / NCI-2022-10168

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

AI 简述这是一项II期试验，研究mini-Hyper-CVD联合利妥昔单抗、伊珠单抗奥佐米星和博纳吐单抗用于儿童复发/难治性B细胞急性淋巴细胞白血病，在美国开展。

?

适用疾病: Leukemia；Recurrent B Acute Lymphoblastic Leukemia；Refractory B Acute Lymphoblastic Leukemia
干预: Cyclophosphamide，Vincristine，Blinatumomab，Methotrexate
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 生物制剂

ClinicalTrials.gov NCT05648019

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

AI 简述这是一项II期试验，研究CD19导向的嵌合抗原受体T细胞疗法用于复发/难治性B细胞白血病/淋巴瘤，在新加坡开展。

?

适用疾病: Lymphoblastic Leukemia；Lymphoblastic Leukemia in Children；Lymphoblastic Leukemia, Acute Adult
干预: Anti-CD19 CAR T-cells
地点: Singapore
申办方: KK Women's and Children's Hospital

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05658640

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

AI 简述这是一项I/II期试验，研究Trametinib联合地塞米松和化疗用于儿童复发/难治性血液肿瘤。

?

适用疾病: Acute Lymphoblastic Leukemia, in Relapse；Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent；Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
干预: Trametinib，Dexamethasone，Cyclophosphamide，Cytarabine
地点: Austria，Belgium，Denmark，Finland 等 11 个
申办方: Princess Maxima Center for Pediatric Oncology

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT05674175 / NCI-2023-06711

Co-administration of CART22-65s and huCART19 for B-ALL

AI 简述这是一项I/II期试验，联合使用CART22-65s和huCART19用于B细胞急性淋巴细胞白血病。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia；B Lineage Lymphoblastic Lymphoma；B Acute Lymphoblastic Leukemia
干预: Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)，Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
地点: United States
申办方: Stephan Grupp MD PhD

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05694312

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

AI 简述这是一项II期试验，研究Ibrutinib用于CLL/SLL相关自身免疫性溶血性贫血，在意大利开展。

?

适用疾病: Autoimmune Hemolytic Anemia；Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma
干预: Ibrutinib 420 mg
地点: Italy
申办方: Gruppo Italiano Malattie EMatologiche dell'Adulto

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT05702853 / NCI-2023-10201

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

AI 简述这是一项I/II期试验，在美国研究代谢优化的CD19 CAR-T细胞治疗用于复发/难治B细胞淋巴瘤。

?

适用疾病: B-cell Non Hodgkin Lymphoma；Chronic Lymphocytic Leukemia；Recurrent Waldenstrom Macroglobulinemia
干预: Cyclophosphamide injection，Fludarabine Injection，CD19-CD34t metabolically programmed CAR transduced T-cells
地点: United States
申办方: Medical University of South Carolina

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05732103 / NCI-2023-02412

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

AI 简述这是一项1/2期试验，研究CTX-712用于复发/难治性急性髓系白血病和骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndromes；Refractory Acute Myeloid Leukemia (AML)
干预: CTX-712
地点: United States
申办方: Chordia Therapeutics, Inc.

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT05735717 / NCI-2023-05517

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

AI 简述这是一项2期试验，研究TCRα/β去除的PBSC移植用于血液恶性肿瘤。

?

适用疾病: Hematologic Malignancy；Acute Leukemia；Remission
干预: Fludarabine，Busulfan，Melphalan，Rituximab
地点: United States
申办方: Masonic Cancer Center, University of Minnesota

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05745714

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

AI 简述这是一项I/II期试验，研究芦可替尼联合维奈托克、地塞米松、环磷酰胺和阿糖胞苷用于复发难治性儿童血液恶性肿瘤。

?

适用疾病: Acute Lymphoblastic Leukemia, in Relapse；Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent；Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
干预: Ruxolitinib，Venetoclax，Dexamethasone，Cyclophosphamide
地点: Austria，Belgium，Denmark，Finland 等 10 个
申办方: Princess Maxima Center for Pediatric Oncology

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05748171

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

AI 简述这是一项II期试验，研究Inotuzumab ozogamicin用于儿童首次复发急性淋巴细胞白血病。

?

适用疾病: ACUTE LYMPHOBLASTIC LEUKEMIA
干预: Inotuzumab ozogamicin，ALLR3
地点: Austria，Belgium，Czechia，Denmark 等 12 个
申办方: Pfizer

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05751044

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

AI 简述这是一项I/II期试验，研究Dasatinib等药物用于儿童复发难治血液肿瘤。

?

适用疾病: Acute Lymphoblastic Leukemia；Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent；Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
干预: Dasatinib，Venetoclax，Dexamethasone，Cyclophosphamide
地点: Austria，Belgium，Denmark，Finland 等 10 个
申办方: Princess Maxima Center for Pediatric Oncology

正在招募 Phase 2 药物其他

ClinicalTrials.gov NCT05788679

A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS

AI 简述这是一项II期试验，研究基于MRD调整移植后治疗用于骨髓增生异常综合征。在瑞典开展。

?

适用疾病: Myelodysplastic Syndromes；Acute Myeloid Leukemia With Myelodysplasia Related Disease and < 30% Blasts；Mixed Myelodysplastic/Myeloproliferative Disease
干预: Azacitidine，Donor lymphocytes，Tapering of immune suppression
地点: Sweden
申办方: Karolinska University Hospital

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05791409

Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

AI 简述这是一项I/II期试验，研究Venetoclax联合Epcoritamab用于复发难治性CLL或SLL。

?

适用疾病: CLL/SLL
干预: Epcoritamab，Venetoclax
地点: Belgium，Denmark，Germany，Netherlands
申办方: Stichting Hemato-Oncologie voor Volwassenen Nederland

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05796570 / NCI-2023-03484

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

AI 简述这是一项II期试验，研究地西他滨联合非格司亭用于儿童和年轻成人造血干细胞移植后预防白血病。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndromes；Myeloid Malignancies
干预: Decitabine，Filgrastim
地点: United States
申办方: Franziska Wachter

正在招募 Phase 2 生物制剂药物放疗

ClinicalTrials.gov NCT05805605

Allo HSCT Using RIC and PTCy for Hematological Diseases

AI 简述这是一项II期试验，研究减低强度预处理和移植后环磷酰胺用于异基因造血干细胞移植治疗血液病。

?

适用疾病: Acute Myelogenous Leukemia；Acute Lymphocytic Leukemia；Biphenotypic Acute Leukemia
干预: Peripheral Blood Stem Cell Transplant，Allopurinol 300 MG，Fludarabine，Cyclophosphamide
地点: United States
申办方: Masonic Cancer Center, University of Minnesota

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05807932

Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML

AI 简述这是一项I/II期试验，研究Venetoclax加入预处理方案用于MDS、CMML或sAML的移植。

?

适用疾病: Myelodysplastic Syndromes；Secondary Acute Myeloid Leukemia；Chronic Myelomonocytic Leukemia
干预: Venetoclax，Amsacrine，Ara-C，Tacrolimus
地点: Germany
申办方: Heinrich-Heine University, Duesseldorf

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT05827549

Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia

AI 简述这是一项II期试验，研究基于风险组的再诱导化疗用于复发性儿童急性淋巴细胞白血病。

?

适用疾病: Acute Lymphoid Leukemia
干预: Reinduction(4weeks)，Cosolodation 1st(3weeks)，Consolidation 2nd(3weeks)，Blinatumomab 1st(High Risk Group)_4 Weeks
地点: South Korea
申办方: Ho Joon Im

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05848687 / NCI-2023-04129

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

AI 简述这是一项I/II期试验，在美国和加拿大开展，研究地塞米松等多种药物用于婴儿急性淋巴细胞白血病。

?

适用疾病: Lymphoblastic Leukemia；Infant Acute Lymphoblastic Leukemia；Acute Undifferentiated Leukemia
干预: Dexamethasone，Mitoxantrone，PEG asparaginase，Bortezomib
地点: United States，Canada
申办方: Tanja Andrea Gruber

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT05869279

Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia

AI 简述这是一项I/II期试验，研究异体CARCIK-CD19用于B细胞非霍奇金淋巴瘤或慢性淋巴细胞白血病。

?

适用疾病: B-cell NHL；CLL
干预: CARCIK-CD19
地点: Italy
申办方: Fondazione Matilde Tettamanti Menotti De Marchi Onlus

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05873712 / NCI-2023-03669

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

AI 简述这是一项II期试验，研究Zanubrutinib联合Lisocabtagene Maraleucel用于Richter综合征，在美国开展。

?

适用疾病: Recurrent Transformed Chronic Lymphocytic Leukemia；Refractory Transformed Chronic Lymphocytic Leukemia；Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma
干预: Biospecimen Collection，Bone Marrow Biopsy，Computed Tomography，Cyclophosphamide
地点: United States
申办方: Aseel Alsouqi

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT05884333 / NCI-2023-04726

Cord Blood Transplant in Adults With Blood Cancers

AI 简述这是一项II期试验，研究脐血移植用于成人血液肿瘤，在美国开展。

?

适用疾病: Acute Myelogenous Leukemia (AML)；Acute Lymphoblastic Leukemia (ALL)；Chronic Myelogenous Leukemia (CML)
干预: Conditioning Chemotherapy，Cord blood graft
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05904106

Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML

AI 简述这是一项II期试验，在德国比较Venetoclax联合Azacitidine与化疗用于新诊断NPM1突变AML。

?

适用疾病: Acute Myeloid Leukemia
干预: Venetoclax plus Azacitidine，standard of care chemotherapy plus gemtuzumab ozogamicin
地点: Germany
申办方: Technische Universität Dresden

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05908409

A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

AI 简述这是一项I/II期试验，在西班牙研究IDP-121用于复发/难治血液恶性肿瘤。

?

适用疾病: Multiple Myeloma (MM)；Diffuse Large B-Cell Lymphoma, Not Otherwise Specified；Double Hit Lymphoma
干预: IDP-121
地点: Spain
申办方: IDP Discovery Pharma S.L.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05909059

CAR T-cell Therapy in Patients With Renal Dysfunction

AI 简述这是一项II期试验，在美国研究CAR-T细胞治疗用于肾功能不全的血液肿瘤。

?

适用疾病: Non-hodgkin Lymphoma,B Cell；Multiple Myeloma；Acute Lymphoblastic Leukemia, Adult
干预: Fludarabine，Cyclophosphamide
地点: United States
申办方: Northside Hospital, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05917405

Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT

AI 简述这是一项II期试验，在法国开展，比较Clofarabine与Fludarabine两种降低强度预处理方案用于缓解期急性髓系白血病成人患者。

?

适用疾病: Acute Myeloid Leukemia in Remission
干预: Fludarabine，Busulfan，ATG，Clofarabine
地点: France
申办方: Nantes University Hospital

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05963074 / NCI-2024-08945

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

AI 简述这是一项II期试验，研究Ibrutinib联合Venetoclax用于既往未治疗的慢性淋巴细胞白血病。

?

适用疾病: Leukemia, Lymphocytic, Chronic, B-Cell；Small Lymphocytic Lymphoma；Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
干预: Ibrutinib，Venetoclax
地点: United States，Canada，Czechia，France 等 4 个
申办方: Janssen Research & Development, LLC

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06014489

A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML

AI 简述这是一项II期试验，研究Cobicistat增强Venetoclax联合阿扎胞苷用于新诊断的急性髓系白血病成人患者。

?

适用疾病: AML, Adult
干预: azacitidine，Venetoclax，Cobicistat
地点: Netherlands
申办方: Stichting Hemato-Oncologie voor Volwassenen Nederland

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06022003

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

AI 简述这是一项II期试验，研究口服阿扎胞苷联合吉瑞替尼用于复发难治性FLT3突变急性髓系白血病。

?

适用疾病: AML, Adult；Refractory AML；Relapsed Adult AML
干预: AzaCITIDine Oral Tablet，Xospata
地点: France
申办方: French Innovative Leukemia Organisation

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06034561

Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia

AI 简述这是一项II期试验，研究Bortezomib方案用于复发性或难治性急性淋巴细胞白血病。

?

适用疾病: Acute Lymphoblastic Leukemia, in Relapse；Acute Lymphoblastic Leukemia With Failed Remission
干预: Bortezomib
地点: Brazil
申办方: Instituto do Cancer do Estado de São Paulo

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06043674 / NCI-2023-09314

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

AI 简述这是一项II期试验，研究Glofitamab单药或联合Polatuzumab Vedotin等用于Richter转化。在美国开展。

?

适用疾病: Chronic Lymphocytic Leukemia；Richter's Transformation；Recurrent Transformed Chronic Lymphocytic Leukemia
干预: Glofitamab，Obinutuzumab，Polatuzumab Vedotin，Atezolizumab
地点: United States
申办方: Christine Ryan

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06055621

Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE

AI 简述这是一项2期试验，研究达沙替尼单药用于对维奈克拉-阿扎胞苷耐药的急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia
干预: Dasatinib
地点: France
申办方: Institut Paoli-Calmettes

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov NCT06059391

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

AI 简述这是一项2期试验，研究CMV-MVA Triplex疫苗接种于HLA匹配的干细胞供者以预防移植后CMV感染。

?

适用疾病: Acute Lymphoblastic Leukemia；Acute Myeloid Leukemia；Chronic Lymphocytic Leukemia
干预: Allogeneic Hematopoietic Stem Cell Transplantation，Biospecimen Collection，Granulocyte Colony-Stimulating Factor，Hematopoietic Cell Transplantation Conditioning Regimen
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 2 药物其他

ClinicalTrials.gov NCT06061094

Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT

AI 简述这是一项2期试验，比较伊马替尼、普纳替尼、博纳吐单抗及化疗联合移植用于PH阳性急性淋巴细胞白血病。

?

适用疾病: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
干预: Imatinib，Ponatinib，Blinatumomab，Indication for stem cell transplantation
地点: Germany
申办方: Goethe University

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT06064903

CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL

AI 简述这是一项I/II期试验，研究CD7-CART01用于儿童复发难治CD7+ T细胞急性淋巴细胞白血病/淋巴瘤。在意大利开展。

?

适用疾病: T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
干预: CD7-CART01
地点: Italy
申办方: Bambino Gesù Hospital and Research Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06099366

Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children

AI 简述这是一项II期试验，在韩国研究多种化疗药物组合用于新诊断标危儿童急性淋巴细胞白血病。

?

适用疾病: Lymphoblastic Leukemia in Children
干预: induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate，Consolidation: Vincristine, Mecaptopurine, Intrathecal Methotrexate，Consolidation: Vincristine, Mecaptopurine, Cyclophosphamide, Cytarabine, L-asparaginase, Intrathecal Methotrexate，Interim Maintenance(IM): Vincristine, Methotrexate, Intrathecal Methotrexate
地点: South Korea
申办方: Hee Young Ju

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT06101381

CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma

AI 简述这是一项I/II期试验，在巴西研究CD19靶向CAR-T细胞疗法用于复发/难治性急性淋巴细胞白血病和非霍奇金淋巴瘤。

?

适用疾病: Leukemia, Acute Lymphoblastic；Lymphoma, Non-Hodgkin
干预: CART-19
地点: Brazil
申办方: University of Sao Paulo

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06124157 / NCI-2023-09214

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

AI 简述这是一项II期试验，研究达沙替尼或伊马替尼联合化疗和博纳吐单抗用于儿童和青少年Ph+或Ph样B细胞急性淋巴细胞白血病。

?

适用疾病: B Acute Lymphoblastic Leukemia
干预: Biospecimen Collection，Blinatumomab，Bone Marrow Biopsy，Calaspargase Pegol
地点: United States，Australia，Canada，Puerto Rico
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06129734 / NCI-2023-10665

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

AI 简述这是一项1/2期试验，研究地西他滨和维奈克拉维持治疗用于异基因移植后髓系恶性肿瘤。

?

适用疾病: Myeloid Malignancy；Acute Myeloid Leukemia；Acute Myeloid Leukemia (AML)
干预: Venetoclax，Decitabine
地点: United States
申办方: Benjamin Tomlinson

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06144606 / NCI-2023-10203

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

AI 简述这是一项II期试验，研究Tecartus用于微小残留病阳性的B细胞急性淋巴细胞白血病。

?

适用疾病: B-Cell Lymphoblastic Leukemia；Acute Lymphoblastic Leukemia；B Acute Lymphoblastic Leukemia
干预: Tecartus
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 1, Phase 2 生物制剂器械药物

ClinicalTrials.gov / NCI NCT06158828 / NCI-2024-02840

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

AI 简述这是一项I/II期试验，研究记忆样自然杀伤细胞用于TCRαβ T细胞去除后的半相合移植治疗急性髓系白血病，在美国开展。

?

适用疾病: AML, Childhood；Aml；Acute Myeloid Leukemia, Pediatric
干预: Rabbit Anti thymocyte globulin，Busulfan，Fludarabine，Thiotepa
地点: United States
申办方: Washington University School of Medicine

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06184009

Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia

AI 简述这是一项II期试验，在韩国开展，治疗新诊断高危儿童急性淋巴细胞白血病。

?

适用疾病: Pediatric Acute Lymphoblastic Leukemia
干预: ALL, High risk
地点: South Korea
申办方: Jae Wook Lee

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06191263

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

AI 简述这是一项II期试验，研究RVU120联合Venetoclax用于复发/难治性急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia
干预: RVU120，Venetoclax
地点: France，Italy，Poland，Spain
申办方: Ryvu Therapeutics SA

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06199557

A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients

AI 简述这是一项I/II期试验，研究羟基脲联合丙戊酸或6-巯基嘌呤联合丙戊酸用于不适合化疗的急性髓系白血病或高危骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia, Adult；Myelodysplastic Syndromes, Adult
干预: Hydroxyurea, Hydroxycarbamide，Valproic acid，6-Mercaptopurine (6-MP)
地点: Norway
申办方: Haukeland University Hospital

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06207123 / NCI-2024-08920

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

AI 简述这是一项1/2期试验，研究LP-118联合Ponatinib、Vincristine和Dexamethasone用于复发/难治性急性淋巴细胞白血病或淋巴母细胞淋巴瘤。

?

适用疾病: Acute Leukemia；Lymphoblastic Leukemia；Lymphoblastic Lymphoma
干预: LP-118，Ponatinib，Vincristine，Dexamethasone
地点: United States
申办方: University of Chicago

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06232655

Cladribine Venetoclax in Monocytic AML

AI 简述这是一项II期试验，研究Cladribine和Venetoclax用于单核细胞性急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia
干预: Cladribine，Venetoclax，Azacitidine
地点: United States
申办方: University of Colorado, Denver

正在招募 Phase 2 基因治疗

ClinicalTrials.gov NCT06247501

Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell Transplantation

AI 简述这是一项II期试验，在韩国研究SNUH-CD19-CAR-T细胞用于适合造血干细胞移植的儿童B细胞急性淋巴细胞白血病。

?

适用疾病: Very High Risk Acute Lymphoblastic Leukemia；CD19 CAR-T Therapy
干预: SNUH-CD19-CAR-T
地点: South Korea
申办方: Seoul National University Hospital

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06257394

Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea

AI 简述这是一项II期试验，在韩国研究達沙替尼用于儿童极高危急性淋巴细胞白血病。

?

适用疾病: Acute Lymphoblastic Leukemia, Pediatric
干预: Dasatinib(Sprycel) arm，Non-Dasatinib(Sprycel) arm
地点: South Korea
申办方: Hyoung Jin Kang

正在招募 Phase 2 药物其他

ClinicalTrials.gov NCT06262438

CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients

AI 简述这是一项II期试验，在荷兰研究Quizartinib联合化疗用于FLT3-ITD阳性儿童急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia in Children
干预: Quizartinib，Etoposide，Dexrazoxane，Mitoxantrone
地点: Netherlands
申办方: Princess Maxima Center for Pediatric Oncology

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06284486 / NCI-2024-01721

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

AI 简述这是一项I/II期试验，研究Venetoclax联合Revumenib用于急性髓系白血病微小残留病。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia (AML)
干预: Venetoclax，Revumenib
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06287229 / NCI-2024-01756

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

AI 简述这是一项I/II期试验，研究Brexucabtagene Autoleucel用于复发/难治和新诊断B细胞急性淋巴细胞白血病。

?

适用疾病: Relapsed/Refractory；B-cell Acute Lymphocytic Leukemia；B Acute Lymphoblastic Leukemia, BCR-ABL1-Like
干预: Blinatumomab，Inotuzumab Ozogamicin，Hyper-CVAD，Mini-hyper-CVD
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 4 药物

ClinicalTrials.gov / NCI NCT06289673 / NCI-2024-01659

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

AI 简述这是一项IV期试验，在新诊断的急性淋巴细胞白血病/淋巴瘤中确定诱导治疗必需信息。

?

适用疾病: Acute Lymphoblastic Leukemia；Lymphoblastic Lymphoma；Mixed Phenotype Acute Leukemia
干预: Dexamethasone，Vincristine，Daunorubicin，Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)
地点: United States
申办方: St. Jude Children's Research Hospital

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06308588 / NCI-2024-02121

Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

AI 简述这是一项I/II期试验，在美国开展，研究Blinatumomab联合Asciminib用于费城染色体阳性急性淋巴细胞白血病。

?

适用疾病: Philadelphia Chromosome-Positive；Acute Lymphoblastic Leukemia；Recurrent B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1
干预: Blinatumomab，Asciminib
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT06317649 / NCI-2024-01987

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

AI 简述一项II期试验，研究Venetoclax联合HMA治疗不适合强化化疗的FLT3突变急性髓系白血病，在美国、波多黎各开展。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia (AML)
干预: Azacitidine，Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy
地点: United States，Puerto Rico
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06317662 / NCI-2024-01994

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

AI 简述这是一项II期试验，在婴儿新发KMT2A重排或非重排白血病中研究Venetoclax和/或Blinatumomab联合化疗。

?

适用疾病: Acute Leukemia of Ambiguous Lineage；B Acute Lymphoblastic Leukemia
干预: Asparaginase Erwinia chrysanthemi，Biospecimen Collection，Blinatumomab，Bone Marrow Aspiration
地点: United States，Puerto Rico
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06333262 / NCI-2024-03573

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

AI 简述这是一项II期试验，研究Pirtobrutinib联合Obinutuzumab用于慢性淋巴细胞白血病。

?

适用疾病: Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma；Chronic Lymphocytic Leukemia (CLL)
干预: Pirtobrutinib，Obinutuzumab
地点: United States
申办方: Inhye Ahn

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06336395

Ma-Spore ALL 2020 Study

AI 简述这是一项II期试验，研究多种药物用于B淋巴母细胞白血病。

?

适用疾病: B Lymphoblastic Leukemia
干预: Prednisolone，Dexamethasone，Vincristine，Methotrexate
地点: Malaysia，Singapore
申办方: National University Hospital, Singapore

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06356922

Study Assessing RLT Using [177Lu]Lu-PentixaTher for Relapsed/Refractory CXCR4+ Acute Leukemia.

AI 简述这是一项I/II期试验，研究[177Lu]Lu-PentixaTher用于复发/难治CXCR4+急性白血病。

?

适用疾病: Acute Leukemia
干预: Experimental drug [177Lu]Lu-PentixaTher
地点: France
申办方: Nantes University Hospital

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT06364423 / NCI-2024-03377

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

AI 简述这是一项I/II期试验，研究抗CD19 CAR T细胞用于B细胞慢性淋巴细胞白血病、急性淋巴细胞白血病等，在美国开展。

?

适用疾病: Leukemia, Lymphocytic, Chronic, B-Cell；B-Lymphocytic Leukemia, Chronic；B-Cell Chronic Lymphocytic Leukemia
干预: Autologous HuCD19 ( Anti-CD19)CAR T cells，Cyclophosphamide，Fludarabine，Rituximab
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 4 药物

ClinicalTrials.gov / NCI NCT06370000 / NCI-2024-09346

Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality

AI 简述这是一项IV期试验，研究口服阿扎胞苷用于适合移植的急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia (AML)
干预: Oral Azacitidine
地点: United States
申办方: Virginia Commonwealth University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06382168 / NCI-2024-07566

DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

AI 简述这是一项I/II期试验，在美国研究DFP-10917联合Venetoclax用于复发/难治性急性髓系白血病。

?

适用疾病: Leukemia, Myeloid, Acute；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)
干预: DFP-10917，Venetoclax
地点: United States
申办方: Delta-Fly Pharma, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06390319 / NCI-2024-03015

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

AI 简述这是一项II期试验，研究达沙替尼或维奈托克联合化疗用于新诊断的T细胞急性淋巴细胞白血病或淋巴瘤，在美国开展。

?

适用疾病: T-cell Acute Lymphoblastic Leukemia；T-cell Lymphoma；Mixed Phenotype Acute Leukemia
干预: Dexamethasone，Vincristine，Daunorubicin，Calaspargase pegol
地点: United States
申办方: St. Jude Children's Research Hospital

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT06395103 / NCI-2024-04094

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

AI 简述这是一项I/II期试验，研究Zilovertamab vedotin用于儿童和年轻成人的血液恶性肿瘤或实体瘤。在美国、澳大利亚等地开展。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia；Diffuse Large B-cell Lymphoma；Burkitt Lymphoma
干预: Zilovertamab vedotin
地点: United States，Australia，Belgium，Brazil 等 19 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT06424340

MB-dNPM1-TCR.1 in Relapsed/Refractory AML

AI 简述这是一项I/II期试验，在荷兰研究MB-dNPM1-TCR.1用于复发/难治性急性髓系白血病。

?

适用疾病: Leukemia, Myeloid, Acute
干预: MB-dNPM1-TCR.1
地点: Netherlands
申办方: Miltenyi Biomedicine GmbH

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06456463 / NCI-2024-09705

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

AI 简述这是一项II期试验，在美国和澳大利亚研究Tagraxofusp联合Venetoclax和阿扎胞苷用于初治CD123+急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia (AML)
干预: Tagraxofusp，Venetoclax，Azacitidine
地点: United States，Australia
申办方: Stemline Therapeutics, Inc.

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT06466122 / NCI-2024-04627

Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi

AI 简述这是一项II期试验，在美国开展，研究Pirtobrutinib联合维奈克拉用于对共价BTK抑制剂耐药的慢性淋巴细胞白血病或小淋巴细胞淋巴瘤。

?

适用疾病: Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma；Chronic Lymphocytic Leukemia (CLL)
干预: Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy，Computed Tomography
地点: United States
申办方: Kerry Rogers

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06477549

BeFluBu vs FluBuRux Conditioning in Haploidentical HCT

AI 简述这是一项II期试验，比较贝FluBu与FluBuRux方案用于半相合移植的血液肿瘤，在俄罗斯开展。

?

适用疾病: Acute Lymphoblastic Leukemia；Acute Myeloid Leukemia；Biphenotypic Acute Leukemia
干预: Bendamustine Hydrochloride，Ruxolitinib
地点: Russia
申办方: St. Petersburg State Pavlov Medical University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06506643

Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms

AI 简述这是一项I/II期试验，研究KLS-1（锌-64天冬氨酸）单药用于恶性实体瘤。

?

适用疾病: CLL；Solid Tumor, Adult
干预: Zinc-64 Aspartate
地点: Ukraine
申办方: Vector Vitale LLC

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06508099

Vitamin A and D Supplementation in Allogeneic HCT

AI 简述这是一项II期试验，研究维生素A和D补充用于移植后白血病和淋巴瘤。

?

适用疾病: Acute Lymphoblastic Leukemia；Acute Myeloid Leukemia；Biphenotypic Acute Leukemia
干预: Vitamin A，Vitamin D3
地点: Russia
申办方: St. Petersburg State Pavlov Medical University

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06511882 / NCI-2024-06243

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

AI 简述这是一项II期试验，研究停用去甲基化药物和维奈克拉用于急性髓系白血病微小残留病阳性患者。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia (AML)
干预: Azacitidine，Decitabine，Venetoclax
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT06514794 / NCI-2025-00960

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

AI 简述这是一项II期试验，研究WU-CART-007用于T细胞急性淋巴细胞白血病和淋巴母细胞淋巴瘤，在美国和澳大利亚开展。

?

适用疾病: T-cell Acute Lymphoblastic Leukemia；Lymphoblastic Lymphoma；Recurrent T Acute Lymphoblastic Leukemia
干预: WU-CART-007
地点: United States，Australia
申办方: Wugen, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06520098

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

AI 简述这是一项II期试验，研究BTK抑制剂联合或不联合Venetoclax用于CLL/SLL患者。

?

适用疾病: Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma
干预: Venetoclax，Ibrutinib, Acalabrutinib, Zanubrutinib
地点: United States
申办方: VA Office of Research and Development

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT06529731 / NCI-2025-00877

Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

AI 简述这是一项2期试验，研究干扰素-γ联合供者淋巴细胞输注用于移植后复发的急性髓系白血病和骨髓增生异常综合征，在美国开展。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndromes；Recurrent Myelodysplastic Syndrome
干预: Interferon gamma-1b，Donor Leukocyte Infusion (DLI)
地点: United States
申办方: Sawa Ito, MD

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06532084

Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen

AI 简述这是一项II期试验，研究Sorafenib用于移植后复发预防的急性髓系白血病、骨髓增生异常综合征等血液肿瘤，在俄罗斯开展。

?

适用疾病: Acute Myeloid Leukemia, in Relapse；Myelodysplastic Syndromes；Chronic Myeloid Leukemia
干预: Sorafenib
地点: Russia
申办方: St. Petersburg State Pavlov Medical University

正在招募 Phase 1, Phase 2 基因治疗

ClinicalTrials.gov NCT06533579

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

AI 简述这是一项I/II期试验，研究VNX-101用于CD19阳性血液恶性肿瘤，包括B细胞急性淋巴细胞白血病、大B细胞淋巴瘤等，在美国开展。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia；Large B-cell Lymphoma；Chronic Lymphocytic Leukemia
干预: Dose Level 1, VNX-101，Dose Level 2, VNX-101，Dose Level 3, VNX-101，Dose Level 4, VNX-101
地点: United States
申办方: Vironexis Biotherapeutics Inc.

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT06533748 / NCI-2024-06013

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

AI 简述一项II期试验，研究Inotuzumab联合Blinatumomab用于新诊断B细胞急性淋巴细胞白血病，在美国开展。

?

适用疾病: Acute Lymphoblastic Leukemia；Lymphoblastic Lymphoma；B Acute Lymphoblastic Leukemia
干预: Dexamethasone，Vincristine，Inotuzumab，Blinatumomab
地点: United States
申办方: St. Jude Children's Research Hospital

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06537843

Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia

AI 简述这是一项II期试验，研究维奈克拉、阿糖胞苷和二甲双胍用于复发难治或不能诱导的急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia
干预: Venetoclax，Cytarabine Injection，Metformin
地点: Brazil
申办方: Hospital Municipal São José

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06544785

Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

AI 简述这是一项II期试验，研究Zanubrutinib联合Obinutuzumab用于未经治疗的慢性淋巴细胞白血病或小淋巴细胞淋巴瘤。在西班牙等地开展。

?

适用疾病: Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma
干预: Zanubrutinib Oral Product，Obinutuzumab
地点: Spain
申办方: PETHEMA Foundation

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06548230 / NCI-2024-06340

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

AI 简述这是一项I/II期试验，研究Nadunolimab联合Azacitidine（联合或不联合Venetoclax）用于MDS和AML，在美国开展。

?

适用疾病: Myelodysplastic Syndrome(MDS)；Acute Myelogenous Leukemia (AML)；Refractory Acute Myeloid Leukemia (AML)
干预: Nadunolimab，Azacitidine，Venetoclax
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06557421

De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients

AI 简述这是一项II期试验，评估Venetoclax联合阿扎胞苷停药用于急性髓系白血病缓解患者。在法国开展。

?

适用疾病: Acute Myeloid Leukemia
干预: Venetoclax，Azacitidine
地点: France
申办方: Institut Paoli-Calmettes

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06561074 / NCI-2024-06907

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

AI 简述这是一项II期试验，研究卡拉斯帕加酶、地西他滨联合维奈克拉用于复发/难治性T细胞急性淋巴细胞白血病和淋巴母细胞淋巴瘤。

?

适用疾病: T-cell Acute Lymphoblastic Leukemia；T-Cell Lymphoblastic Lymphoma；Recurrent T Acute Lymphoblastic Leukemia
干预: Decitabine，Venetoclax，Calaspargase pegol-mknl
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06561152 / NCI-2025-01963

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

AI 简述这是一项I/II期试验，研究Tagraxofusp联合低强度化疗用于CD123阳性复发/难治性急性髓系白血病。

?

适用疾病: Refractory Acute Myeloid Leukemia；Relapsed Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia (AML)
干预: Tagraxofusp，Cladribine (CLAD)，Cytarabine
地点: United States
申办方: Stanford University

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06588478 / NCI-2025-02626

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

AI 简述这是一项II期试验，研究Pirtobrutinib用于复发或难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤，在美国、澳大利亚、比利时、加拿大等地开展。

?

适用疾病: Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma；Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
干预: Pirtobrutinib
地点: United States，Australia，Belgium，Canada 等 14 个
申办方: Loxo Oncology, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06599762

Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia

AI 简述这是一项II期试验，研究氨甲环酸用于骨髓增生异常综合征和急性髓系白血病。

?

适用疾病: Myelodysplastic Syndromes；Acute Myeloid Leukemia；Myelodysplastic/Myeloproliferative Neoplasm
干预: Tranexamic acid，Placebo
地点: Canada
申办方: University of Manitoba

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT06635330

Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL

AI 简述这是一项I/II期试验，在伊朗研究抗CD19 CAR T细胞治疗用于复发/难治性B细胞急性淋巴细胞白血病。

?

适用疾病: Relapse/Refractory B-cell Acute Lymphoblastic Leukemia
干预: anti-CD19 CAR T cell therapy
地点: Iran
申办方: Kara Yakhteh Tajhiz Azma Company

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06644183 / NCI-2025-02224

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

AI 简述这是一项I/II期试验，研究Roginolisib联合Venetoclax和Rituximab用于复发/难治性慢性淋巴细胞白血病。

?

适用疾病: Leukemia；Relapsed Leukemia；Chronic Lymphocytic Leukemia
干预: Roginolisib，Venetoclax，Rituximab
地点: United States
申办方: Jennifer R. Brown, MD, PhD

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06648889

Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

AI 简述这是一项II期试验，研究Isatuximab用于CD38阳性复发/难治性T细胞急性淋巴细胞白血病。

?

适用疾病: T-ALL
干预: Isatuximab，Isatuximab
地点: Germany
申办方: Goethe University

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06660368 / NCI-2024-09349

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

AI 简述这是一项2期试验，研究BCL2抑制剂Venetoclax联合CLAG-M方案用于复发难治性急性髓系白血病，在美国开展。

?

适用疾病: Relapsed or Refractory Acute Myeloid Leukemia (AML)；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)
干预: Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen，Venetoclax
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06668558

Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

AI 简述这是一项II期试验，研究Venetoclax联合Azacitidine用于急性髓系白血病，在西班牙开展。

?

适用疾病: Acute Myeloid Leukemia
干预: Azacitidine (AZA)，Venetoclax
地点: Spain
申办方: Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT06672146 / NCI-2024-08951

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

AI 简述这是一项II期试验，研究Decitabine and Cedazuridine等用于新诊断的IDH2突变急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia (AML)
干预: Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy，Decitabine and Cedazuridine
地点: United States，Puerto Rico
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT06680752 / NCI-2025-05694

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

AI 简述一项I/II期试验，研究ARD103 CAR-T细胞治疗用于复发/难治性AML或MDS。

?

适用疾病: Acute Myeloid Leukemia, in Relapse；Acute Myeloid Leukemia Refractory；MDS (Myelodysplastic Syndrome)
干预: ARD103，Cyclophosphamide，Fludarabine
地点: United States
申办方: ARCE Therapeutics, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06696183

Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment

AI 简述这是一项2期试验，研究吉瑞替尼联合维奈克拉和阿扎胞苷用于FLT3突变急性髓系白血病。

?

适用疾病: AML - Acute Myeloid Leukemia
干预: Gilteritinib (GILT)，Venetoclax (VEN)，Azacitidine (AZA)
地点: Germany
申办方: Technische Universität Dresden

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06697184 / NCI-2024-10535

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

AI 简述这是一项1/2期试验，研究Sonrotoclax联合Zanubrutinib用于血癌患者的新剂量递增方案。

?

适用疾病: Chronic Lymphocytic Leukemia；CLL；Mantle Cell Lymphoma
干预: Sonrotoclax，Zanubrutinib
地点: United States，Australia，France，United Kingdom
申办方: BeOne Medicines

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06698003

A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1

AI 简述这是一项2期试验，研究Mogamulizumab用于预防成人T细胞白血病/淋巴瘤。

?

适用疾病: T-Cell Leukemia/Lymphoma, Adult；T-cell Leukemia/Lymphoma；T-cell Leukemia
干预: Mogamulizumab
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06704152 / NCI-2024-09869

BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS

AI 简述这是一项I/II期试验，研究BSB-1001联合标准方案用于复发/难治性AML、ALL或MDS患者接受移植后，在美国开展。

?

适用疾病: AML, Adult Recurrent；ALL, Recurrent, Adult；MDS
干预: SOC + BSB-1001 Dose Escalation Cohort，SOC+BSB-1001 Expansion Dose
地点: United States
申办方: BlueSphere Bio, Inc

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06707493 / NCI-2025-07663

Ivosidenib as Post-HSCT Maintenance for AML

AI 简述这是一项II期试验，在美国开展，研究Ivosidenib用于IDH1突变急性髓系白血病HSCT后维持。

?

适用疾病: IDH1 Mutation；Acute Myeloid Leukemia (AML)；Hematopoietic Stem Cell Transplant (HSCT)
干预: Ivosidenib，Placebo
地点: United States
申办方: Massachusetts General Hospital

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06712121

Venetoclax and Decitabine in R/R T-ALL

AI 简述这是一项II期试验，研究地西他滨联合Venetoclax用于复发/难治性T淋巴细胞白血病/淋巴瘤。在韩国开展。

?

适用疾病: T Lymphoblastic Leukemia/Lymphoma
干预: decitabine plus venetoclax
地点: South Korea
申办方: Seoul National University Hospital

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06717958

Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation

AI 简述这是一项II期试验，研究Ivosidenib维持治疗用于IDH1突变急性髓系白血病或高危骨髓增生异常肿瘤。

?

适用疾病: AML；MDS
干预: Ivosidenib 250 MG (milligram)
地点: Germany
申办方: Technische Universität Dresden

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06738368 / NCI-2024-09417

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

AI 简述这是一项II期试验，研究DA-EPOCH联合或不联合利妥昔单抗加JZP458用于新诊断的Ph阴性B或T急性淋巴细胞白血病。

?

适用疾病: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative；T Acute Lymphoblastic Leukemia；T cell acute lymphoblastic leukemia
干预: Asparaginase Erwinia chrysanthemi，Biospecimen Collection，Bone Marrow Collection，Computed Tomography
地点: United States
申办方: University of Washington

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT06757647 / NCI-2024-10481

Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

AI 简述这是一项II期试验，研究Acalabrutinib用于慢性淋巴细胞白血病/小淋巴细胞淋巴瘤。

?

适用疾病: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
干预: Acalabrutinib，Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy
地点: United States
申办方: Seema Bhat

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06773208 / NCI-2025-00338

A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

AI 简述这是一项II期试验，研究Azacitidine和Venetoclax用于急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia (AML)
干预: Azacitidine (AZC)，Venetoclax
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06778187

Oral-ATO for TP53-mutated Myeloid Malignancies

AI 简述这是一项II期试验，研究口服三氧化二砷用于TP53突变髓系肿瘤。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Neoplasm；Chronic Myelomonocytic Leukemia
干预: Oral arsenic trioxide
地点: Hong Kong
申办方: The University of Hong Kong

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06782542 / NCI-2025-02985

Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

AI 简述这是一项II期试验，研究Olutasidenib、Venetoclax联合Azacitidine用于IDH1突变的新诊断急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；IDH1 Mutation；Secondary Acute Myeloid Leukemia (AML)
干预: Olutasidenib，Venetoclax，Azacitidine
地点: United States
申办方: Justin Watts, MD

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT06802315

Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)

AI 简述这是一项II期试验，研究调强全骨髓照射联合化疗用于高风险急性髓系白血病、慢性髓系白血病和骨髓增生异常综合征的移植治疗。

?

适用疾病: Acute Myeloid Leukemia, Relapsed, Adult；Acute Myeloid Leukemia Refractory；Chronic Myeloid Leukemia - Accelerated Phase
干预: Intensity modulated total marrow irradiation，Cyclophosphamide (CTX)，Fludarabine (Fludara)，Busulfan (conditioning for ALLO Transplant)
地点: United States
申办方: University of Illinois at Chicago

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06810778

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

AI 简述这是一项I/II期试验，研究Duvelisib联合Venetoclax用于复发或难治性外周T细胞淋巴瘤。

?

适用疾病: T-cell-prolymphocytic Leukemia；Cutaneous T-Cell Lymphoma Refractory
干预: Duvelisib，Venetoclax
地点: United States
申办方: Jonsson Comprehensive Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06812715

Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib

AI 简述这是一项II期试验，在澳大利亚开展，研究Pirtobrutinib用于既往接受Zanubrutinib治疗的CLL。

?

适用疾病: Chronic Lymphocytic Leukemia
干预: Pirtobrutinib
地点: Australia
申办方: Peter MacCallum Cancer Centre, Australia

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06839053 / NCI-2025-00319

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

AI 简述这是一项II期试验，在美国研究Sonrotoclax、利妥昔单抗和泽布替尼用于慢性淋巴细胞白血病、小淋巴细胞淋巴瘤和套细胞淋巴瘤。

?

适用疾病: Chronic Lymphocytic Leukemia；Mantle Cell Lymphoma；Recurrent Chronic Lymphocytic Leukemia
干预: Biospecimen Collection，Bone Marrow Biopsy，Computed Tomography，Gastrointestinal Endoscopy
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT06847269 / NCI-2025-01423

CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia

AI 简述这是一项II期试验，研究CD19-CAR T细胞疗法用于儿童和年轻成人CD19阳性白血病。

?

适用疾病: Acute Lymphoblastic Leukemia；Refractory Acute Lymphoblastic Leukemia；Refractory Acute Lymphoblastic Leukemia (ALL)
干预: Fludarabine，Cyclophosphamide，Mesna，CD19-CAR T cell Infusion
地点: United States
申办方: St. Jude Children's Research Hospital

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06849713 / NCI-2025-03732

Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL

AI 简述这是一项II期试验，研究Zanubrutinib、Obinutuzumab、Sonrotoclax用于初治慢性淋巴细胞白血病或小淋巴细胞淋巴瘤。

?

适用疾病: Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma (SLL)；Chronic Lymphocytic Leukemia (CLL)
干预: Zanubrutinib，Sonrotoclax，Obinutuzumab
地点: United States
申办方: Massachusetts General Hospital

正在招募 Phase 2 药物其他手术/操作

ClinicalTrials.gov / NCI NCT06859424 / NCI-2025-03113

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

AI 简述这是一项II期试验，研究移植后环磷酰胺方案预防移植物抗宿主病用于血液恶性肿瘤。

?

适用疾病: AML (Acute Myelogenous Leukemia)；Acute Lymphoid Leukemia (ALL)；Acute Leukemia (Category)
干预: Conditioning Regimen A，Conditioning Regimen B，Conditioning Regimen C，Conditioning Regimen D
地点: United States
申办方: Center for International Blood and Marrow Transplant Research

正在招募 Phase 4 药物

ClinicalTrials.gov / NCI NCT06876649 / NCI-2025-03405

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

AI 简述这是一项4期试验，评估Pirtobrutinib用于慢性淋巴细胞白血病或非霍奇金淋巴瘤的长期安全性。

?

适用疾病: Chronic Lymphocytic Leukemia；Non-Hodgkin Lymphoma；Chronic Lymphocytic Leukemia (CLL)
干预: Pirtobrutinib
地点: United States，Australia，France，Italy 等 4 个
申办方: Eli Lilly and Company

正在招募 Phase 4 药物

ClinicalTrials.gov / NCI NCT06876662 / NCI-2025-06033

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

AI 简述这是一项4期试验，研究Pirtobrutinib用于既往治疗过的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤或非霍奇金淋巴瘤。

?

适用疾病: Chronic Lymphocytic Leukemia；Non-Hodgkin Lymphoma；Chronic Lymphocytic Leukemia (CLL)
干预: Pirtobrutinib
地点: United States，Australia，France，Italy 等 4 个
申办方: Eli Lilly and Company

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06886074

Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL

AI 简述这是一项II期试验，研究短疗程Blinatumomab用于清除B-ALL微小残留病，在墨西哥开展。

?

适用疾病: Acute Lymphoblastic Leukemia；Measurable Residual Disease (MRD)
干预: Short course of blinatumomab
地点: Mexico
申办方: Hospital Universitario Dr. Jose E. Gonzalez

正在招募 Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT06904482 / NCI-2025-02621

Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood

AI 简述这是一项II期试验，研究半相合移植物联合脐血共移植用于急性白血病或骨髓增生异常综合征，在美国开展。

?

适用疾病: aGVHD；Acute Myelogenous Leukemia；Acute Lymphocytic Leukemia
干预: Haplo-Identical / Cord Blood Transplant
地点: United States
申办方: Case Comprehensive Cancer Center

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT06917911 / NCI-2025-02426

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

AI 简述这是一项II期试验，在标准治疗基础上加用Venetoclax或Gemtuzumab Ozogamicin用于核心结合因子急性髓系白血病。

?

适用疾病: Core Binding Factor Acute Myeloid Leukemia
干预: Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy，Cytarabine
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06918431 / NCI-2025-02184

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

AI 简述这是一项II期试验，研究Erwinia Chrysanthemi天冬酰胺酶联合化疗用于新诊断的高危急性淋巴细胞白血病。

?

适用疾病: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative；Lymphoblastic Lymphoma
干预: Asparaginase Erwinia chrysanthemi，Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1, Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06928662 / NCI-2025-01992

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

AI 简述这是一项I/II期试验，研究地西他滨联合化疗和全身放疗后干细胞移植用于高危髓系恶性肿瘤。

?

适用疾病: Acute Myeloid Leukemia；Acute Undifferentiated Leukemia；Mixed Phenotype Acute Leukemia
干预: Decitabine，Bone Marrow Aspiration，Bone Marrow Biopsy，Chest Radiography
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 1, Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06965114 / NCI-2025-03281

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

AI 简述这是一项I/II期试验，研究Tovorafenib联合Rituximab用于毛细胞白血病。

?

适用疾病: Hairy Cell Leukemia；Recurrent Hairy Cell Leukemia；Refractory Hairy Cell Leukemia
干预: Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy，Cladribine
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06967610 / NCI-2025-03338

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

AI 简述这是一项II期试验，研究Pirtobrutinib、Venetoclax和Obinutuzumab用于复发慢性淋巴细胞白血病/小淋巴细胞淋巴瘤。

?

适用疾病: Chronic Lymphocytic Leukemia；Small Lymphocytic Leukemia (SLL)；Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
干预: Pirtobrutinib，Venetoclax，Obinutuzumab
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06969430 / NCI-2025-04465

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

AI 简述这是一项I/II期试验，研究Debio 1562M用于急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia (AML)；Refractory Myelodysplastic Syndrome
干预: Debio 1562M
地点: United States
申办方: Debiopharm International SA

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06978088

LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

AI 简述这是一项II期试验，研究LP-168联合Obinutuzumab用于慢性淋巴细胞白血病/小淋巴细胞淋巴瘤，在美国开展。

?

适用疾病: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma；Small Lymphocytic Lymphoma；CLL/SLL
干预: LP-168，Obinutuzumab
地点: United States
申办方: Zulfa Omer

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06982274

Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia

AI 简述这是一项II期试验，研究口服砷剂联合ATRA用于新诊断APL。

?

适用疾病: Acute Promyelocytic Leukemia (APL)
干预: Realgar-Indigo Naturalis Formulation
地点: Brazil
申办方: Instituto do Cancer do Estado de São Paulo

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07008638 / NCI-2025-04097

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

AI 简述这是一项I/II期试验，研究Bortezomib联合CPX-351用于新诊断TP53突变急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；TP53；Acute Myeloid Leukemia with Mutated TP53
干预: Bortezomib，CPX-351
地点: United States
申办方: Masonic Cancer Center, University of Minnesota

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07014917

Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

AI 简述这是一项II期试验，比较间歇与连续服用Venetoclax联合Acalabrutinib用于CLL/SLL，在美国开展。

?

适用疾病: Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma；CLL Variant
干预: Venetoclax，Acalabrutinib，Venetoclax，Acalabrutinib
地点: United States
申办方: Zulfa Omer

正在招募 Phase 4 药物

ClinicalTrials.gov NCT07016165

Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies

AI 简述这是一项IV期试验，比较环丙沙星与头孢他啶经验性治疗儿童血液肿瘤高热伴中性粒细胞减少。

?

适用疾病: Neutropenic Fever；Acute Lymphoblastic Leukemia；Acute Myeloblastic Leukemia
干预: Ceftazidime，Ciprofloxacin
地点: Indonesia
申办方: Gadjah Mada University

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07021677

Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"

AI 简述这是一项II期试验，研究Daratumumab用于T细胞急性淋巴细胞白血病，在印度开展。

?

适用疾病: T Acute Lymphoblastic Leukemia
干预: Daratumumab Injection
地点: India
申办方: Tata Memorial Centre

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07024706 / NCI-2026-00233

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

AI 简述这是一项II期试验，研究Acalabrutinib联合Venetoclax用于复发CLL/SLL，在美国等地开展。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma (SLL)；Small Lymphocytic Lymphoma
干预: Acalabrutinib，Venetoclax
地点: United States，Austria，Brazil，Czechia 等 4 个
申办方: AstraZeneca

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07039877

Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients

AI 简述这是一项II期试验，研究低剂量维奈克拉联合伊曲康唑用于复发/难治急性淋巴细胞白血病，在墨西哥开展。

?

适用疾病: Acute Lymphobkastic Leukemia；Acute Lymphoblastic Leukaemia Recurrent；Philadelphia Chromosome Negative ALL
干预: Venetoclax low dose with itraconazole
地点: Mexico
申办方: Hospital Universitario Dr. Jose E. Gonzalez

正在招募 Phase 4 药物

ClinicalTrials.gov NCT07044687

Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India

AI 简述这是一项IV期试验，研究口服Venetoclax联合阿扎胞苷用于新诊断且不适合标准诱导治疗的急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia
干预: Venetoclax，Azacitidine，Azacitidine
地点: India
申办方: AbbVie

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07052695 / NCI-2025-08486

Mosunetuzumab for CLL MRD Clearance

AI 简述这是一项I/II期试验，研究Mosunetuzumab联合BTK抑制剂用于慢性淋巴细胞白血病微小残留病灶清除。

?

适用疾病: Leukemia；Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma
干预: Mosunetuzumab，Ibrutinib，Acalabrutinib，Zanubrutinib
地点: United States
申办方: Inhye Ahn

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07053059 / NCI-2025-04660

Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)

AI 简述这是一项II期试验，研究Obecabtagene autoleucel用于新诊断高危B细胞急性淋巴细胞白血病巩固治疗。

?

适用疾病: Acute Lymphocytic Leukemia (ALL)；B Acute Lymphoblastic Leukemia
干预: Obecabtagene autoleucel
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT07061951 / NCI-2025-04637

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

AI 简述这是一项II期试验，研究Mirdametinib用于复发/难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤。

?

适用疾病: Recurrent Chronic Lymphocytic Leukemia；Recurrent Small Lymphocytic Lymphoma；Refractory Chronic Lymphocytic Leukemia
干预: Biospecimen Collection，Bone Marrow Biopsy，Computed Tomography，Echocardiography Test
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07070219 / NCI-2025-06834

A Study of CTD402 in T-ALL/LBL Patients

AI 简述这是一项I/II期试验，研究CTD402 CAR-T用于复发难治T细胞急性淋巴细胞白血病/淋巴瘤。

?

适用疾病: Acute Lymphocytic Leukemia Refractory；Lymphoma, Lymphoblastic；Recurrent T Acute Lymphoblastic Leukemia
干预: CTD402 CAR T Cell Injection
地点: United States
申办方: BIOHENG THERAPEUTICS US LLC

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07108998

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

AI 简述这是一项II期试验，研究Epcoritamab作为CLL/SLL的巩固治疗。

?

适用疾病: CLL/SLL；CLL；SLL
干预: Epcoritamab
地点: United States
申办方: Zulfa Omer

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07148180 / NCI-2025-08489

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

AI 简述这是一项1/2期试验，研究Tagraxofusp、Azacitidine和Venetoclax用于急性髓系白血病。

?

适用疾病: Acute Myeloid Leukaemia (AML)；Leukemia；Blood Cancer
干预: Tagraxofusp，Azacitidine (AZA)，Venetoclax
地点: United States
申办方: Jacqueline Garcia, MD

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07163793

Pilot Study of Reduced Venetoclax Exposure

AI 简述这是一项2期试验，研究减低Venetoclax剂量用于急性髓系白血病缓解期，在美国开展。

?

适用疾病: Acute Myeloid Leukemia in Remission
干预: Azacitidine，Decitabine，Venetoclax
地点: United States
申办方: Northwell Health

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT07194980 / NCI-2025-06406

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

AI 简述这是一项II期试验，研究Nemtabrutinib和Lisocabtagene Maraleucel用于复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤。

?

适用疾病: Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma；Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
干预: Nemtabrutinib，Lisocabtagene Maraleucel
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT07216443 / NCI-2025-07791

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

AI 简述这是一项2期试验，研究Orca-T在减低强度预处理后用于急性髓系白血病或骨髓增生异常综合征。

?

适用疾病: Leukemia, Myeloid, Acute；Myelodysplastic Syndromes；Mixed Phenotype Acute Leukemia
干预: Orca-T
地点: United States
申办方: Orca Biosystems, Inc.

正在招募 Phase 2 生物制剂药物其他

ClinicalTrials.gov / NCI NCT07218510 / NCI-2025-07205

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

AI 简述这是一项II期试验，研究Venetoclax、Obinutuzumab联合Epcoritamab用于未经治疗的慢性淋巴细胞白血病。

?

适用疾病: Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma；Chronic Lymphocytic Leukemia (CLL)
干预: Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy，Computed Tomography
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07221500 / NCI-2025-09040

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

AI 简述这是一项II期试验，研究NX-5948用于既往治疗后的CLL/SLL。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma (SLL)；Refractory Chronic Lymphocytic Leukemia (CLL)
干预: NX-5948
地点: United States，France，Italy，Poland 等 1 个
申办方: Nurix Therapeutics, Inc.

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT07224100 / NCI-2025-07631

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

AI 简述这是一项II期试验，研究DA-EPOCH联合或不联合Rituximab及Ponatinib用于新诊断的Ph+急性淋巴细胞白血病/淋巴瘤。

?

适用疾病: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1；B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1；Lymphoblastic Lymphoma
干预: Cyclophosphamide，Doxorubicin，Etoposide，Filgrastim
地点: United States
申办方: University of Washington

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07238712

Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor

AI 简述这是一项II期试验，研究Ruxolitinib和Abatacept用于高危髓系恶性肿瘤移植后。在俄罗斯开展。

?

适用疾病: Acute Myeloid Leukemia (AML)；Chronic Myeloid Leukemia；Myelodysplastic Syndromes (MDS)
干预: Ruxolitinib，Abatacept (Orencia)
地点: Russia
申办方: St. Petersburg State Pavlov Medical University

正在招募 Phase 2 生物制剂

ClinicalTrials.gov NCT07256210

Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation

AI 简述这是一项II期试验，在俄罗斯研究供者NK细胞输注用于造血干细胞移植后白血病复发预防。

?

适用疾病: Acute Myeloid Leukemia；Acute Lymphoblastic T-cell Leukemia；Mixed Phenotype Acute Leukemia
干预: Donor-derived Natural Killer Cell
地点: Russia
申办方: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07271667 / NCI-2026-00807

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

AI 简述这是一项II期试验，研究Emavusertib联合BTKi用于慢性淋巴细胞白血病等B细胞恶性肿瘤，在美国、意大利、西班牙等地开展。

?

适用疾病: Chronic Lymphocytic Leukemia；B-cell Malignancies；Chronic Lymphocytic Leukemia (CLL)
干预: Emavusertib，Zanubrutinib
地点: United States，Italy，Spain
申办方: Curis, Inc.

正在招募 Phase 1, Phase 2 药物其他

ClinicalTrials.gov NCT07284433

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

AI 简述这是一项I/II期试验，研究异体CAR-T（靶向CD19/CD20）用于复发或难治性B细胞恶性肿瘤。在美国和德国开展。

?

适用疾病: Lymphoma Diffuse Large B-cell；Leukemia and Lymphoma；Leukemia Relapse
干预: Cyclophosphamide (Non-IMP, Lymphodepletion)，Fludarabine (Non-IMP, Lymphodepletion)，Allo-QuadCAR01-T
地点: United States，Germany
申办方: AvenCell Therapeutics, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07304011 / NCI-2025-09023

Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent

AI 简述这是一项II期试验，研究Olutasidenib联合Azacitidine用于IDH1突变急性髓系白血病，在美国开展。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia (AML)
干预: Azacitidine，Olutasidenib
地点: United States
申办方: University of California, Davis

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT07328503 / NCI-2026-00569

CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

AI 简述这是一项II期试验，研究CD22 CAR T细胞用于儿童、青少年和成人复发/难治性B细胞急性淋巴细胞白血病。

?

适用疾病: Acute Lymphoblastic Leukemia；B-All；Recurrent B Acute Lymphoblastic Leukemia
干预: CD22 CAR-transduced T cells，Cyclophosphamide，Fludarabine
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07356154 / NCI-2026-00501

A Study of Revumenib and Mezigdomide in People With Leukemia

AI 简述这是一项I/II期试验，在美国研究Revumenib联合Mezigdomide用于复发/难治性急性白血病。

?

适用疾病: Leukemia；Acute Leukemia；Relapse Leukemia
干预: Revumenib，Mezigdomide
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT07356245 / NCI-2026-00140

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

AI 简述这是一项II期试验，在美国研究芦可替尼维持治疗用于T细胞淋巴瘤造血干细胞移植后。

?

适用疾病: T-cell Lymphoma；Graft Versus Host Disease；Lymphoma, T-Cell
干预: Ruxolitinib，Positron emission tomography-computed tomography，Bone Marrow Biopsy，Biopsy Procedure
地点: United States
申办方: Jonathan Brammer

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07392242 / NCI-2026-00961

A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

AI 简述这是一项II期试验，研究Ivosidenib联合阿扎胞苷和Venetoclax用于急性髓系白血病。在美国开展。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia (AML)
干预: Ivosidenib，Azacitidine，Venetoclax
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07400029 / NCI-2026-01028

A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia

AI 简述这是一项II期试验，在美国研究Obecabtagene Autoleucel用于B细胞急性淋巴细胞白血病。

?

适用疾病: Acute Lymphoblastic Leukemia；B Acute Lymphoblastic Leukemia
干预: Obecabtagene Autoleucel
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07471789

Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).

AI 简述这是一项I/II期试验，研究CART84用于复发难治急性髓系白血病和T细胞急性淋巴细胞白血病。

?

适用疾病: Acute Myeloblastic Leukaemia；Leukemia, T-Cell
干预: CART84
地点: Spain
申办方: Gyala Therapeutics

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07471841 / NCI-2026-02972

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

AI 简述这是一项II期试验，研究Olutasidenib用于既往接受Venetoclax的IDH1突变复发难治AML。

?

适用疾病: IDH1 Mutation；Relapsed / Refractory AML；Refractory Acute Myeloid Leukemia (AML)
干预: Olutasidenib，Azacitidine (AZA)
地点: United States
申办方: Timothy Pardee

正在招募 Phase 2 生物制剂药物放疗

ClinicalTrials.gov / NCI NCT07493538 / NCI-2026-02579

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

AI 简述这是一项II期试验，研究Treosulfan、Fludarabine等预处理方案用于血液病异基因移植，在美国开展。

?

适用疾病: AML；MDS；Acute Leukemia
干预: Treosulfan，Fludarabine，Total Body Irradiation，Tacrolimus
地点: United States
申办方: Masonic Cancer Center, University of Minnesota

正在招募 Phase 1, Phase 2 放疗

ClinicalTrials.gov NCT07532824

Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS

AI 简述这是一项I/II期试验，研究质子束全骨髓照射用于异基因移植治疗高危急性髓系白血病/骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia (AML)；Myelodysplastic Syndrome (MDS)/AML；Proton Therapy
干预: Proton Total Marrow Irradiation
地点: Czechia
申办方: Institute of Hematology and Blood Transfusion, Czech Republic

正在招募 Phase 2 生物制剂药物放疗

ClinicalTrials.gov / NCI NCT07566377 / NCI-2026-03537

Cord Blood Transplantation in Children and Young Adults With Blood Cancer

AI 简述这是一项II期试验，研究脐带血移植用于儿童和年轻成人血癌。

?

适用疾病: Acute Myelogenous Leukemia；Acute Lymphoblastic Leukemia；Myelodysplastic Syndromes
干预: Cord Blood Units，Total Body Irradiation，Cyclophosphamide，Fludarabine
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov NCT07591649

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

AI 简述这是一项I/II期试验，在美国开展，研究Adapt NK用于高危髓系疾病作为异基因造血干细胞移植的桥梁。

?

适用疾病: Relapsed Adult AML；Refractory AML；Acute Myelogenous Leukemia
干预: AdaptNK，Fludarabine，Cyclophosphamide，IL-2
地点: United States
申办方: Masonic Cancer Center, University of Minnesota

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07604064

A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia

AI 简述这是一项II期试验，研究Olutasidenib用于IDH1突变的复发难治性急性髓系白血病，在日本开展。

?

适用疾病: Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia
干预: Olutasidenib
地点: Japan
申办方: Kissei Pharmaceutical Co., Ltd.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07623616

A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

AI 简述这是一项II期试验，研究ziftomenib用于复发性或难治性NPM1突变急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia (AML)
干预: ziftomenib
地点: Japan
申办方: Kyowa Kirin Co., Ltd.

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07082452

A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction

AI 简述这是一项III期试验，比较7天Venetoclax暴露与标准连续Venetoclax暴露联合Azacitidine用于初治急性髓系白血病，在法国开展。

?

适用疾病: Leukemia, B-Cell, Chronic；Leukemia
干预: Venetoclax，Azacitidine
地点: France
申办方: Gustave Roussy, Cancer Campus, Grand Paris

即将招募 Phase 2, Phase 3 联合产品药物其他

ClinicalTrials.gov NCT07297914

Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL

AI 简述这是一项II/III期试验，优化儿童急性淋巴细胞白血病造血干细胞移植管理方案。

?

适用疾病: Acute Lymphoblastic Leukemia (ALL)；Stem Cell Transplant；Graft -Versus-host-disease
干预: Total Body Irradiation 8 Gy，Ruxolitinib，Blinatumomab，Cyclophosphamide
地点: Austria，Czechia，Denmark，Finland 等 5 个
申办方: Bambino Gesù Hospital and Research Institute

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07478991

Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)

AI 简述这是一项III期试验，研究阿扎胞苷、维奈托克联合Quizartinib用于老年/不适合的急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia, Adult
干预: Azacitidine，Venetoclax，Quizartinib
地点: Spain
申办方: PETHEMA Foundation

即将招募 Phase 2

NCI NCT06930352 / NCI-2025-02414

Ziftomenib for the Treatment of Patients with NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

AI 简述这是一项II期试验，研究Ziftomenib用于NPM1突变或KMT2A重排的AML患者。

?

适用疾病: Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: Ohio State University Comprehensive Cancer Center

即将招募 Phase 2

NCI NCT07557056 / NCI-2026-02422

Nemtabrutinib and Venetoclax for the Treatment of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

AI 简述一项II期试验，研究Nemtabrutinib和Venetoclax用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤。在美国开展。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: Ohio State University Comprehensive Cancer Center

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05054465

A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL

AI 简述这是一项I/II期试验，研究Venetoclax和Navitoclax用于高危T细胞急性淋巴细胞白血病。

?

适用疾病: Acute Lymphoblastic Leukemia
干预: Navitoclax，Venetoclax
地点: Israel
申办方: Israeli Medical Association

即将招募 Phase 2 药物放疗

ClinicalTrials.gov NCT05565105

CD34+ Transplants for Leukemia and Lymphoma

AI 简述这是一项II期试验，研究CD34+移植用于急性髓系白血病和急性淋巴细胞白血病。

?

适用疾病: Leukemia, Myeloid, Acute；Leukemia, Lymphocytic, Acute
干预: Total Body Irradiation (TBI)，Thiotepa，Cyclophosphamide，Busulfan
地点: United States
申办方: Guenther Koehne

即将招募 Phase 1, Phase 2 基因治疗

ClinicalTrials.gov NCT06281847

An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia

AI 简述这是一项I/II期试验，确定CCTx-001的推荐II期剂量并评估其用于复发/难治性急性髓系白血病。在法国、德国、西班牙、瑞典等地开展。

?

适用疾病: Acute Myeloid Leukemia, in Relapse；Acute Myeloid Leukemia Refractory
干预: CCTx-001
地点: France，Germany，Spain，Sweden
申办方: Advesya SAS

即将招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT06631040

Cell Therapy with Anti-CD19 CAR-NK Cells in Patients with Relapsed or Resistant B-ALL

AI 简述这是一项I/II期试验，研究抗CD19 CAR-NK细胞用于复发性B-ALL，在伊朗开展。

?

适用疾病: Acute Lymphocytic Leukemia in Relapse
干预: anti CD19 CAR NK cells
地点: Iran
申办方: Shahid Beheshti University of Medical Sciences

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06703216

Pre-emptive Anakinra for Cytokine Event Reduction

AI 简述这是一项I/II期试验，研究Anakinra用于降低B-ALL患者接受CAR-T后的细胞因子释放综合征风险，在美国开展。

?

适用疾病: B-Acute Lymphoblastic Leukemia；CAR-T Cell Therapy；Cytokine Release Syndrome
干预: Anakinra (Kineret®)
地点: United States
申办方: Ann & Robert H Lurie Children's Hospital of Chicago

即将招募 Phase 2 生物制剂其他

ClinicalTrials.gov NCT06783478

NK Cell Infusion for Remission Consolidation in AML: A Phase II Trial

AI 简述这是一项II期试验，研究NK细胞输注用于急性髓系白血病缓解后巩固治疗，在巴西开展。

?

适用疾病: Acute Myeloid Leukaemia (AML)
干预: NK cell infusion，Placebo
地点: Brazil
申办方: Hospital de Clinicas de Porto Alegre

即将招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT06903702 / NCI-2025-04171

A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia

AI 简述这是一项II期试验，比较阿扎胞苷和维奈克拉与干细胞移植用于65岁及以上急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia (AML)
干预: Azacitidine (AZA)，Venetoclax，Allogeneic hematopoietic stem cell transplantation
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06987058

RVU120 Rollover Study

AI 简述这是一项2期试验，研究RVU120用于晚期实体瘤、急性髓系白血病和高危骨髓增生异常综合征。在波兰、西班牙等地开展。

?

适用疾病: Advanced Solid Tumors；Acute Myeloid Leukaemia (AML)；High-risk Myelodysplastic Syndrome
干预: RVU120
地点: Poland，Spain
申办方: Ryvu Therapeutics SA

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07025824

Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation

AI 简述这是一项II期试验，比较Treosulfan与Melphalan预处理方案在AML和MDS患者异基因移植后使用PTCy，在德国开展。

?

适用疾病: AML - Acute Myeloid Leukemia；MDS (Myelodysplastic Syndrome)
干预: Treosulfan (Treo)，Melphalan (Mel)，Fludarabine (Flud)
地点: Germany
申办方: Technische Universität Dresden

即将招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT07026942 / NCI-2025-04622

Phase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML

AI 简述这是一项I/II期试验，研究通用供体来源的CD33 CAR-NK细胞用于复发/难治性急性髓系白血病，在美国开展。

?

适用疾病: Relapsed/Refractory AML；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)
干预: Universal donor derived CD33 CAR-NK
地点: United States
申办方: Nationwide Children's Hospital

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07053020

A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)

AI 简述这是一项I/II期试验，研究口服克拉屈滨联合阿糖胞苷用于急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia (AML)
干预: Cytarabine，Oral Cladribine
地点: United States
申办方: M.D. Anderson Cancer Center

即将招募 Phase 2 诊断检测药物

ClinicalTrials.gov NCT07060001

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

AI 简述这是一项II期试验，比较去甲基化药物与强化化疗用于急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia (AML)；Acute Myeloid Leukaemia (AML)
干预: 5hmC Biomarker，Venetoclax，Decitabine 20 mg/m²/day for 5 days，Azacitidine (AZA)
地点: United States
申办方: The Methodist Hospital Research Institute

即将招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT07162571

This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.

AI 简述这是一项1/2期试验，研究CD19/22 CAR-T细胞用于复发/难治性急性淋巴细胞白血病/淋巴瘤，在白俄罗斯开展。

?

适用疾病: Acute Lymphobkastic Leukemia；B Cell Lymphoma
干预: CD19/22 CAR-T cells
地点: Belarus
申办方: Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology

即将招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07178912 / NCI-2025-06675

Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)

AI 简述这是一项II期试验，研究皮下注射Blinatumomab联合Olverembatinib用于费城染色体阳性急性淋巴细胞白血病，在美国开展。

?

适用疾病: Phase II Clinical Trial；Blinatumomab；Olverembatinib
干预: Blinatumomab，olverembatinib
地点: United States
申办方: M.D. Anderson Cancer Center

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07192237

Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia

AI 简述这是一项II期试验，研究皮下注射Blinatumomab用于MRD阳性B细胞急性淋巴细胞白血病。

?

适用疾病: Phase 2 Study；Blinatumomab；Acute Lymphoblastic Leukemia
干预: Blinatumomab
地点: United States
申办方: M.D. Anderson Cancer Center

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07214064

Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation

AI 简述这是一项II期试验，在德国研究Venetoclax增强Treosulfan为基础的预处理后行异基因干细胞移植。

?

适用疾病: AML (Acute Myeloid Leukemia)；MDS/AML；MDS (Myelodysplastic Syndrome)
干预: RIC regimen
地点: Germany
申办方: University Hospital Tuebingen

即将招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07227584 / NCI-2026-02349

ALL Backbone in AYAs

AI 简述这是一项II期试验，研究Blinatumomab联合化疗用于费城染色体阴性的急性淋巴细胞白血病。

?

适用疾病: Acute Lymphoblastic Leukemia；Philadelphia Chromosome-Negative Lymphoblastic Leukemia；Acute Lymphoblastic Leukemia (ALL)
干预: Blinatumomab，Oncaspar，Cyclophosphamide，Cytarabine
地点: United States
申办方: Dana-Farber Cancer Institute

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07301424

Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL

AI 简述这是一项II期试验，研究皮下Blinatumomab联合Ponatinib用于BCR-ABL阳性急性淋巴细胞白血病。在加拿大开展。

?

适用疾病: Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)；BCR-ABL Positive Acute Lymphoblastic Leukemia
干预: Treatment with blinatumomab given subcutaneously.
地点: Canada
申办方: University of Alberta

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07311746

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

AI 简述这是一项I/II期试验，研究Cladribine、Ruxolitinib和Venetoclax用于复发/难治性T细胞幼淋巴细胞白血病，在美国开展。

?

适用疾病: T-cell Prolymphocytic Leukemia；Refractory T-Cell Prolymphocytic Leukemia
干预: Ruxolitinib，Cladribine，Venetoclax
地点: United States
申办方: M.D. Anderson Cancer Center

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07313852

A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia

AI 简述这是一项I/II期试验，研究Inotuzumab和Blinatumomab用于B细胞急性淋巴细胞白血病。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia；B-Cell Acute Lymphoblastic Leukemia, Adult；B-ALL
干预: Blinatumomab Injection
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

即将招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT07372885

GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia

AI 简述这是一项I/II期试验，在英国研究粒细胞增强脐血移植用于高危白血病。

?

适用疾病: Acute Myeloid Leukemia；Stem Cell Transplantation；Stem Cell Transplantation, Hematopoietic
干预: Cord blood transplantation + conditioning + granulocytes of variable days according to study design
地点: United Kingdom
申办方: University of Manchester

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07463768

Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.

AI 简述这是一项II期试验，研究Ivosidenib联合口服阿扎胞苷用于IDH1突变急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia
干预: Ivosidenib + oral azacitidine
地点: France
申办方: French Innovative Leukemia Organisation

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07493408

Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML

AI 简述这是一项II期试验，研究Asciminib联合标准治疗用于Ph+ B-ALL或CML急变期患者异基因移植后维持治疗，在香港开展。

?

适用疾病: Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)；Blastic Transformation of Chronic Myeloid Leukemia；Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL)
干预: Asciminib add-on，Imatinib，Dasatinib，Nilotinib
地点: Hong Kong
申办方: The University of Hong Kong

即将招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT07507760

Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients

AI 简述这是一项II期试验，在Spain研究口服地西他滨联合艾伏尼布用于老年或不适合强化疗的初治急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia With Gene Mutations
干预: Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET，Ivosidenib Oral Tablet，Hydroxyurea，Cytarabine
地点: Spain
申办方: PETHEMA Foundation

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07508995

A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

AI 简述这是一项II期试验，在United States研究BTK降解剂BGB-16673联合BCL-2抑制剂Sonrotoclax用于初治慢性淋巴细胞白血病。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)
干预: BGB-16673，BGB-11417
地点: United States
申办方: M.D. Anderson Cancer Center

即将招募 Phase 2 生物制剂

ClinicalTrials.gov NCT07552649

Matched Sibling Allogenic Stem Cell Transplantation With Adoptive Immunotherapy With Regulatory And Conventional T Cells For High Risk Acute Myeloid Leukemia

AI 简述这是一项II期试验，研究Treg/Tcon过继免疫疗法联合全相合同胞异基因干细胞移植用于高危急性髓系白血病，在意大利开展。

?

适用疾病: AML (Acute Myeloid Leukemia)
干预: HSCT with Treg/Tcon adoptive immunotherapy
地点: Italy
申办方: Antonio Pierini

即将招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07566364 / NCI-2026-03445

Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD

AI 简述这是一项II期试验，研究Mosunetuzumab用于慢性淋巴细胞白血病MRD阳性患者。

?

适用疾病: Lymphocytic Leukemia；Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma；Chronic Lymphocytic Leukemia (CLL)
干预: Mosunetuzumab
地点: United States
申办方: M.D. Anderson Cancer Center

即将招募 Phase 2 药物其他

ClinicalTrials.gov NCT07572929

A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant

AI 简述这是一项II期试验，评估移植前针对髓系恶性肿瘤可测量病变的干预以预防复发。

?

适用疾病: Myeloid Disorders；Myelodysplastic Syndromes；Myeloproliferative Neoplasm
干预: Maintenance Therapy，No intervention
地点: United States
申办方: Medical College of Wisconsin

即将招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov NCT07582159

Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

AI 简述这是一项II期试验，研究Tafasitamab联合Acalabrutinib和Venetoclax用于慢性淋巴细胞白血病/小淋巴细胞淋巴瘤。

?

适用疾病: Chronic Lymphocytic Leukemia；Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma；Small Lymphocytic Lymphoma
干预: Acalabrutinib，Biospecimen Collection，Bone Marrow Biopsy，Computed Tomography
地点: United States
申办方: City of Hope Medical Center

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07604233

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

AI 简述这是一项I/II期试验，研究FLAG-IDA、维奈克拉和阿西米尼用于慢性髓系白血病和费城染色体阳性急性髓系白血病，在美国开展。

?

适用疾病: Myeloid Leukemia
干预: Fludarabine，Cytarabine，Idarubicin，Filgrastim
地点: United States
申办方: M.D. Anderson Cancer Center

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07605949

Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML

AI 简述这是一项II期试验，研究阿扎胞苷、维奈克拉和Revumenib用于新诊断的KMT2A重排急性髓系白血病，在美国开展。

?

适用疾病: Leukemia Acute Myeloid
干预: Azacitidine，Venetoclax，Revumenib
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

即将招募 Phase 2 生物制剂药物放疗

ClinicalTrials.gov NCT07634536

Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant

AI 简述这是一项II期试验，研究全骨髓淋巴照射用于异基因造血干细胞移植，在美国开展。

?

适用疾病: Acute Myeloid Leukemia；Myeloproliferative Neoplasm；Myelodysplastic Syndromes
干预: VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI)，Fludarabine，Cyclophosphamide，Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT)
地点: United States
申办方: Stanford University

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07674810

A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia

AI 简述这是一项2期试验，在美国研究Zanubrutinib、Sonrotoclax和Obinutuzumab用于初治慢性淋巴细胞白血病。

?

适用疾病: Chronic Lymphocytic Leukemia
干预: Zanubrutinib，Obinutuzumab，Sonrotoclax
地点: United States
申办方: M.D. Anderson Cancer Center

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07690891

Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia

AI 简述这是一项II期试验，研究Nemtabrutinib联合Venetoclax和Obinutuzumab用于慢性淋巴细胞白血病。在美国等地开展。

?

适用疾病: Chronic Lymphocytic Leukemia
干预: Nemtabrutinib，Venetoclax，Obinutuzumab
地点: United States
申办方: Medical College of Wisconsin

正在招募 Phase 2, Phase 3 药物放疗

ClinicalTrials.gov NCT01949129

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

AI 简述这是一项2/3期试验，研究异基因干细胞移植用于儿童和青少年急性淋巴细胞白血病，在多国开展。

?

适用疾病: Acute Lymphoblastic Leukaemia
干预: VP16，TBI，Thiotepa，Treosulfan
地点: Argentina，Australia，Austria，Belarus 等 27 个
申办方: St. Anna Kinderkrebsforschung

正在招募 Phase 2, Phase 3 生物制剂药物

ClinicalTrials.gov NCT03937544

Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL

AI 简述这是一项II/III期试验，研究CD19 CAR-T细胞用于复发难治B细胞急性淋巴细胞白血病，在马来西亚开展。

?

适用疾病: Relapsed B Acute Lymphoblastic Leukaemia；Refractory B Acute Lymphoblastic Leukaemia
干预: CD19 CAR-T CELLS，Cyclophosphamide，Fludarabine
地点: Malaysia
申办方: National University of Malaysia

正在招募阶段未标明

NCI NCT00550992 / NCI-2014-00665

Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia

AI 简述这是一项研究不同疗法用于新诊断急性白血病婴儿的试验。

?

适用疾病: Acute Lymphoblastic Leukemia (ALL)
干预: 未列出
地点: United States
申办方: Dutch Childhood Oncology Group

正在招募 Phase 1

NCI NCT03016377 / NCI-2016-01799

Autologous IC9-CAR19 T cells in Treating Patients with Recurrent or Refractory Acute Lymphoblastic Leukemia

AI 简述这是一项I期试验，研究自体IC9-CAR19 T细胞用于复发难治B急性淋巴细胞白血病。

?

适用疾病: Recurrent B Acute Lymphoblastic Leukemia；Refractory B Acute Lymphoblastic Leukemia；Acute Lymphoblastic Leukemia (ALL)
干预: 未列出
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT03328104 / NCI-2017-01717

Everolimus, Nelarabine, Cyclophosphamide, and Etoposide Phosphate in Treating Patients with Relapsed or Refractory T Cell Lymphoblastic Leukemia or Lymphoma

AI 简述一项I期试验，研究Everolimus、Nelarabine等药物用于复发/难治性T细胞淋巴母细胞白血病或淋巴瘤。

?

适用疾病: Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified；Recurrent T Lymphoblastic Leukemia/Lymphoma；Refractory T Lymphoblastic Leukemia/Lymphoma
干预: 未列出
地点: United States
申办方: Children's Healthcare of Atlanta - Arthur M Blank Hospital

正在招募 Phase 1

NCI NCT03494569 / NCI-2018-00497

Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Patients with High-Risk Acute Leukemia or Myelodysplastic Syndrome

AI 简述这是一项I期试验，研究TMLI联合氟达拉滨和美法仑用于高危急性白血病或骨髓增生异常综合征的供者干细胞移植前预处理。在美国开展。

?

适用疾病: Secondary Acute Myeloid Leukemia (AML)；Acute Lymphoblastic Leukemia (ALL)；Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 O

NCI NCT03537482 / NCI-2018-02408

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

AI 简述这是一项其他阶段的试验，研究APG-2575用于血液系统恶性肿瘤。

?

适用疾病: Recurrent Waldenstrom Macroglobulinemia；Refractory Acute Myeloid Leukemia (AML)；Refractory Waldenstrom Macroglobulinemia
干预: 未列出
地点: United States
申办方: Ascentage Pharma

正在招募 Phase 1

NCI NCT03647800 / NCI-2019-00146

Study of APVO436 in Patients With AML or MDS

AI 简述这是一项I期试验，研究APVO436用于复发或难治性急性髓系白血病或骨髓增生异常综合征。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Refractory Myelodysplastic Syndrome；Recurrent Myelodysplastic Syndrome
干预: 未列出
地点: United States
申办方: Aptevo Research and Development LLC

正在招募 Phase 1

NCI NCT03874052 / NCI-2019-03272

Ruxolitinib in Combination with Venetoclax with and without Azacitidine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究Ruxolitinib联合Venetoclax加或不加阿扎胞苷用于复发/难治性急性髓系白血病。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)；Recurrent Secondary Acute Myeloid Leukemia
干预: 未列出
地点: United States
申办方: OHSU Knight Cancer Institute

正在招募 Phase 1

NCI NCT02650414 / NCI-2019-05330

Genetically Engineered Cells (CART22 T Cells) for the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Pediatric Patients

AI 简述这是一项I期试验，研究CART22细胞用于儿童复发或难治性B细胞急性淋巴细胞白血病。

?

适用疾病: Recurrent B Acute Lymphoblastic Leukemia；Refractory B Acute Lymphoblastic Leukemia；Allogeneic Hematopoietic Stem Cell Transplantation Recipient
干预: 未列出
地点: United States
申办方: Children's Hospital of Philadelphia

正在招募 Phase 1

NCI NCT03921879 / NCI-2019-05350

Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma

AI 简述这是一项I期试验，研究OT-82用于复发难治性淋巴瘤，在美国开展。

?

适用疾病: Refractory Lymphoma；Recurrent Lymphoma；Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
干预: 未列出
地点: United States
申办方: Oncotartis, Inc.

正在招募 Phase 1

NCI NCT03810196 / NCI-2019-05828

CD45RA Depleted T Cell Infusion after Alpha/Beta Depleted Stem Cell Transplant for the Reduction of Complications in Patients at Risk for Viral or Fungal Infections

AI 简述这是一项I期试验，研究CD45RA耗竭T细胞输注用于接受干细胞移植后病毒感染风险的患者。在美国开展。

?

适用疾病: Matched Related Donor；Matched Unrelated Donor；Allogeneic Hematopoietic Stem Cell Transplantation Recipient
干预: 未列出
地点: United States
申办方: Children's Hospital of Philadelphia

正在招募 Phase 1

NCI NCT04429191 / NCI-2020-06415

JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

AI 简述这是一项I期试验，研究JSP191抗体预处理方案用于MDS/AML患者异基因造血干细胞移植。

?

适用疾病: Acute Myeloid Leukemia (AML)；Myelodysplastic Syndrome
干预: 未列出
地点: United States
申办方: Jasper Therapeutics, Inc.

正在招募 O

NCI NCT03719105 / NCI-2021-00444

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

AI 简述一项早期I期试验，研究化疗免疫联合异基因干细胞移植用于NK/T细胞白血病/淋巴瘤，在美国开展。

?

适用疾病: Hematopoietic and Lymphoid Cell Neoplasm；T-Cell and NK-Cell Neoplasm；Mature T-Cell and NK-Cell Neoplasm
干预: 未列出
地点: United States
申办方: New York Medical College

正在招募 Phase 1

NCI NCT04848064 / NCI-2021-01375

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

AI 简述这是一项I期试验，研究第三方自然杀伤细胞和Mogamulizumab用于复发性或难治性皮肤T细胞淋巴瘤。

?

适用疾病: Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma；Recurrent Adult T-Cell Leukemia/Lymphoma；Refractory Adult T-Cell Leukemia/Lymphoma
干预: 未列出
地点: United States
申办方: Ohio State University Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT04684563 / NCI-2021-05843

huCART19-IL18 Cells for the Treatment of Relapsed or Refractory CD19+ Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Acute Lymphoblastic Leukemia

AI 简述这是一项I期试验，研究huCART19-IL18细胞用于复发/难治CD19+非霍奇金淋巴瘤、慢性淋巴细胞白血病或急性淋巴细胞白血病，在美国开展。

?

适用疾病: Recurrent B Acute Lymphoblastic Leukemia；Refractory B Acute Lymphoblastic Leukemia；Refractory Double-Hit Lymphoma
干预: 未列出
地点: United States
申办方: University of Pennsylvania/Abramson Cancer Center

正在招募 Phase 1

NCI NCT04640987 / NCI-2021-06751

T-allo10 Infusion Therapy to Prevent Graft Versus Host Disease and Improve Potential Immune Reconstitution in Patients who received Hematopoietic Stem Cell Transplantation

AI 简述这是一项I期试验，研究T-allo10输注预防移植物抗宿主病并改善造血干细胞移植患者的免疫重建。

?

适用疾病: Recurrent B Acute Lymphoblastic Leukemia；Recurrent Myelodysplastic Syndrome；Recurrent Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: Lucile Packard Children's Hospital Stanford University

正在招募 Phase 1

NCI NCT04996160 / NCI-2021-09313

Palbociclib, Bortezomib, Dexamethasone, and Doxorubicin for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia, RELPALL2 Study

AI 简述这是一项I期试验，研究Palbociclib、硼替佐米、地塞米松和阿霉素用于复发或难治性急性淋巴细胞白血病，在美国开展。

?

适用疾病: Refractory Acute Lymphoblastic Leukemia (ALL)；Recurrent Acute Lymphoblastic Leukemia
干预: 未列出
地点: United States
申办方: Lucile Packard Children's Hospital Stanford University

正在招募 Phase 1

NCI NCT05011422 / NCI-2022-03995

Donor Blood Stem Cells (Ex Vivo TCR Alpha/Beta and CD19-Depleted Stem Cells) for the Prevention of Graft-versus-Host Disease in Pediatric Patients with Blood Cancer

AI 简述这是一项I期试验，研究TCRαβ/CD19去除的供体干细胞用于儿童血液肿瘤。

?

适用疾病: Acute Myeloid Leukemia (AML) with Abnormalities of Chromosome 5q；Acute Myeloid Leukemia (AML) with FLT3/ITD；Refractory Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: Siteman Cancer Center at Washington University

正在招募 Phase 1

NCI NCT05003141 / NCI-2022-04194

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

AI 简述这是一项I期试验，研究PSB202用于复发难治惰性B细胞恶性肿瘤。

?

适用疾病: Recurrent Waldenstrom Macroglobulinemia；Refractory Waldenstrom Macroglobulinemia；Refractory Marginal Zone Lymphoma
干预: 未列出
地点: United States
申办方: Qilu Puget Sound Biotherapeutics (dba Sound Biologics)

正在招募 Phase 1

NCI NCT05487651 / NCI-2022-07299

Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies

AI 简述这是一项I期试验，研究同种异体CAR-T细胞（靶向CD19）用于B细胞恶性肿瘤。

?

适用疾病: Refractory Acute Lymphoblastic Leukemia (ALL)；Recurrent Acute Lymphoblastic Leukemia；Recurrent B Acute Lymphoblastic Leukemia
干预: 未列出
地点: United States
申办方: Athenex, Inc.

正在招募 Phase 1

NCI NCT05457010 / NCI-2022-08124

Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS

AI 简述这是一项I期试验，研究细胞疗法用于复发难治性急性髓系白血病或高危骨髓增生异常综合征。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Refractory Myelodysplastic Syndrome；Recurrent Myelodysplastic Syndrome
干预: 未列出
地点: United States
申办方: Arcellx

正在招募 Phase 1

NCI NCT05304377 / NCI-2022-08261

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

AI 简述这是一项1期试验，研究ELVN-001用于复发或难治性慢性粒细胞白血病。在美国开展。

?

适用疾病: Recurrent Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive；Refractory Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive；Refractory Chronic Myelogenous Leukemia (CML)
干预: 未列出
地点: United States
申办方: EnLiven Therapeutics

正在招募 Phase 1

NCI NCT05798897 / NCI-2023-03005

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

AI 简述这是一项I期试验，研究MT-601用于复发/难治性淋巴瘤，在美国开展。

?

适用疾病: Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma；Recurrent Central Nervous System Lymphoma；Refractory Central Nervous System Lymphoma
干预: 未列出
地点: United States
申办方: Marker Therapeutics, Inc.

正在招募阶段未标明

NCI NCT05893940 / NCI-2023-03605

Low-Intensity Mechanical Stimulation for Hematologic Malignancy Patients

AI 简述这是一项研究低强度机械刺激用于血液系统恶性肿瘤患者。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Follicular Lymphoma；Hematopoietic and Lymphoid System Neoplasm
干预: 未列出
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 1

NCI NCT05943496 / NCI-2023-04657

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

AI 简述这是一项I期试验，研究Tafasitamab、Acalabrutinib和Obinutuzumab用于未经治疗的慢性淋巴细胞白血病。在美国开展。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: OHSU Knight Cancer Institute

正在招募阶段未标明

NCI NCT05528939 / NCI-2023-05652

Feasibility/Acceptability of Attentional-Control Training in Survivors

AI 简述这是一项可行性研究，评估注意力控制训练用于脑肿瘤或急性淋巴细胞白血病幸存者。

?

适用疾病: Brain Tumor；Acute Lymphoblastic Leukemia (ALL)
干预: 未列出
地点: United States
申办方: Children's National Research Institute

正在招募 Phase 1

NCI NCT05967416 / NCI-2023-10268

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

AI 简述这是一项I期试验，研究SIRPant-M用于复发难治非霍奇金淋巴瘤。

?

适用疾病: Recurrent Primary Cutaneous (Skin) Diffuse Large B-Cell Lymphoma, Leg Type；Refractory Primary Cutaneous (Skin) Diffuse Large B-Cell Lymphoma, Leg Type；Recurrent Sezary Syndrome
干预: 未列出
地点: United States
申办方: SIRPant Immunotherapeutics, Inc.

正在招募 Phase 1

NCI NCT05780034 / NCI-2023-10648

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

AI 简述这是一项I期试验，研究AC676用于复发/难治性B细胞恶性肿瘤。在美国开展。

?

适用疾病: Recurrent Waldenstrom Macroglobulinemia；Refractory Waldenstrom Macroglobulinemia；Refractory Marginal Zone Lymphoma
干预: 未列出
地点: United States
申办方: Accutar Biotechnology Inc

正在招募 Phase 1

NCI NCT06357182 / NCI-2024-01262

Iadademstat in Combination with Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究Iadademstat联合Azacitidine和Venetoclax用于新诊断急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia (AML)；Myelodysplastic Syndrome/Acute Myeloid Leukemia
干预: 未列出
地点: United States
申办方: OHSU Knight Cancer Institute

正在招募 Phase 1

NCI NCT06071624 / NCI-2024-01323

CD4CAR T Cell Therapy for the Treatment of Patients with Relapsed or Refractory CD4 Positive CMML

AI 简述这是一项I期试验，研究CD4CAR T细胞用于复发或难治性CD4阳性慢性粒单核细胞白血病。

?

适用疾病: Recurrent Chronic Myelomonocytic Leukemia；Refractory Chronic Myelomonocytic Leukemia (CMML)
干预: 未列出
地点: United States
申办方: Indiana University/Melvin and Bren Simon Cancer Center

正在招募 Phase 1

NCI NCT06008808 / NCI-2024-02152

Ruxolitinib with or without Abatacept for the Prevention of Graft Versus Host Disease and Cytokine Release Syndrome after T-cell Haploidentical Stem Cell Transplant in Patients with Hematologic Malignancies

AI 简述这是一项I期试验，研究Ruxolitinib联合或不联合Abatacept用于预防单倍体干细胞移植后的移植物抗宿主病和细胞因子释放综合征，适用于血液恶性肿瘤。

?

适用疾病: Graft Versus Host Disease；Acute Lymphoblastic Leukemia (ALL)；Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: Siteman Cancer Center at Washington University

正在招募 Phase 1

NCI NCT06447987 / NCI-2024-03338

Humanized CD19-Specific CAR T Cells for the Treatment of Patients with Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

AI 简述这是一项I期试验，研究人源化CD19 CAR-T细胞用于复发或难治性CD19阳性B细胞急性淋巴细胞白血病。

?

适用疾病: Refractory Acute Lymphoblastic Leukemia (ALL)；Recurrent Acute Lymphoblastic Leukemia
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT06498973 / NCI-2024-05359

Tagraxofusp and Azacitidine for Maintenance Treatment in Patients with CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

AI 简述这是一项I期试验，研究Tagraxofusp联合Azacitidine用于CD123阳性AML和MDS移植后维持。

?

适用疾病: Acute Myeloid Leukemia (AML)；Myelodysplastic Syndrome
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT06575296 / NCI-2024-06738

Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant

AI 简述这是一项I期试验，研究Revumenib用于治疗异基因造血干细胞移植后急性白血病儿童患者。

?

适用疾病: Childhood Acute Leukemia；Childhood Acute Leukemia of Ambiguous Lineage；Acute Lymphoblastic Leukemia (ALL)
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT06712810 / NCI-2024-09563

Q702 for the Treatment of Patients with Hematologic Malignancies

AI 简述这是一项I期试验，研究Q702用于复发性/难治性血液系统恶性肿瘤。

?

适用疾病: Recurrent Waldenstrom Macroglobulinemia；Recurrent Langerhans Cell Histiocytosis；Refractory Langerhans Cell Histiocytosis
干预: 未列出
地点: United States
申办方: Mayo Clinic in Rochester

正在招募 Phase 1

NCI NCT06763341 / NCI-2024-10209

AOH1996 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

AI 简述这是一项I期试验，在美国研究AOH1996用于复发或难治性急性髓系白血病或骨髓增生异常综合征。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Refractory Myelodysplastic Syndrome；Recurrent Myelodysplastic Syndrome
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT06590961 / NCI-2025-00075

UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies

AI 简述这是一项I期试验，研究UBX-303061用于复发/难治性B细胞恶性肿瘤，在美国开展。

?

适用疾病: Recurrent Waldenstrom Macroglobulinemia；Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma；Refractory Waldenstrom Macroglobulinemia
干预: 未列出
地点: United States
申办方: Ubix Therapeutics, Inc.

正在招募 Phase 1

NCI NCT07168486 / NCI-2025-00309

Autologous CAR19.20.22 Chimeric Antigen Receptor T Cells (CAR19.20.22 CART) for the Treatment of Recurrent or Refractory B-Cell Lymphomas

AI 简述这是一项I期试验，在United States开展，研究自体CAR19.20.22 CAR-T细胞用于复发或难治性B细胞淋巴瘤。

?

适用疾病: Refractory Marginal Zone Lymphoma；Recurrent Transformed Chronic Lymphocytic Leukemia；Refractory Transformed Chronic Lymphocytic Leukemia
干预: 未列出
地点: United States
申办方: University of Maryland/Greenebaum Cancer Center

正在招募 Phase 1

NCI NCT06859008 / NCI-2025-01388

Zanubrutinib in Combination with Sonrotoclax for the Treatment of Underrepresented Minorities with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

AI 简述这是一项I期试验，研究泽布替尼联合Sonrotoclax用于复发或难治性B细胞非霍奇金淋巴瘤。

?

适用疾病: Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma；Recurrent Grade 3a Follicular Lymphoma；Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT06871410 / NCI-2025-01523

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究CD83 CAR-T细胞用于复发难治性急性髓系白血病。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 1

NCI NCT06823167 / NCI-2025-03470

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

AI 简述这是一项I期试验，在美国开展，研究IM-1021用于多种晚期实体瘤。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: Immunome, Inc.

正在招募 Phase 1

NCI NCT06996119 / NCI-2025-03603

Emapalumab with Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

AI 简述这是一项I期试验，在美国研究Emapalumab联合移植后环磷酰胺等预防移植物抗宿主病。

?

适用疾病: Graft Versus Host Disease；Acute Myeloid Leukemia (AML)；Myelodysplastic Syndrome
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT07040982 / NCI-2025-04103

Asciminib as Maintenance Treatment after Cellular Therapies for Adults with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

AI 简述这是一项I期试验，研究Asciminib用于费城染色体阳性急性淋巴细胞白血病细胞治疗后的维持治疗，在美国开展。

?

适用疾病: B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募阶段未标明

NCI NCT06047886 / NCI-2025-05184

Selection of CD34 Positive Stem Cells using CliniMACS Prodigy Device for the Prevention of Graft-versus-Host Disease

AI 简述这是一项在美国开展的试验，使用CliniMACS Prodigy设备筛选CD34阳性干细胞用于预防移植物抗宿主病。

?

适用疾病: Primary Myelofibrosis；Acute Lymphoblastic Leukemia (ALL)；Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: University of Alabama at Birmingham Cancer Center

正在招募 Phase 1

NCI NCT07140016 / NCI-2025-08161

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

AI 简述这是一项I期试验，在美国、法国、西班牙等地开展，研究Gilteritinib用于ALK阳性晚期非小细胞肺癌。

?

适用疾病: Stage III Lung Cancer；Stage IV Lung Cancer；Metastatic Lung Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 1

NCI NCT07444632 / NCI-2026-01395

TGFBR2 KO CAR27/IL-15 Natural Killer Cells for the Treatment of Relapsed/Refractory Lymphoid Cancers

AI 简述这是一项I期试验，研究CAR.70工程化的NK细胞用于复发/难治性淋巴恶性肿瘤。

?

适用疾病: Recurrent B Acute Lymphoblastic Leukemia；Refractory B Acute Lymphoblastic Leukemia；Recurrent Hodgkin Lymphoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1

NCI NCT07444268 / NCI-2026-01865

How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers

AI 简述这是一项I期试验，研究[14C]-DSP-5336在晚期血液癌症患者体内的吸收和代谢，在美国开展。

?

适用疾病: Refractory Myelodysplastic Syndrome；Recurrent Myelodysplastic Syndrome；Recurrent Acute Leukemia
干预: 未列出
地点: United States
申办方: Sumitomo Pharma America, Inc.

正在招募 Phase 1

NCI NCT07572006 / NCI-2026-03867

A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

AI 简述这是一项I期试验，研究JNJ-95804306用于复发/难治血液恶性肿瘤。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Refractory Myelodysplastic Syndrome；Recurrent Myelodysplastic Syndrome
干预: 未列出
地点: United States
申办方: Janssen Research & Development, LLC

正在招募 Phase 1

NCI NCT07451054 / NCI-2026-04589

CD45 Base Edited Hematopoietic and Progenitor Stem Cell Transplant Followed by Anti-CD45 Chimeric Antigen Receptor T-cells for the Treatment of Relapsed or Refractory Lymphoma

AI 简述这是一项1期试验，研究CD45BE-HSPC联合CART-45细胞用于复发/难治性淋巴瘤，在美国开展。

?

适用疾病: Recurrent Classical Hodgkin Lymphoma；Refractory Classical Hodgkin Lymphoma；High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
干预: 未列出
地点: United States
申办方: University of Pennsylvania/Abramson Cancer Center

正在招募 Phase 1 基因治疗

ClinicalTrials.gov / NCI NCT01853631 / NCI-2013-01017

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

AI 简述这是一项I期试验，研究CD19特异性CAR-T细胞用于晚期B细胞淋巴瘤和白血病，在美国开展。

?

适用疾病: Non-Hodgkin Lymphoma；Chronic Lymphocytic Leukemia；Acute Lymphocytic Leukemia
干预: Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells，Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells
地点: United States
申办方: Baylor College of Medicine

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT02074839 / NCI-2014-00720

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

AI 简述这是一项1期试验，研究口服AG-120用于IDH1突变的晚期血液恶性肿瘤，在美国和法国开展。

?

适用疾病: Relapsed or Refractory Acute Myeloid Leukemia (AML)；Untreated AML；Other IDH1-mutated Positive Hematologic Malignancies
干预: AG-120
地点: United States，France
申办方: Institut de Recherches Internationales Servier

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT02203903 / NCI-2019-05453

Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies

AI 简述这是一项I期试验，研究多抗原特异性淋巴细胞治疗高危血液系统恶性肿瘤，在美国开展。

?

适用疾病: Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS；Acute Myeloid Leukemia (AML)；Myelodysplastic Syndrome
干预: Tumor associated antigen lymphocytes (TAA-T)
地点: United States
申办方: Catherine Bollard

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT02390752 / NCI-2018-02301

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

AI 简述这是一项I期试验，研究Pexidartinib用于儿童和年轻成人难治性白血病、实体瘤及神经纤维瘤病1型相关丛状神经纤维瘤。

?

适用疾病: Neurofibroma, Plexiform；Precursor Cell Lymphoblastic Leukemia-Lymphoma；Leukemia, Promyelocytic, Acute
干预: TURALIO(R)
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov NCT02443831

CARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia

AI 简述这是一项I期试验，研究CD19+CD22 CAR T细胞用于CD19+和CD22+急性淋巴细胞白血病。

?

适用疾病: Acute Lymphoblastic Leukemia
干预: Leukapheresis，Total Body Irradiation (TBI)，Lymphodepletion with Fludarabine，Lymphodepletion with Cyclophosphamide
地点: United Kingdom
申办方: University College, London

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT02508038 / NCI-2015-01163

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

AI 简述这是一项I期试验，研究TCRαβ+/CD19+去除的半相合移植联合唑来膦酸用于儿童血液恶性肿瘤和实体瘤。

?

适用疾病: Acute Myeloid Leukemia；Acute Lymphoblastic Leukemia；Hodgkin Lymphoma
干预: TCRαβ+/CD19+ depleted Haploidentical HSCT，Zoledronate
地点: United States
申办方: University of Wisconsin, Madison

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT03017820 / NCI-2017-00049

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

AI 简述这是一项I期试验，研究疫苗VSV-hIFNβ-NIS联合或不联合免疫治疗用于复发难治多发性骨髓瘤、急性髓系白血病或淋巴瘤。

?

适用疾病: B-Cell Non-Hodgkin Lymphoma；Histiocytic and Dendritic Cell Neoplasm；Myelodysplastic Syndrome
干预: Biopsy Procedure，Biospecimen Collection，Bone Marrow Biopsy，Computed Tomography
地点: United States
申办方: Mayo Clinic

正在招募 Phase 1 基因治疗

ClinicalTrials.gov / NCI NCT03081910 / NCI-2018-00726

Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen

AI 简述这是一项I期试验，研究CD5.CAR T细胞治疗T细胞恶性肿瘤，在美国开展。

?

适用疾病: T-cell Acute Lymphoblastic Lymphoma；T-non-Hodgkin Lymphoma；T-cell Acute Lymphoblastic Leukemia
干预: Autologous CD5.CAR/28zeta CAR T cells，Allogeneic CD5.CAR/28zeta CAR T cells
地点: United States
申办方: Baylor College of Medicine

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT03113643 / NCI-2017-01200

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

AI 简述这是一项I期试验，研究SL-401联合Azacitidine加或不加Venetoclax用于急性髓系白血病等。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndrome；Blastic Plasmacytoid Dendritic Cell Neoplasm
干预: Azacitidine，SL-401，Venetoclax
地点: United States
申办方: Dana-Farber Cancer Institute

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT03219450 / NCI-2021-03482

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

AI 简述这是一项I期试验，研究个性化新抗原疫苗NeoVax联合环磷酰胺和帕博利珠单抗用于未治疗的慢性淋巴细胞白血病。

?

适用疾病: Lymphocytic Leukemia；Chronic Lymphocytic Leukemia (CLL)
干预: NeoVax，Cyclophosphamide，Pembrolizumab
地点: United States
申办方: Dana-Farber Cancer Institute

正在招募 Phase 1 生物制剂手术/操作

ClinicalTrials.gov / NCI NCT03326921 / NCI-2017-01054

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

AI 简述一项I期试验，研究HA-1 T细胞受体T细胞免疫治疗用于供体干细胞移植后复发的急性白血病。

?

适用疾病: Juvenile Myelomonocytic Leukemia；Recurrent Acute Biphenotypic Leukemia；Recurrent Acute Undifferentiated Leukemia
干预: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR，Bone Marrow Aspiration，Biospecimen Collection
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT03533816 / NCI-2020-01655

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

AI 简述这是一项I期试验，研究扩增/活化γδT细胞输注用于造血干细胞移植后。在美国开展。

?

适用疾病: Acute Myeloid Leukemia；Chronic Myeloid Leukemia；Acute Lymphoblastic Leukemia
干预: EAGD T-cell infusion (Phase I)，EAGD T-cell infusion (Expansion)
地点: United States
申办方: University of Kansas Medical Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT03571321 / NCI-2018-02108

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

AI 简述这是一项I期试验，研究Ruxolitinib联合化疗用于青少年和青年Ph样急性淋巴细胞白血病。

?

适用疾病: Acute Lymphoblastic Leukemia；ALL, Childhood；ALL
干预: Ruxolitinib，Cyclophosphamide，Cytarabine，Mercaptopurine
地点: United States
申办方: University of Chicago

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT03595917 / NCI-2018-02377

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

AI 简述这是一项I期试验，研究ABL001、Dasatinib、强的松和Blinatumomab用于BCR-ABL阳性B细胞急性淋巴细胞白血病或慢性粒细胞白血病。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia；Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis；Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
干预: ABL001，Dasatinib，Prednisone，Blinatumomab
地点: United States
申办方: Marlise Luskin, MD

正在招募 Phase 1 Dietary_Supplement药物

ClinicalTrials.gov NCT03630991

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

AI 简述这是一项I期试验，研究Ca-EDTA或succimer用于接受化疗的急性髓系白血病或骨髓增生异常综合征患者。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome；Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
干预: Edetate Calcium Disodium，Multivitamin，Succimer
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT03666000 / NCI-2019-01892

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

AI 简述这是一项I期试验，研究Azer-cel用于复发/难治性非霍奇金淋巴瘤和B细胞急性淋巴细胞白血病。

?

适用疾病: Non-Hodgkin Lymphoma；B-cell Acute Lymphoblastic Leukemia；Chronic Lymphocytic Leukemia
干预: Azer-cel，Fludarabine，Cyclophosphamide，IL-2
地点: United States，Australia
申办方: Imugene Limited

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT03802695 / NCI-2019-01953

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

AI 简述这是一项I期试验，研究OrcaGraft用于血液恶性肿瘤接受异基因移植的受者。在美国开展。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndromes；Mixed Phenotype Acute Leukemia
干预: OrcaGraft (Orca-Q)
地点: United States
申办方: Orca Biosystems, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT03826992

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

AI 简述这是一项I期试验，研究Venetoclax联合Vyxeos用于复发或难治性急性白血病。

?

适用疾病: Leukemia
干预: Vyxeos，Venetoclax
地点: United States
申办方: Children's Hospital Medical Center, Cincinnati

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT03829540

CD4CAR for CD4+ Leukemia and Lymphoma

AI 简述这是一项I期试验，研究CD4CAR用于CD4阳性白血病和淋巴瘤。

?

适用疾病: T-cell Lymphoma；T-cell Leukemia
干预: CD4CAR
地点: United States
申办方: Huda Salman

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT03896269 / NCI-2019-01558

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

AI 简述这是一项I期试验，研究CPX-351用于复发/难治性高危骨髓增生异常综合征或慢性粒单核细胞白血病。

?

适用疾病: Blasts 10-19 Percent of Bone Marrow Nucleated Cells；Blasts More Than 5 Percent of Bone Marrow Nucleated Cells；High Risk Chronic Myelomonocytic Leukemia
干预: Liposome-encapsulated Daunorubicin-Cytarabine
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 EARLY / Phase 1 药物

ClinicalTrials.gov / NCI NCT03964506 / NCI-2025-05987

Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

AI 简述这是一项早期I期试验，研究高压氧治疗用于血液肿瘤患者的异基因移植。在美国开展。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndromes；Chronic Myelomonocytic Leukemia
干预: Hyperbaric oxygen
地点: United States
申办方: Omar Aljitawi

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT03969446 / NCI-2019-03153

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

AI 简述这是一项I期试验，研究Pembrolizumab和Decitabine联合或不联合Venetoclax用于急性髓系白血病或骨髓增生异常综合征。在美国开展。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndrome；Recurrent Acute Myeloid Leukemia
干预: Decitabine，Pembrolizumab，Venetoclax
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT04024761 / NCI-2019-07889

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

AI 简述这是一项I期试验，研究CIML NK细胞输注用于造血细胞移植后复发的髓系疾病，在美国开展。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndromes；Myeloproliferative Neoplasm
干预: CIML NK，Fludarabine，Cyclophosphamide
地点: United States
申办方: Dana-Farber Cancer Institute

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT04167696 / NCI-2020-05652

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

AI 简述这是一项I期试验，在美比利时研究CYAD-02用于复发/难治性急性髓系白血病或骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndrome；Refractory Acute Myeloid Leukemia (AML)
干预: CYAD-02，ENDOXAN，Fludara
地点: United States，Belgium
申办方: Celyad Oncology SA

正在招募阶段未标明药物手术/操作

ClinicalTrials.gov NCT04179929

Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults

AI 简述这是一项试验，研究儿童型化疗联合异基因造血干细胞移植用于BCR-ABL阴性成人急性淋巴细胞白血病，在西班牙开展。

?

适用疾病: Acute Lymphoblastic Leukemia
干预: Pediatric-type of chemotherapy，allogeneic HSCT
地点: Spain
申办方: PETHEMA Foundation

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04215809 / NCI-2020-05583

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

AI 简述这是一项I期试验，研究APG-2575单药或联合其他药物用于CLL/SLL，在美国、澳大利亚等地开展。

?

适用疾病: CLL/SLL；Refractory Chronic Lymphocytic Leukemia (CLL)；Recurrent Small Lymphocytic Lymphoma
干预: Lisaftoclax
地点: United States，Australia
申办方: Ascentage Pharma Group Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04223765 / NCI-2019-08780

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

AI 简述这是一项I期试验，研究CAR.k.28细胞治疗用于复发/难治性非霍奇金淋巴瘤和慢性淋巴细胞白血病。

?

适用疾病: Mantle Cell Lymphoma；Follicular Lymphoma；Splenic Marginal Zone Lymphoma
干预: CAR.k.28，Fludarabine，Cyclophosphamide，Bendamustine
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04227847 / NCI-2020-00570

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

AI 简述这是一项I期试验，研究SEA-CD70用于骨髓增生异常综合征和急性髓系白血病，在美国、日本、荷兰等地开展。

?

适用疾病: Myelodysplastic Syndrome；Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia (AML)
干预: SEA-CD70，azacitidine，Venetoclax
地点: United States，Japan，Netherlands
申办方: Seagen, a wholly owned subsidiary of Pfizer

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04243785 / NCI-2020-00934

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

AI 简述这是一项I期试验，研究BTX-A51联合阿扎胞苷用于复发/难治急性髓系白血病或高危骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndrome；Refractory Acute Myeloid Leukemia (AML)
干预: BTX-A51，Azacitidine
地点: United States
申办方: Edgewood Oncology Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04260022 / NCI-2020-01100

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

AI 简述这是一项I期试验，研究HQP1351联合博纳吐单抗用于难治性慢性粒细胞白血病和Ph+急性淋巴细胞白血病。

?

适用疾病: Leukemia, Myeloid, Chronic；Myeloid Leukemia；Chronic Myeloid Leukemia
干预: Ascentage Pharma HQP1351 bioavailable inhibitor，Blinatumomab
地点: United States，Canada
申办方: Ascentage Pharma Group Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04318678 / NCI-2020-02416

CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

AI 简述这是一项I期试验，研究CD123-CAR T细胞用于急性髓系白血病。

?

适用疾病: AML/MDS；B-ALL；T-ALL
干预: CD123-CAR T，Cyclophosphamide，Fludarabine，Mesna
地点: United States
申办方: St. Jude Children's Research Hospital

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04365179 / NCI-2020-05316

Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML

AI 简述这是一项I期试验，研究Nerofe用于晚期骨髓增生异常综合征和急性髓系白血病。

?

适用疾病: Advanced MDS；AML；Refractory Acute Myeloid Leukemia (AML)
干预: Nerofe
地点: United States
申办方: Immune System Key Ltd

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT04375631 / NCI-2020-02616

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

AI 简述这是一项I期试验，研究CLAG-M或FLAG-Ida化疗及干细胞移植用于复发难治性急性髓系白血病等。

?

适用疾病: Recurrent Acute Myeloid Leukemia；Recurrent Chronic Myelomonocytic Leukemia；Recurrent Myelodysplastic Syndrome
干预: Cladribine，Cyclophosphamide，Cyclosporine，Cytarabine
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 EARLY / Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT04512716 / NCI-2021-01361

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

AI 简述这是一项早期I期试验，研究131-I Apamistamab后接CD19靶向CAR T细胞治疗用于复发难治B细胞急性淋巴细胞白血病或弥漫大B细胞淋巴瘤。

?

适用疾病: B-ALL；DLBCL；B ALL
干预: 131-I Apamistamab，CAR T-cell
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov NCT04545762

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

AI 简述这是一项1期试验，在美国研究抗CD19 CAR-T细胞用于复发/难治非霍奇金淋巴瘤。

?

适用疾病: Refractory Non-Hodgkin Lymphoma；Burkitt Lymphoma；Mantle Cell Lymphoma
干预: Fludarabine，Cyclophosphamide，anti-CD19 CAR-T cells
地点: United States
申办方: C. Babis Andreadis

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT04659616 / NCI-2020-05267

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究Pemigatinib联合化疗用于新诊断急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia (AML)
干预: Biospecimen Collection，Bone Marrow Aspirate，Bone Marrow Biopsy，Cytarabine
地点: United States
申办方: OHSU Knight Cancer Institute

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT04678401 / NCI-2021-00578

IS-free Treg HaploHCT

AI 简述这是一项I期试验，研究Fludarabine、Thiotepa等用于急性髓系白血病或骨髓增生异常综合征的干细胞移植并发症。

?

适用疾病: Stem Cell Transplant Complications；Graft Vs Host Disease；Myeloid Leukemia, Acute
干预: Radiation，Fludarabine，Thiotepa，Cyclophosphamide
地点: United States
申办方: Dana-Farber Cancer Institute

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04704323 / NCI-2021-08719

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

AI 简述这是一项I期试验，研究CAP-100用于复发/难治性慢性淋巴细胞白血病，在美国和西班牙开展。

?

适用疾病: Lymphocytic Leukemia, Chronic；SLL；Refractory Chronic Lymphocytic Leukemia (CLL)
干预: CAP-100
地点: United States，Spain
申办方: Catapult Therapeutics

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04716452 / NCI-2025-07927

Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究C6神经酰胺纳米脂质体用于复发/难治性急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia, in Relapse；Acute Myeloid Leukemia, Refractory；Refractory/Relapse Acute Myeloid Leukemia
干预: Ceramide NanoLiposome (Ceraxa)
地点: United States
申办方: Keystone Nano, Inc

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04771572 / NCI-2021-03470

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

AI 简述这是一项I期试验，研究LP-118用于复发性或难治性血液恶性肿瘤。

?

适用疾病: Non Hodgkin Lymphoma；Richter Transformation；Multiple Myeloma
干预: LP-118
地点: United States
申办方: Newave Pharmaceutical Inc

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04775745 / NCI-2021-06802

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

AI 简述这是一项I期试验，研究口服LP-168用于复发或难治性B细胞恶性肿瘤（包括慢性淋巴细胞白血病/小淋巴细胞淋巴瘤、华氏巨球蛋白血症、滤泡淋巴瘤、弥漫大B细胞淋巴瘤、套细胞淋巴瘤），在美国开展。

?

适用疾病: CLL/SLL；Waldenstrom Macroglobulinemia；Follicular Lymphoma
干预: LP-168
地点: United States
申办方: Newave Pharmaceutical Inc

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT04815356 / NCI-2021-02775

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant

AI 简述这是一项I期试验，研究CD22CART细胞用于复发/难治性毛细胞白血病。

?

适用疾病: Hairy Cell Leukemia；Hairy Cell Leukemia Variant；Recurrent Hairy Cell Leukemia
干预: CD22CART cell infusion
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04830137 / NCI-2021-06410

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

AI 简述这是一项I期试验，研究NX-2127用于复发/难治性B细胞恶性肿瘤。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma (SLL)；Waldenstrom Macroglobulinemia (WM)
干预: NX-2127
地点: United States
申办方: Nurix Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04872478 / NCI-2021-13604

Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

AI 简述这是一项I期试验，研究MRX-2843用于复发/难治性AML、ALL或MPAL。

?

适用疾病: Acute Myeloid Leukemia；Acute Lymphoblastic Leukemia；Mixed Phenotype Acute Leukemia
干预: MRX-2843
地点: United States
申办方: Meryx, Inc.

正在招募 Phase 1 生物制剂器械药物

ClinicalTrials.gov / NCI NCT04881240 / NCI-2021-04591

Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

AI 简述这是一项I期试验，研究CD19同种异体记忆T细胞疗法用于复发/难治性CD19+白血病。

?

适用疾病: Acute Lymphoblastic Leukemia, in Relapse；Acute Lymphoblastic Leukemia, Refractory；Pediatric ALL
干预: CD19-CAR(Mem) T-cells，Cyclophosphamide，Fludarabine，Mesna
地点: United States
申办方: St. Jude Children's Research Hospital

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT04892277 / NCI-2021-03969

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

AI 简述这是一项I期试验，研究CD19靶向CAR-T细胞治疗复发/难治性B细胞恶性肿瘤。

?

适用疾病: Recurrent B-Cell Non-Hodgkin Lymphoma；Recurrent Chronic Lymphocytic Leukemia；Recurrent Small Lymphocytic Lymphoma
干预: Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563，Bendamustine，Biospecimen Collection，Bone Marrow Aspiration
地点: United States
申办方: Mayo Clinic

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04953897 / NCI-2025-07472

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

AI 简述这是一项1期试验，研究口服Decitabine和Cedazuridine用于肾功能不全的癌症患者。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndromes；Metastatic Malignant Solid Tumor
干预: ASTX727
地点: United States，Armenia，Bulgaria，Lithuania 等 4 个
申办方: Taiho Oncology, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04953910 / NCI-2025-07526

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

AI 简述这是一项1期试验，研究口服Decitabine和Cedazuridine用于肝功能不全的癌症患者。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndromes；Metastatic Malignant Solid Tumor
干预: ASTX727
地点: United States，Armenia，Bulgaria，Lithuania 等 4 个
申办方: Taiho Oncology, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04972942 / NCI-2024-02686

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

AI 简述这是一项I期试验，研究Daratumumab用于异基因移植后的高危T细胞急性淋巴细胞白血病，在美国开展。

?

适用疾病: T-cell Acute Lymphoblastic Leukemia；T-Cell Acute Lymphoblastic Lymphoma；High Risk Acute Lymphoblastic Leukemia
干预: Daratumumab
地点: United States
申办方: New York Medical College

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05010005 / NCI-2021-09242

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

AI 简述这是一项I期试验，研究Ruxolitinib和Duvelisib用于淋巴瘤。

?

适用疾病: T-cell Lymphomas；NK-Cell Lymphomas；T-cell Prolymphocytic Leukemia
干预: Ruxolitinib，Duvelisib
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 基因治疗

ClinicalTrials.gov / NCI NCT05010564 / NCI-2023-04792

Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)

AI 简述这是一项I期试验，研究TRICAR-ALL T细胞用于复发/难治B细胞急性淋巴细胞白血病。

?

适用疾病: Leukemia, B-Cell；Recurrent B Acute Lymphoblastic Leukemia；Refractory B Acute Lymphoblastic Leukemia
干预: Autologous TRICAR-ALL T-cells and lymphodepletion chemotherapy
地点: United States
申办方: Baylor College of Medicine

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05010772 / NCI-2021-08496

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

AI 简述这是一项I期试验，研究地西他滨单药或联合靶向药用于急性髓系白血病缓解后维持。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia (AML)
干预: Decitabine and Cedazuridine，Enasidenib，Gilteritinib，Ivosidenib
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05024552

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

AI 简述这是一项I期试验，研究Vyxeos联合Gilteritinib用于复发/难治性FLT3突变急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia With FLT3/ITD Mutation
干预: Gilteritinib，Vyxeos
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT05038696

ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.

AI 简述这是一项I期试验，研究CAR T细胞疗法用于急性B淋巴细胞白血病。

?

适用疾病: Lymphoblastic Leukemia, Acute, Childhood；Lymphoblastic Leukemia；Lymphoblastic Leukemia, Acute Adult
干预: CAR T-cell therapy
地点: Singapore
申办方: National University Hospital, Singapore

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT05043571

CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia

AI 简述这是一项I期试验，研究CAR T细胞疗法用于复发/难治性T细胞急性淋巴细胞白血病。

?

适用疾病: Lymphoblastic Leukemia, Acute, Childhood；Lymphoblastic Leukemia；Lymphoblastic Leukemia, Acute Adult
干预: CAR T-cell therapy
地点: Singapore
申办方: National University Hospital, Singapore

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05054257

CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

AI 简述这是一项I期试验，研究CART19细胞用于复发难治B细胞急性淋巴细胞白血病和非霍奇金淋巴瘤。

?

适用疾病: Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia；Non-Hodgkin's Lymphoma Refractory；Non-Hodgkin's Lymphoma, Relapsed
干预: Autologous CAR19 T lymphocytes
地点: Czechia
申办方: Institute of Hematology and Blood Transfusion, Czech Republic

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05101551 / NCI-2024-00302

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

AI 简述这是一项I期试验，研究Talazoparib联合化疗用于复发儿童急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Undifferentiated Leukemia
干预: Talazoparib，Topotecan，Gemcitabine
地点: United States
申办方: Norman J. Lacayo

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT05105152 / NCI-2021-09818

PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML

AI 简述这是一项I期试验，研究SC-DARIC33 CAR T细胞用于复发或难治CD33+急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia Refractory；Acute Myeloid Leukemia, in Relapse
干预: SC-DARIC33
地点: United States
申办方: Seattle Children's Hospital

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05131022 / NCI-2023-01623

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

AI 简述这是一项I期试验，研究NX-5948用于复发/难治性B细胞恶性肿瘤，在美国、法国等地开展。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma (SLL)；Diffuse Large B Cell Lymphoma (DLBCL)
干预: NX-5948
地点: United States，France，Italy，Netherlands 等 4 个
申办方: Nurix Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05143996 / NCI-2021-13598

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

AI 简述这是一项I期试验，研究CLN-049用于复发或难治性急性髓系白血病或骨髓增生异常综合征。

?

适用疾病: Relapsed/Refractory Acute Myeloid Leukemia (AML)；Myelodysplastic Syndrome (MDS)；Refractory Acute Myeloid Leukemia (AML)
干预: CLN-049
地点: United States
申办方: Cullinan Therapeutics Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05188170 / NCI-2022-09974

Niclosamide in Pediatric Patients With Relapsed and Refractory AML

AI 简述这是一项I期试验，研究Niclosamide用于儿童复发难治性急性髓系白血病。在美国开展。

?

适用疾病: Acute Myeloid Leukemia (AML)；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)
干预: Niclosamide
地点: United States
申办方: Stanford University

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05190471 / NCI-2022-02254

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

AI 简述这是一项I期试验，研究BP1002单药或联合地西他滨用于复发/难治性急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia, in Relapse；Acute Myeloid Leukemia Refractory；Refractory Acute Myeloid Leukemia (AML)
干预: BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide，Decitabine (in combination with BP1002)
地点: United States
申办方: Bio-Path Holdings, Inc.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT05210907

Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia

AI 简述这是一项I期试验，研究医院生产的CD19 CAR-T细胞用于儿童和青少年急性淋巴细胞白血病，在韩国开展。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia
干预: SNUH-CD19-CAR-T
地点: South Korea
申办方: Seoul National University Hospital

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05233618 / NCI-2022-04826

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)

AI 简述这是一项I期试验，研究Tagraxofusp用于CD123阳性血液肿瘤移植后维持。

?

适用疾病: Myelofibrosis；Chronic Myelomonocytic Leukemia；Acute Myeloid Leukemia
干预: Tagraxofusp
地点: United States
申办方: Karen Ballen, MD

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05263284 / NCI-2022-00234

8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究8-Chloroadenosine联合Venetoclax用于复发/难治性急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Recurrent Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia
干预: 8-Chloroadenosine，Venetoclax
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05287568

CC-486 and Venetoclax for Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究CC-486联合Venetoclax用于急性髓系白血病。

?

适用疾病: AML
干预: Venetoclax，CC-486
地点: United States
申办方: University of Colorado, Denver

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05292664 / NCI-2022-07956

Venetoclax Basket Trial for High Risk Hematologic Malignancies

AI 简述这是一项I期试验，研究Venetoclax联合Azacitidine、Cytarabine、Methotrexate用于高风险血液恶性肿瘤，在美国开展。

?

适用疾病: Myelodysplastic Syndromes, de Novo；Myelodysplastic Syndromes, Secondary；Myelodysplastic Syndromes, Previously Treated
干预: Venetoclax，Azacitidine，Cytarabine，Methotrexate
地点: United States
申办方: Andrew E. Place, MD

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05317403 / NCI-2025-07167

Venetoclax to Augment Epigenetic Modification and Chemotherapy

AI 简述这是一项1期试验，在美国研究Venetoclax联合表观遗传修饰和化疗用于复发难治急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia, in Relapse；Acute Myeloid Leukemia Refractory；Refractory Acute Myeloid Leukemia (AML)
干预: Venetoclax，Azacitadine，Vorinostat，Cytarabine
地点: United States
申办方: Medical College of Wisconsin

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov NCT05333302

Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma

AI 简述这是一项1期试验，研究CD19 CAR-T细胞用于儿童/青年CD19+复发/难治性白血病或淋巴瘤，在白俄罗斯开展。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia；Lymphoblastic B-Cell Lymphoma
干预: CD19 CAR-T-cells，Tocilizumab
地点: Belarus
申办方: Belarusian Research Center for Pediatric Oncology, Hematology and Immunology

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05342584 / NCI-2022-05682

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS

AI 简述这是一项I期试验，研究Venetoclax联合化疗用于急性髓系白血病和高级别骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndromes；Myelodysplastic Syndrome
干预: Venetoclax Oral Tablet，Daunorubicin，Cytarabine
地点: United States
申办方: Montefiore Medical Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05362773 / NCI-2023-00598

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

AI 简述这是一项I期试验，研究MGD024用于复发或难治性血液恶性肿瘤，在美国开展。

?

适用疾病: Leukemia, Acute Myeloid；Myelodysplastic Syndromes；Classical Hodgkin Lymphoma
干预: MGD024
地点: United States
申办方: MacroGenics

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05418088 / NCI-2022-02972

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

AI 简述这是一项1期试验，研究抗CD19/CD20/CD22 CAR T细胞用于复发或难治性淋巴系统恶性肿瘤。

?

适用疾病: Recurrent Acute Lymphoblastic Leukemia；Recurrent B Acute Lymphoblastic Leukemia；Recurrent B-Cell Prolymphocytic Leukemia
干预: Anti-CD19/CD20/CD22 CAR T-Cells，Cyclophosphamide，Fludarabine Phosphate，Echocardiography
地点: United States
申办方: Sumithira Vasu

正在招募 Phase 1 药物其他

ClinicalTrials.gov / NCI NCT05473910 / NCI-2022-06900

A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation

AI 简述这是一项I期试验，研究TSC-100或TSC-101用于AML、ALL和MDS患者接受异基因外周血干细胞移植。

?

适用疾病: AML；Myelodysplastic Syndromes；ALL, Adult
干预: SOC + TSC-100，SOC + TSC-101，Control
地点: United States
申办方: TScan Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05476770

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

AI 简述这是一项1期试验，研究Tagraxofusp用于儿童复发或难治CD123阳性血液恶性肿瘤，在美国、澳大利亚等地开展。

?

适用疾病: Hematologic Malignancy；AML；ALL
干预: Tagraxofusp，Fludarabine，Cytarabine，Dexamethasone
地点: United States，Australia
申办方: Therapeutic Advances in Childhood Leukemia Consortium

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05506332

Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究Venetoclax联合嘌呤类似物用于复发/难治性急性髓系白血病，在比利时开展。

?

适用疾病: Acute Myeloid Leukemia, in Relapse；Acute Myeloid Leukemia Refractory
干预: Venetoclax，6-mercaptopurine
地点: Belgium
申办方: University Hospital, Antwerp

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05512390 / NCI-2023-03269

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

AI 简述这是一项I期试验，研究ABBV-319用于复发/难治性弥漫大B细胞淋巴瘤、滤泡性淋巴瘤或慢性淋巴细胞白血病，在美国等国家开展。

?

适用疾病: Diffuse Large B-Cell Lymphoma；Chronic Lymphocytic Leukemia；Follicular Lymphoma
干预: ABBV-319
地点: United States，Australia，Canada，Israel 等 2 个
申办方: AbbVie

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05535855 / NCI-2023-05480

UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1

AI 简述这是一项I期试验，研究UCD19 CAR T细胞用于B细胞急性淋巴细胞白血病。

?

适用疾病: Acute Lymphoid Leukemia；Acute Lymphoblastic Leukemia；B Acute Lymphoblastic Leukemia
干预: CD19 Directed CAR T Cell
地点: United States
申办方: University of Colorado, Denver

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05544019

Study of SGR-1505 in Mature B-Cell Neoplasms

AI 简述这是一项I期试验，研究SGR-1505用于成熟B细胞肿瘤，在美国、法国等地开展。

?

适用疾病: Mature B-Cell Neoplasm；Non Hodgkin Lymphoma；DLBCL
干预: SGR-1505
地点: United States，France，Italy，Moldova 等 4 个
申办方: Schrödinger, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05544968

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

AI 简述一项I期试验，研究anti-CD30 biAb-AATC用于复发/难治性CD30阳性血液恶性肿瘤。

?

适用疾病: Hodgkin Disease；CD30-Positive Diffuse Large B-Cell Lymphoma；CD30+ Anaplastic Large Cell Lymphoma
干预: anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)，GM-CSF
地点: United States
申办方: Medical College of Wisconsin

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05546580 / NCI-2022-11092

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

AI 简述一项I期试验，研究Iadademstat联合Gilteritinib用于FLT3突变复发/难治性AML。

?

适用疾病: Acute Myeloid Leukemia, in Relapse；Acute Myeloid Leukemia Refractory；Recurrent Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes
干预: Iadademstat，Gilteritinib Oral Tablet
地点: United States
申办方: Oryzon Genomics S.A.

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT05549661 / NCI-2022-07695

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

AI 简述一项I期试验，研究Onvansertib用于复发/难治性慢性粒单核细胞白血病和MDS/MPN重叠肿瘤。

?

适用疾病: Recurrent Chronic Myelomonocytic Leukemia；Refractory Chronic Myelomonocytic Leukemia；Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified
干预: Biospecimen Collection，Bone Marrow Aspiration and Biopsy，Onvansertib，Ultrasound Imaging
地点: United States
申办方: Mayo Clinic

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05558124 / NCI-2022-08285

CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

AI 简述这是一项I期试验，研究CPX-351联合Gemtuzumab Ozogamicin用于新诊断急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia (AML)
干预: Vyxeos，Gemtuzumab Ozogamicin
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05581030 / NCI-2022-08795

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

AI 简述这是一项1期试验，研究Calaspargase Pegol联合化疗用于新诊断急性淋巴细胞白血病。

?

适用疾病: Acute Lymphoblastic Leukemia；B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative；T cell acute lymphoblastic leukemia
干预: Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy)，Calaspargase Pegol，Rituximab
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05597306 / NCI-2022-09456

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究Venetoclax联合Bomedemstat用于复发/难治性急性髓系白血病，在美国开展。

?

适用疾病: Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia；Acute Myeloid Leukemia, in Relapse
干预: Bomedemstat，Venetoclax
地点: United States
申办方: Terrence J Bradley, MD

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05602363 / NCI-2023-06023

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

AI 简述这是一项I期试验，研究Docirbrutinib用于既往治疗过的慢性淋巴细胞白血病或非霍奇金淋巴瘤。

?

适用疾病: B-cell Malignancy；Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma
干预: Docirbrutinib
地点: United States
申办方: Carna Biosciences, Inc.

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT05627232 / NCI-2022-08813

Tazemetostat and Palbociclib With CPX-351for R/R AML

AI 简述这是一项I期试验，研究Tazemetostat和Palbociclib联合CPX-351用于复发难治性急性髓系白血病。

?

适用疾病: Recurrent Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia (AML)
干预: Tazemetostat，Liposome-encapsulated Daunorubicin-Cytarabine，Bone Marrow Aspiration and Biopsy，Biospecimen Collection
地点: United States
申办方: Thomas Jefferson University

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05636514

Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS

AI 简述这是一项I期试验，研究Decitabine/Cedazuridine联合Defactinib用于骨髓增生异常综合征和急性髓系白血病。

?

适用疾病: Myelodysplastic Syndromes；Chronic Myelomonocytic Leukemia；Acute Myeloid Leukemia
干预: Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET，Defactinib
地点: Australia
申办方: Clinical Hub for Interventional Research (CHOIR)

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05659732

A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer

AI 简述这是一项I期试验，研究PEP07用于晚期癌症。

?

适用疾病: Acute Myeloid Leukemia；Lymphoma, Mantle-Cell
干预: PEP07
地点: Australia，Taiwan
申办方: PharmaEngine

正在招募 Phase 1 生物制剂手术/操作

ClinicalTrials.gov / NCI NCT05672147 / NCI-2022-10310

CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究抗CD33 CAR-T细胞用于复发或难治性急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Recurrent Adult Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia
干预: Anti-CD33 CAR T-cells，Lymphodepletion Therapy
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT05679895

Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL

AI 简述这是一项I期试验，研究CD1a-CAR T细胞疗法用于复发/难治性T细胞急性淋巴细胞白血病或淋巴母细胞淋巴瘤。在西班牙开展。

?

适用疾病: T-cell Acute Lymphoblastic Leukemia；Lymphoblastic T-Cell Lymphoma
干预: CD1a-CAR T
地点: Spain
申办方: OneChain Immunotherapeutics

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05703542

BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome

AI 简述这是一项I期试验，在美国研究BXCL701用于复发/难治急性髓系白血病或骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndrome With Excess Blasts-2
干预: BXCL701
地点: United States
申办方: Eric Stephen Winer, MD

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov NCT05705570

Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies

AI 简述这是一项I期试验，研究CAR-T细胞用于复发难治CD19阳性B淋巴恶性肿瘤。

?

适用疾病: Acute Lymphoblastic Leukemia, in Relapse；Acute Lymphoblastic Leukemia Refractory；B-cell Lymphoma Recurrent
干预: Cyclophosphamide，Fludarabine，Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0
地点: Brazil
申办方: Nelson Hamerschlak

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05735184 / NCI-2023-04854

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

AI 简述这是一项1期试验，研究Ziftomenib联合Venetoclax/阿扎胞苷等用于急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Mixed Lineage Leukemia Gene Mutation；Refractory AML
干预: Ziftomenib，Venetoclax，Azacitidine，Daunorubicin
地点: United States
申办方: Kura Oncology, Inc.

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT05748197 / NCI-2024-03441

A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究ADCLEC.syn1 CAR T细胞用于急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)
干预: ADCLEC.syn1 CAR T cells，Conditioning chemotherapy
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05749276

Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)

AI 简述这是一项I期试验，研究Daratumumab联合化疗用于60岁以上高危急性髓系白血病。

?

适用疾病: Adult Patients With Adverse Risk Acute Myeloblastic Leukemia
干预: Darzalex
地点: France
申办方: Nantes University Hospital

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05756777 / NCI-2023-03271

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

AI 简述这是一项1期试验，研究Gilteritinib联合Ivosidenib或Enasidenib用于急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia (AML)；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)
干预: Gilteritinib，Ivosidenib，Enasidenib
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 联合产品药物

ClinicalTrials.gov / NCI NCT05768932 / NCI-2023-02515

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

AI 简述这是一项1期试验，研究BAL0891用于晚期实体瘤或复发/难治性急性髓系白血病，在美国、韩国等地开展。

?

适用疾病: Advanced Solid Tumor；TNBC - Triple-Negative Breast Cancer；Gastric Cancer
干预: BAL0891，Tislelizumab，Paclitaxel
地点: United States，South Korea
申办方: SillaJen, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05834244 / NCI-2023-03179

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

AI 简述这是一项I期试验，研究Azacitidine、Venetoclax和NK细胞用于复发难治性急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia (AML)；Refractory Myelodysplastic Syndrome
干预: Azacitidine，Venetoclax，NK Cells
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT05886049 / NCI-2023-04141

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

AI 简述这是一项I期试验，研究SNDX-5613联合柔红霉素和阿糖胞苷用于初治急性髓系白血病，在美国开展。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia With KMT2A Rearrangement；Acute Myeloid Leukemia With NPM1 Mutation
干预: Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy，Cytarabine
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT05887167

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

AI 简述这是一项I期试验，研究收集并联合自体造血干细胞与CAR-T细胞疗法用于复发/难治性血液恶性肿瘤。

?

适用疾病: Hematologic Malignancy；Large B-cell Lymphoma；Acute Lymphoblastic Leukemia
干预: autologous hematopoietic stem cells added to planned CAR T
地点: United States
申办方: Joshua Sasine, MD, PhD

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT05945849 / NCI-2024-01952

CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML

AI 简述这是一项1期试验，研究CD33KO-HSPC输注后CART33输注用于复发难治急性髓系白血病。

?

适用疾病: Leukemia, Myeloid, Acute；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)
干预: CD33KO-HSPC; CART33
地点: United States
申办方: University of Pennsylvania

正在招募 Phase 1 药物其他

ClinicalTrials.gov NCT05949125

Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

AI 简述这是一项1期试验，研究Allo-RevCAR01-T-CD123用于CD123阳性血液恶性肿瘤，在德国、荷兰等地开展。

?

适用疾病: Acute Myeloid Leukemia, in Relapse；Acute Myeloid Leukemia Refractory
干预: Cyclophosphamide (Non-IMP, Lymphodepletion)，Fludarabine (Non-IMP, Lymphodepletion)，R-TM123，Allo-RevCAR01-T
地点: Germany，Netherlands
申办方: AvenCell Europe GmbH

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov NCT05963217

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

AI 简述这是一项I期试验，研究TBI-2001（CAR-T）用于复发难治CD19+B细胞淋巴瘤、CLL/SLL。

?

适用疾病: Relapsed or Refractory CD19+ B-cell Lymphoma；Relapsed or Refractory Chronic Lymphocytic Leukemia；Relapsed or Refractory Small Lymphocytic Lymphoma
干预: TBI-2001，Cyclophosphamide，Fludarabine
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 1 联合产品药物

ClinicalTrials.gov / NCI NCT05986240 / NCI-2024-03174

Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

AI 简述这是一项I期试验，研究Danvatirsen单药后联合Venetoclax用于复发/难治MDS和AML。

?

适用疾病: AML/MDS；Acute Myeloid Leukemia；Myelodysplastic Syndromes
干预: Danvatirsen，Danvatirsen + Venetoclax
地点: United States
申办方: Montefiore Medical Center

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT06001788 / NCI-2023-06933

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究Ziftomenib组合用于复发/难治性急性髓系白血病。

?

适用疾病: AML；AML With Mutated NPM1；Hematologic Malignancy
干预: Ziftomenib，Fludarabine，Idarubicin，Cytarabine
地点: United States，Italy，Spain
申办方: Kura Oncology, Inc.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06017258 / NCI-2023-06968

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究CD371-YSNVZIL-18 CAR T细胞用于复发难治性急性髓系白血病。

?

适用疾病: Refractory Acute Myeloid Leukemia；Relapsed Acute Myeloid Leukemia；Acute Myeloid Leukemia
干预: CD371-specific/YSNVz/I-18 CAR T cells
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06034275 / NCI-2023-09318

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

AI 简述这是一项I期试验，研究VIP943用于美国CD123+血液恶性肿瘤。

?

适用疾病: Acute Myeloid Leukemia；B-cell Acute Lymphoblastic Leukemia；High-risk Myelodysplastic Syndrome
干预: VIP943 (QW)，VIP943 (BIW)
地点: United States
申办方: Vincerx Pharma, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06080191

Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL

AI 简述这是一项I期试验，研究通用型CD19-CAR T细胞用于儿童复发/难治B细胞急性淋巴细胞白血病，在意大利开展。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia
干预: CD19-CAR_Lenti_ALLO
地点: Italy
申办方: Bambino Gesù Hospital and Research Institute

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06138587 / NCI-2024-00762

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

AI 简述这是一项I期试验，研究Cytokine Induced Memory-like Natural Killer Cells用于干细胞移植后的白血病等，在美国开展。

?

适用疾病: Acute Myeloid Leukemia；Leukemia；Leukemia, Myeloid
干预: Cytokine Induced Memory-like Natural Killer Cells，Interleukin-2
地点: United States
申办方: Dana-Farber Cancer Institute

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06146257 / NCI-2023-10199

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

AI 简述这是一项I期试验，研究GLB-001用于复发或难治性急性髓系白血病或高危骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndromes；Refractory Acute Myeloid Leukemia (AML)
干预: GLB-001
地点: United States
申办方: GluBio Therapeutics Inc.

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT06152809 / NCI-2024-04921

CIML NK Cells With Venetoclax for AML

AI 简述这是一项I期试验，研究细胞因子诱导的记忆样自然杀伤细胞联合Venetoclax用于急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia Recurrent；Leukemia
干预: Cytokine-Induced Memory-like Natural Killer Cells，Interleukin-2，Venetoclax
地点: United States
申办方: Dana-Farber Cancer Institute

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06173518 / NCI-2024-02788

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

AI 简述这是一项I期试验，研究AUTO1用于复发或难治性B细胞急性淋巴细胞白血病和B细胞非霍奇金淋巴瘤儿童患者。

?

适用疾病: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia；Relapsed or Refractory B Cell Non-Hodgkin Lymphoma；Recurrent B Acute Lymphoblastic Leukemia
干预: AUTO1
地点: United States，Spain，United Kingdom
申办方: Autolus Limited

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06177067 / NCI-2023-10509

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究Revumenib联合Azacitidine、Venetoclax用于儿童和年轻成人复发/难治性急性髓系白血病。在美国开展。

?

适用疾病: Refractory Acute Myeloid Leukemia；Relapsed Acute Myeloid Leukemia；Acute Leukemia of Ambiguous Lineage
干预: Revumenib，Venetoclax，Azacitidine，intrathecal (IT) chemotherapy
地点: United States
申办方: St. Jude Children's Research Hospital

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06191887 / NCI-2023-10077

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

AI 简述这是一项I期试验，研究BAFFR靶向CAR-T细胞用于复发或难治性B细胞血液恶性肿瘤。

?

适用疾病: B-Cell Non-Hodgkin Lymphoma；Recurrent Chronic Lymphocytic Leukemia；Recurrent Diffuse Large B-Cell Lymphoma
干预: Autologous BAFFR-targeting CAR T Cells，Bendamustine，Biopsy，Biospecimen Collection
地点: United States
申办方: Mayo Clinic

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06191978 / NCI-2023-10826

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

AI 简述这是一项I期试验，研究Venetoclax联合ASTX727用于儿童复发/难治性急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)
干预: ASTX727，Venetoclax
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06195891 / NCI-2023-08816

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

AI 简述这是一项I期试验，研究Orca-T用于急性白血病或骨髓增生异常综合征。

?

适用疾病: Acute Lymphoblastic Leukemia；Acute Myeloid Leukemia；Myelodysplastic Syndrome
干预: Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy，Dual-Energy Computed Tomography
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06197672 / NCI-2024-02380

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant

AI 简述这是一项I期试验，研究CD4CAR T细胞用于复发难治性急性髓系白血病，作为异基因干细胞移植的桥接治疗。

?

适用疾病: Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)
干预: CD4CAR
地点: United States
申办方: Huda Salman

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT06208735

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

AI 简述这是一项1期试验，在加拿大研究CLIC-2201用于复发/难治性B细胞恶性肿瘤。

?

适用疾病: B-Cell Leukemia；Non-Hodgkin's Lymphoma；B-cell Acute Lymphoblastic Leukemia
干预: CLIC-2201
地点: Canada
申办方: British Columbia Cancer Agency

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT06222580 / NCI-2024-00036

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

AI 简述这是一项I期试验，研究SNDX-5613和Gilteritinib用于复发/难治FLT3突变急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia With FLT3/ITD Mutation；Acute Myeloid Leukemia With KMT2A Rearrangement；Acute Myeloid Leukemia With NPM1 Mutation
干预: Biospecimen Collection，Bone Marrow Aspiration and Biopsy，Gilteritinib，Revumenib
地点: United States
申办方: Uma Borate

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06227026 / NCI-2024-00442

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies

AI 简述这是一项I期试验，研究抗CD19 CAR-T细胞用于复发/难治性CD19+恶性肿瘤。在美国开展。

?

适用疾病: Acute Lymphoblastic Leukemia；Diffuse Large B Cell Lymphoma；Refractory Acute Lymphoblastic Leukemia (ALL)
干预: Anti-CD19 CAR-T cells
地点: United States
申办方: University of Utah

正在招募阶段未标明药物

ClinicalTrials.gov NCT06237192

MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients

AI 简述这是一项研究，基于MRD指导的非强化但不中断治疗用于Ph阴性急性淋巴细胞白血病成人患者。

?

适用疾病: Precursor Cell Lymphoblastic Leukemia-Lymphoma
干预: blinatumomab for B-ALL, venetoclax for T-ALL
地点: Russia
申办方: National Research Center for Hematology, Russia

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06247787 / NCI-2023-11026

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

AI 简述这是一项I期试验，在美国研究imetelstat联合氟达拉滨和阿糖胞苷用于复发/难治儿童急性髓系白血病、MDS或JMML。

?

适用疾病: Recurrent Childhood Acute Myeloid Leukemia；Recurrent Childhood Myelodysplastic Syndrome；Recurrent Juvenile Myelomonocytic Leukemia
干预: Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy，Cytarabine
地点: United States
申办方: Children's Oncology Group

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06285890 / NCI-2024-01733

Phase I Study of HC-7366 for Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究HC-7366用于急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)
干预: HC-7366
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06287528 / NCI-2024-01950

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

AI 简述这是一项I期试验，研究19-28z/IL-18 CAR-T细胞用于急性淋巴细胞白血病。

?

适用疾病: Philadelphia-Negative ALL；Philadelphia-Positive ALL；Relapsed ALL, Adult
干预: 19-28z/IL-18 CAR T cells
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06287944 / NCI-2024-01131

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

AI 简述这是一项I期试验，研究225Ac-DOTA-Anti-CD38 Daratumumab联合氟达拉滨、美法仑及全身照射用于高危急性白血病或骨髓增生异常综合征的供体干细胞移植前预处理。

?

适用疾病: Acute Lymphoblastic Leukemia；Acute Myeloid Leukemia；Myelodysplastic Syndrome
干预: Actinium Ac 225-DOTA-Daratumumab，Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06297941 / NCI-2024-03443

Study of REM-422 in Patients With AML or Higher Risk MDS

AI 简述这是一项I期试验，研究REM-422用于急性髓系白血病或高危骨髓增生异常综合征。

?

适用疾病: Myelodysplastic Syndromes；Higher Risk Myelodysplastic Syndromes；Acute Myeloid Leukemia
干预: REM-422
地点: United States，France
申办方: Remix Therapeutics

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06313437 / NCI-2024-04789

Revumenib in Combination With 7+3 + Midostaurin in AML

AI 简述这是一项I期试验，研究Revumenib联合7+3方案及米哚妥林用于急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；AML, Adult；AML With Gene Mutations
干预: Revumenib，Midostaurin，Cytarabine，Daunorubicin
地点: United States
申办方: Richard Stone, MD

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06326463 / NCI-2024-03240

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

AI 简述这是一项I期试验，研究CD70靶向CAR-T细胞用于儿童血液恶性肿瘤，在美国开展。

?

适用疾病: Hematologic Malignancy；ALL, Childhood；AML, Childhood
干预: Fludarabine，Cyclophosphamide，CD70-CAR T cell infusion (Autologous)，Mesna
地点: United States
申办方: St. Jude Children's Research Hospital

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06340737 / NCI-2024-03048

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

AI 简述这是一项I期试验，研究自体CD22 CAR-T细胞用于复发/难治性B细胞淋巴瘤，在美国开展。

?

适用疾病: Follicular Lymphoma；Mantle Cell Lymphoma；Hairy Cell Leukemia
干预: CD22CART Infusion
地点: United States
申办方: Stanford University

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06366789 / NCI-2025-02381

Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究ZE46-0134用于FLT3突变或剪接体突变的复发/难治急性髓系白血病，在多国开展。

?

适用疾病: AML With Gene Mutations；Acute Myeloid Leukemia (AML) with FLT3/ITD；Refractory Acute Myeloid Leukemia (AML)
干预: ZE46-0134
地点: United States，Australia，South Korea，Taiwan
申办方: Lomond Therapeutics Holdings, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06372717

A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

AI 简述这是一项I期试验，研究APL-4098单药或联合用药用于复发或难治性急性髓系白血病或骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia Refractory；Myelodysplastic Syndrome Acute Myeloid Leukemia；Myelodysplastic Syndrome With Excess Blasts
干预: APL-4098，Azacitidine and APL-4098，Azacitidine and Venetoclax and APL-4098
地点: Australia，United Kingdom
申办方: Apollo Therapeutics Ltd

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06376162 / NCI-2024-03916

Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

AI 简述这是一项I期试验，研究Ziftomenib联合化疗用于儿童复发/难治性急性白血病。

?

适用疾病: Relapsed/Refractory KMT2A-r Acute Leukemia；Relapsed/Refractory NUP98-r Acute Leukemia；Relapsed/Refractory NPM1-m Acute Leukemia
干预: Ziftomenib，Cytarabine，Fludarabine
地点: United States，Austria，Canada，France 等 3 个
申办方: PedAL BCU, LLC

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06397027 / NCI-2024-03798

A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

AI 简述这是一项I期试验，研究Ziftomenib联合Venetoclax和阿扎胞苷用于儿童复发难治性急性白血病。在美国开展。

?

适用疾病: Refractory Acute Leukemia；Pediatric Relapsed；Refractory Acute Myeloid Leukemia (AML)
干预: Ziftomenib，Venetoclax，Azacitidine
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 EARLY / Phase 1 器械药物

ClinicalTrials.gov NCT06398457

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

AI 简述这是一项早期I期试验，研究Daratumumab和透明质酸酶-fihj用于高危原发移植物失败的患者。在美国开展。

?

适用疾病: Hematologic Malignancy；Bone Marrow Transplant Rejection；Acute Myeloid Leukemia (AML)
干预: Darzalex Faspro (Daratumumab and hyaluronidase-fihj)，JH-DSA Semi-Quant Screen and Response Score
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT06399640 / NCI-2024-03343

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究Eltanexor联合Venetoclax用于复发难治性骨髓增生异常综合征和急性髓系白血病。在美国开展。

?

适用疾病: Relapsed Myelodysplastic Syndrome；Refractory Myelodysplastic Syndrome；Acute Myeloid Leukemia
干预: Eltanexor，Venetoclax，Bone Marrow Aspiration and Biopsy，Biospecimen Collection
地点: United States
申办方: Vanderbilt-Ingram Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06401603 / NCI-2024-03867

A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究Decitabine、Lisaftoclax和Olverembatinib用于晚期慢性髓系白血病和Ph阳性急性髓系白血病。

?

适用疾病: Advanced Chronic Myeloid Leukemia；Philadelphia Chromosome-Positive Acute Myeloid Leukemia；Acute Myeloid Leukemia (AML)
干预: Decitabine，Listaftoclax，Olverembatinib
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06408194 / NCI-2024-04331

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

AI 简述这是一项I期试验，研究自体CD22 CAR-T细胞用于B细胞恶性肿瘤，在美国开展。

?

适用疾病: Leukemia；Acute Lymphoblastic Leukemia；Recurrent B Acute Lymphoblastic Leukemia
干预: CD22CART infusion，Tisagenlecleucel
地点: United States
申办方: Stanford University

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06419634 / NCI-2024-06190

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

AI 简述这是一项I期试验，在美国等地研究BMS-986497单药或联合阿扎胞苷和维奈克拉用于复发/难治性急性髓系白血病或骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndrome；Refractory Acute Myeloid Leukemia (AML)
干预: BMS-986497，Azacitidine，Venetoclax
地点: United States，Canada，France，Spain
申办方: Bristol-Myers Squibb

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06429449 / NCI-2024-04761

Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究米托蒽醌联合Venetoclax和阿扎胞苷用于Venetoclax耐药的急性髓系白血病，在美国开展。

?

适用疾病: Leukemia；Myeloid Leukemia；Monocytic Leukemia
干预: Venetoclax，Azacitidine，Mitoxantrone
地点: United States
申办方: University of Colorado, Denver

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06440135 / NCI-2024-04920

Ziftomenib Maintenance Post Allo-HCT

AI 简述这是一项I期试验，研究Ziftomenib用于急性髓系白血病或急性淋巴细胞白血病。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia in Remission；NPM1 Mutation
干预: Ziftomenib
地点: United States
申办方: Massachusetts General Hospital

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06448013 / NCI-2024-04821

A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究Menin抑制剂Ziftomenib联合Venetoclax和Gemtuzumab用于儿童急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Refractory Childhood Acute Myeloid Leukemia；Recurrent Childhood Mixed Phenotype Acute Leukemia
干预: Venetoclax，Gemtuzumab，Ziftomenib
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06466395 / NCI-2024-05154

A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias

AI 简述这是一项I期试验，研究Hyper-CVAD联合Venetoclax用于儿童复发或难治性急性淋巴细胞白血病。

?

适用疾病: Refractory Acute Leukemia；Relapsed Acute Leukemia；Undifferentiated Leukemia
干预: Venetoclax，Hyper-CVAD
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT06484062 / NCI-2024-05326

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

AI 简述这是一项I期试验，研究Cirtuvivint联合ASTX727用于急性髓系白血病和骨髓增生异常综合征，在美国开展。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndrome；Myelodysplastic Syndrome/Acute Myeloid Leukemia
干预: Biospecimen Collection，Bone Marrow Aspiration，Cirtuvivint，Decitabine and Cedazuridine
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 生物制剂手术/操作

ClinicalTrials.gov / NCI NCT06492707 / NCI-2024-04811

DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial

AI 简述这是一项I期试验，研究DR-18用于预防或治疗急性髓系白血病或骨髓增生异常综合征移植后复发。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndrome；Recurrent Acute Myeloid Leukemia
干预: Decoy-resistant interleukin-18，Biospecimen Collection，Bone Marrow Aspiration
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06501196 / NCI-2024-06415

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

AI 简述这是一项I期试验，研究BH-30236联合Venetoclax用于复发/难治性急性髓系白血病和骨髓增生异常综合征，在美国开展。

?

适用疾病: Leukemia；Leukemia, Myeloid；Leukemia, Myeloid, Acute
干预: BH-30236，Venetoclax
地点: United States
申办方: BlossomHill Therapeutics

正在招募 Phase 1 药物基因治疗

ClinicalTrials.gov / NCI NCT06528301 / NCI-2024-09413

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

AI 简述这是一项1期试验，研究UB-VV111联合或不联合雷帕霉素用于复发/难治性CD19阳性B细胞恶性肿瘤，在美国和澳大利亚开展。

?

适用疾病: Lymphoma, B-Cell；Lymphoma, Non-Hodgkin (NHL)；Lymphoma, Large B-Cell, Diffuse (DLBCL)
干预: UB-VV111，rapamycin
地点: United States，Australia
申办方: Umoja Biopharma

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06533761 / NCI-2025-00739

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

AI 简述一项I期试验，研究Eganelisib单药或联合阿糖胞苷用于复发/难治性AML，在美国和西班牙开展。

?

适用疾病: AML, Adult；MDS；Refractory Acute Myeloid Leukemia (AML)
干预: Eganelisib，Eganelisib in combination with cytarabine
地点: United States，Spain
申办方: Stelexis BioSciences

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT06543381 / NCI-2024-06471

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

AI 简述这是一项I期试验，研究Olutasidenib用于IDH1突变的AML、MDS或CMML患者移植后治疗，在美国开展。

?

适用疾病: Acute Myeloid Leukemia；Chronic Myelomonocytic Leukemia；Myelodysplastic Syndrome
干预: Biospecimen Collection，Olutasidenib
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06547528

A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL

AI 简述这是一项I期试验，研究ONO-4685单药用于复发或难治性T细胞淋巴瘤和CLL/SLL。在日本等地开展。

?

适用疾病: Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
干预: ONO-4685
地点: Japan
申办方: Ono Pharmaceutical Co., Ltd.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06549790 / NCI-2024-08988

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究NMS-03597812用于复发/难治性急性髓系白血病，在美国开展。

?

适用疾病: Relapsed/Refractory Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)
干预: NMS-03597812
地点: United States
申办方: Nerviano Medical Sciences

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06551584 / NCI-2026-03469

Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT

AI 简述这是一项I期试验，研究ORCA-T用于接受异基因造血干细胞移植的晚期血液恶性肿瘤患者，在美国开展。

?

适用疾病: Acute Myeloid Leukemia；Acute Lymphoid Leukemia；Mixed Phenotype Acute Leukemia
干预: ORCA-T
地点: United States
申办方: Stanford University

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06552416 / NCI-2025-03247

Safety of MT-401-OTS in Patients With Relapsed AML or MDS

AI 简述这是一项I期试验，研究MT-401-OTS用于复发性急性髓系白血病或骨髓增生异常综合征患者，在美国开展。

?

适用疾病: Acute Myeloid Leukemia, in Relapse；MDS；Recurrent Myelodysplastic Syndrome
干预: MT-401-OTS
地点: United States
申办方: Marker Therapeutics, Inc.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06559189 / NCI-2024-06242

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL

AI 简述这是一项I期试验，研究CD19x22 CAR T细胞用于儿童B细胞急性淋巴细胞白血病。在美国开展。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia；Recurrent B Acute Lymphoblastic Leukemia；Refractory B Acute Lymphoblastic Leukemia
干预: CD19x22 CAR T
地点: United States
申办方: University of Colorado, Denver

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT06593145

CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms

AI 简述这是一项I期试验，研究FCTX-CL19-1 CAR-T细胞用于难治复发CD19+ B细胞肿瘤。

?

适用疾病: Acute Lymphoblastic Leukemia (ALL)；Mantle Cell Lymphoma (MCL)；Large B-cell Lymphoma
干预: FCTX-CL19-1 (Tarcidomgen Kimleucel)
地点: Poland
申办方: FamiCordTx

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06594445 / NCI-2024-10399

HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

AI 简述这是一项I期试验，研究GTB-360用于高危骨髓增生异常综合征和复发难治急性髓系白血病。

?

适用疾病: Myeloid Malignancy；Acute Myeloid Leukemia；Myelodysplastic Syndromes
干预: GTB-360
地点: United States
申办方: Masonic Cancer Center, University of Minnesota

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06609928 / NCI-2024-06808

FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究FOLR1 CAR T细胞用于复发或难治性儿童急性髓系白血病。

?

适用疾病: Recurrent Childhood Acute Myeloid Leukemia；Refractory Childhood Acute Myeloid Leukemia；Recurrent Acute Myeloid Leukemia (AML)
干预: FOLR1 CAR T-cells，Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06613217 / NCI-2025-02082

Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究口服zelenirstat用于复发/难治性急性髓系白血病。

?

适用疾病: Relapsed Adult AML；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)
干预: zelenirstat
地点: United States
申办方: Pacylex Pharmaceuticals

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06616636 / NCI-2024-08191

A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

AI 简述这是一项I期试验，研究Rezatapopt联合Azacitidine用于TP53Y220C突变髓系恶性肿瘤。

?

适用疾病: Myelodysplastic Syndrome；Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia (AML)
干预: Azacitidine，Rezatapopt
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06634394 / NCI-2024-08621

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

AI 简述这是一项I期试验，研究APVO436联合Venetoclax与Azacitidine用于新诊断AML患者。

?

适用疾病: Acute Myeloid Leukemia (AML)
干预: APVO436，Venetoclax，Azacitidine
地点: United States
申办方: Aptevo Therapeutics

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06649227

Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19

AI 简述这是一项I期试验，研究CD19 CAR-T细胞用于表达CD19的复发/难治性急性髓系白血病。

?

适用疾病: Relapsed Adult AML
干预: CAR-T cell therapy
地点: France
申办方: University Hospital, Lille

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06651229

A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

AI 简述这是一项I期试验，在澳大利亚、法国、西班牙研究JNJ-90189892用于复发/难治性急性髓系白血病或骨髓增生异常肿瘤。

?

适用疾病: Leukemia, Myeloid, Acute；Myelodysplastic Neoplasms
干预: JNJ-90189892，Azacitadine (AZA)，Venetoclax (VEN)
地点: Australia，France，Spain
申办方: Janssen Research & Development, LLC

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06708897 / NCI-2025-01918

A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas

AI 简述这是一项I期试验，在美国开展，研究ZE50-0134用于复发难治CLL/SLL及低级别淋巴瘤。

?

适用疾病: CLL / SLL；CLL (Chronic Lymphocytic Leukemia)；SLL (Small Lymphocytic Lymphoma)
干预: ZE 50-0134
地点: United States
申办方: Lomond Therapeutics Holdings, Inc.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT06709469

Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults

AI 简述这是一项I期试验，在西班牙开展，研究CAR T细胞用于儿童、青少年和年轻成人复发难治急性淋巴细胞白血病。

?

适用疾病: Precursor Cell Lymphoblastic Leukemia-Lymphoma
干预: Autologous CD19/CD22 CAR T cells，Allogeneic CART-NKG2D cells
地点: Spain
申办方: Instituto de Investigación Hospital Universitario La Paz

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06714591 / NCI-2025-01852

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

AI 简述这是一项I期试验，研究BL-M11D1用于复发性/难治性急性髓系白血病。

?

适用疾病: Relapsed/Refractory Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)
干预: BL-M11D1
地点: United States
申办方: SystImmune Inc.

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06735664 / NCI-2024-10074

Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation

AI 简述这是一项I期试验，研究泽布替尼联合Odronextamab治疗Richter转化患者。在美国开展。

?

适用疾病: Recurrent Transformed Chronic Lymphocytic Leukemia；Refractory Transformed Chronic Lymphocytic Leukemia；Richter Syndrome
干预: Biopsy，Biospecimen Collection，Bone Marrow Biopsy，Computed Tomography
地点: United States
申办方: City of Hope Medical Center

正在招募 EARLY / Phase 1 生物制剂其他手术/操作

ClinicalTrials.gov / NCI NCT06735690 / NCI-2024-10005

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

AI 简述这是一项早期I期试验，研究异体CMV特异性CD19-CAR-T细胞联合CMV-MVA三价疫苗用于高危急性淋巴细胞白血病移植后。在美国开展。

?

适用疾病: Acute Lymphoblastic Leukemia；Acute Lymphoblastic Leukemia (ALL)
干预: Allogeneic Hematopoietic Stem Cell Transplantation，Anti-CD19-CAR CMV-specific T-lymphocytes，Biospecimen Collection，Bone Marrow Aspiration
地点: United States
申办方: City of Hope Medical Center

正在招募 EARLY / Phase 1 生物制剂

ClinicalTrials.gov NCT06765876

CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial

AI 简述这是一项早期I期试验，研究CART123 T细胞用于复发难治CD123+血液恶性肿瘤。

?

适用疾病: Leukemia, Myeloid, Acute(AML)；Precursor Cell Lymphoblastic Leukemia-Lymphoma；Myelodysplastic Syndromes (MDS)
干预: Autologous CAR123 T lymphocytes
地点: Czechia
申办方: Institute of Hematology and Blood Transfusion, Czech Republic

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06769490 / NCI-2025-00080

Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究Ziftomenib联合Quizartinib用于急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)
干预: Ziftomenib，Quizartinib
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 器械药物

ClinicalTrials.gov / NCI NCT06777979 / NCI-2024-10103

CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia

AI 简述这是一项I期试验，研究CD19-CD22 CAR T细胞用于儿童急性淋巴细胞白血病。

?

适用疾病: Acute Lymphoblastic Leukemia；Recurrent Acute Lymphoblastic Leukemia；Recurrent B Acute Lymphoblastic Leukemia
干预: Fludarabine，Cyclophosphamide，Mesna，CD19-CD22 CAR T cell infusion
地点: United States
申办方: St. Jude Children's Research Hospital

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06786533 / NCI-2025-00864

Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML

AI 简述这是一项I期试验，研究抗FLT3 CAR-T细胞用于复发/难治性急性髓系白血病，在美国开展。

?

适用疾病: Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)
干预: Anti-FLT3 CAR-T cells
地点: United States
申办方: Hemogenyx Pharmaceuticals LLC

正在招募阶段未标明放疗

ClinicalTrials.gov / NCI NCT06803745 / NCI-2025-02380

Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)

AI 简述这是一项试验，比较200cGy与400cGy全身照射用于急性白血病患者首次异基因移植前的预处理。

?

适用疾病: Acute Leukemia；Acute Lymphoblastic Lymphoma；Myelodysplastic/Myeloproliferative Neoplasm with SF3B1 Mutation and Thrombocytosis
干预: 200 cGy or 400 cGy total body irradiation (TBI)
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06810583

A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia

AI 简述这是一项I期试验，研究Dalbavancin预防用于高危及儿童白血病。

?

适用疾病: Leukemia；Acute Myeloid Leukemia；Lymphoblastic Leukemia in Children
干预: Dalbavancin，Fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician)
地点: United States
申办方: St. Jude Children's Research Hospital

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06812104

Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies.

AI 简述这是一项I期试验，在日本开展，研究KK2845用于复发/难治性AML和其他血液恶性肿瘤。

?

适用疾病: Relapsed or Refractory AML and Other Hematologic Malignancies
干预: KK2845_1，KK2845_2，KK2845_3，KK2845_4
地点: Japan
申办方: Kyowa Kirin Co., Ltd.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06834282 / NCI-2025-02383

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

AI 简述这是一项I期试验，研究CER-1236用于急性髓系白血病、骨髓增生异常综合征和骨髓纤维化。

?

适用疾病: AML；Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia
干预: CER-1236，Cyclophosphamide，Fludarabine，Mesna
地点: United States
申办方: CERo Therapeutics Holdings, Inc.

正在招募阶段未标明放疗

ClinicalTrials.gov NCT06845592

Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia

AI 简述这是一项试验，研究全骨髓/淋巴照射后免疫治疗用于高危急性白血病干细胞移植。

?

适用疾病: Acute Myeloid Leukaemia (AML)；Acute Lymphoblastic Leukemia ALL；High Risk Leukaemia
干预: total marrow/lymphoid irradiation
地点: Italy
申办方: University Of Perugia

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06863259

Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL

AI 简述这是一项I期试验，研究Inotuzumab Ozogamicin、Venetoclax和地塞米松用于复发B细胞ALL。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia
干预: Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone
地点: United States
申办方: Children's Hospital Medical Center, Cincinnati

正在招募阶段未标明生物制剂

ClinicalTrials.gov NCT06866873

CD-19 CAR-T Cell for Pediatric ALL or Lymphoma

AI 简述这是一项试验，研究CD-19 CAR-T细胞用于儿童B细胞ALL或淋巴瘤。

?

适用疾病: Lymphoma, B-Cell；Acute Lymphoblastic Leukemia, Pediatric
干预: CAR-T
地点: Hong Kong
申办方: Hong Kong Children's Hospital

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06879340 / NCI-2025-03905

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

AI 简述这是一项I期试验，研究DuoCAR20.19.22-D95用于复发或难治性B细胞恶性肿瘤，以及氟达拉滨和环磷酰胺作为条件治疗，在美国开展。

?

适用疾病: B-Cell Non-Hodgkin Lymphoma；B-cell Acute Lymphoblastic Leukemia；Recurrent Primary Cutaneous (Skin) Diffuse Large B-Cell Lymphoma, Leg Type
干预: DuoCAR20.19.22-D95，Fludarabine (Conditional therapy)，Cyclophosphamide (Conditional therapy)
地点: United States
申办方: University of Kansas Medical Center

正在招募阶段未标明生物制剂

ClinicalTrials.gov NCT06885476

Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients

AI 简述这是一项研究异体NK细胞输注用于MRD阳性急性髓系白血病的临床试验，在意大利开展。

?

适用疾病: Acute Myeloid Leukemia；Minimal Residual Disease；Natural Killer Cell
干预: Infusion of alloreactive NK cells
地点: Italy
申办方: IRCCS Azienda Ospedaliero-Universitaria di Bologna

正在招募 Phase 1 生物制剂器械药物

ClinicalTrials.gov / NCI NCT06904066 / NCI-2025-03016

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

AI 简述这是一项I期试验，研究自体T细胞转导识别新抗原的TCR用于血液恶性肿瘤，在美国开展。

?

适用疾病: Malignancy, Hematologic；Neoplasms, Hematologic；Neoplasms, Hematopoietic
干预: aldesleukin，cyclophosphamide，fludarabine phosphate，Individual Patient TCR-Transduced PBL
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06916767 / NCI-2025-05415

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

AI 简述这是一项I期试验，研究BAFF CAR-T细胞（LMY-920）用于复发难治性CLL/小淋巴细胞淋巴瘤。

?

适用疾病: Relapsed CLL；Refractory CLL；Refractory Lymphoma
干预: BAFF CAR-T，Obinutuzumab，Cyclophosphamide，Fludarabine
地点: United States
申办方: Paolo Caimi, MD

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06934382 / NCI-2025-05470

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

AI 简述这是一项I期试验，研究Anti-CD7 CAR-T细胞用于复发/难治性T细胞急性淋巴细胞白血病或淋巴瘤。

?

适用疾病: T-Cell Acute Lymphoblastic Leukemia/Lymphoma；Recurrent T Acute Lymphoblastic Leukemia；Refractory T Acute Lymphoblastic Leukemia
干预: Allogeneic anti-CD7 CAR-T cells (BEAM-201)
地点: United States
申办方: Stephan Grupp MD PhD

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT06947044

Biomarkers in Patients With Anemia-Induced Thrombocytopenic Bleeding

AI 简述这是一项观察性研究，探讨贫血致血小板减少性出血患者的生物标志物。

?

适用疾病: Acute Leukemia；Acute Myeloid Leukemia (AML)；Acute Lymphocytic Leukaemia
干预: RBC transfusion strategy
地点: Canada
申办方: Donald Arnold

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06950034 / NCI-2025-03929

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

AI 简述这是一项I期试验，在美国开展，研究STX-0712用于晚期血液恶性肿瘤，包括CMML和AML。

?

适用疾病: Chronic Myelomonocytic Leukemia；Chronic Myelomonocytic Leukemia (CMML)；Chronic Myelomonocytic Leukemia-1
干预: STX-0712
地点: United States
申办方: Solu Therapeutics, Inc

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06980116

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

AI 简述这是一项I期试验，研究EXS73565用于复发难治B细胞恶性肿瘤，在格鲁吉亚、摩尔多瓦、西班牙、乌克兰开展。

?

适用疾病: Relapsed or Refractory B-cell Malignancies；Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)；Follicular Lymphoma (FL)
干预: EXS73565
地点: Georgia，Moldova，Spain，Ukraine 等 1 个
申办方: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06994676 / NCI-2025-04962

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

AI 简述这是一项I期试验，在美国研究CBX-250用于复发或难治性髓系白血病。

?

适用疾病: High-risk Myelodysplastic Syndrome；Chronic Myelomonocytic Leukemia (CMML)；AML - Acute Myeloid Leukemia
干预: CBX-250
地点: United States
申办方: Crossbow Therapeutics, Inc.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT07011004 / NCI-2025-04272

A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia

AI 简述这是一项I期试验，研究Cytokine Induced Memory-Like Natural Killer Cells联合Atezolizumab用于复发难治急性髓系白血病，在美国开展。

?

适用疾病: Acute Myeloid Leukemia Refractory；Acute Myeloid Leukemia, in Relapse；Refractory Acute Myeloid Leukemia (AML)
干预: Cytokine Induced Memory-Like Natural Killer Cells，Atezolizumb，CIML-NK cell therapy
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT07012044 / NCI-2025-03946

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究Cedazuridine和Decitabine联合Filgrastim用于儿童高危急性髓系白血病造血干细胞移植后，在美国开展。

?

适用疾病: Acute Myeloid Leukemia Post Cytotoxic Therapy；Recurrent Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia
干预: Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy，Decitabine
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT07025564 / NCI-2025-03912

MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究MiRisten用于治疗复发或难治性急性髓系白血病，在美国开展。

?

适用疾病: Recurrent Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia (AML)
干预: Biospecimen Collection，Echocardiography Test，miR-126 Inhibitor miRisten
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07044544

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

AI 简述这是一项I期试验，在氟达拉滨/美法仑减低强度预处理移植中联合新型抗白血病药物用于髓系恶性肿瘤。

?

适用疾病: Myeloid Malignancy；Hematologic Malignancy；Acute Myeloid Leukemia
干预: G-CSF，Decitabine，Venetoclax
地点: United States
申办方: University of Alabama at Birmingham

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT07059624

Femoral Arterial Cannulation in Pediatrics

AI 简述这是一项试验，比较两种动脉穿刺技术用于儿科股动脉插管。

?

适用疾病: Pediatric ALL；Cardiac Complication；Anesthesia
干预: "Modified Dynamic Needle Tip Positioning, Short-Axis, Out-Of-Plane" (MDNTP-SAOP)，"Conventional, Short-Axis, Out-Of-Plane" (C-SAOP)
地点: Lebanon
申办方: American University of Beirut Medical Center

正在招募 EARLY / Phase 1 药物其他

ClinicalTrials.gov / NCI NCT07059975 / NCI-2026-00530

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

AI 简述这是一项早期I期试验，更新监测和治疗方案用于儿童急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Pediatric AML；Acute Myeloid Leukemia with t(7;12)(q36;p13); HLXB9-ETV6
干预: Idarubicin Hydrochloride，Fludarabine，Cytarabine (Ara-C)，Venetoclax
地点: United States
申办方: Joanna Yi

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov NCT07066397

A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL

AI 简述这是一项I期试验，在台湾开展，研究FIT-CD19-CAR-T细胞用于复发/难治性B细胞急性淋巴细胞白血病。

?

适用疾病: Acute Lymphoblastic Leukemia
干预: ARM011，Fludarabine，Cyclophosphamide
地点: Taiwan
申办方: TriArm Therapeutics (Taiwan) Limited

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07078929

Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL)

AI 简述这是一项I期试验，在泰国研究CD19-IL7Ra CAR-T细胞用于复发/难治儿童急性淋巴细胞白血病。

?

适用疾病: Relapse B Acute Lymphoblastic Leukemia；Refactory Childhood Acute Lymphoblastic Leukemia
干预: CD19-IL7Ra CAR-T cells
地点: Thailand
申办方: Chulalongkorn University

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07107126 / NCI-2026-01277

Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

AI 简述这是一项I期试验，研究RPT1G用于美国急性髓系白血病和高危骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndrome；Refractory Acute Myeloid Leukemia (AML)
干预: RPT1G
地点: United States
申办方: Remedy Plan, Inc.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07108868

A Phase I Dose Finding Study of MB-CART2219.1

AI 简述这是一项I期试验，研究MB-CART2219.1（靶向CD19和CD22的CAR-T细胞）用于淋巴瘤、CLL和急性淋巴细胞白血病。

?

适用疾病: Lymphoma；CLL；Acute Lymphoblastic Leukemia, Pediatric
干预: CAR-T cells targeting CD19 and CD22
地点: Germany
申办方: University Hospital Tuebingen

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07130695 / NCI-2026-00868

Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation

AI 简述这是一项I期试验，研究Olutasidenib单药或联合用于IDH1突变AML患者。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia (AML)
干预: Olutasidenib Investigational Agent Administration
地点: United States
申办方: Virginia Commonwealth University

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT07133997 / NCI-2025-05656

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

AI 简述这是一项I期试验，研究门冬酰胺酶、维奈克拉联合博纳吐单抗用于复发/难治B细胞急性淋巴细胞白血病。

?

适用疾病: Recurrent B Acute Lymphoblastic Leukemia；Refractory B Acute Lymphoblastic Leukemia
干预: Asparaginase Erwinia chrysanthemi，Biospecimen Collection，Blinatumomab，Bone Marrow Aspiration
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT07166419 / NCI-2025-05721

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

AI 简述这是一项I期试验，在United States开展，研究抗CD19/20/22 CAR-T细胞用于复发或难治性非霍奇金淋巴瘤和急性淋巴细胞白血病。

?

适用疾病: Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive；Recurrent Acute Lymphoblastic Leukemia；Recurrent Chronic Lymphocytic Leukemia
干预: Autologous Anti-CD19/CD20/CD22 CAR T-cells，Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy
地点: United States
申办方: Ohio State University Comprehensive Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07177079 / NCI-2025-08506

High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

AI 简述这是一项I期试验，研究高剂量维生素C联合阿扎胞苷和Venetoclax用于急性髓系白血病，在美国开展。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia (AML)
干预: Azacitidine，Venetoclax，High-dose ascorbate，Decitabine
地点: United States
申办方: Kittika Poonsombudlert

正在招募 Phase 1 基因治疗

ClinicalTrials.gov NCT07220993

Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells

AI 简述这是一项I期试验，研究CD7靶向CAR-T细胞用于T细胞恶性肿瘤。

?

适用疾病: T-cell Acute Lymphoblastic Lymphoma；T-non-Hodgkin Lymphoma；T-cell Acute Lymphoblastic Leukemia
干预: CD7.CAR/28zeta T Cells
地点: United States
申办方: Baylor College of Medicine

正在招募阶段未标明药物

ClinicalTrials.gov NCT07244367

Maintenance Venetoclax in AML Fit Patients

AI 简述这是一项试验，研究Venetoclax联合阿糖胞苷用于急性髓系白血病的维持治疗，在埃及开展。

?

适用疾病: Acute Myeloid Leukaemia (AML)
干预: SC cytarabine +Venetoclax
地点: Egypt
申办方: Sohag University

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07250087 / NCI-2025-09209

Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL

AI 简述这是一项I期试验，研究Asciminib维持治疗用于移植或CAR-T后的Ph+急性淋巴细胞白血病。

?

适用疾病: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia；B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1
干预: Asciminib
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07250646 / NCI-2026-04006

A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis

AI 简述这是一项I期试验，研究rebecsinib用于复发/难治性继发性急性髓系白血病或高危骨髓纤维化。

?

适用疾病: Secondary AML；Myelofibrosis；Recurrent Secondary Acute Myeloid Leukemia
干预: rebecsinib
地点: United States
申办方: Aspera Biomedicines, Inc.

正在招募 Phase 1 器械药物

ClinicalTrials.gov NCT07257419

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

AI 简述这是一项1期试验，研究CD45RA去除的CD19-CAR T细胞用于复发难治CD19+ ALL和淋巴瘤。在美国开展。

?

适用疾病: Relapsed Pediatric ALL；Hematopoietic Cell Transplantation；Hematologic Malignancy
干预: Anti-Thymocyte Globulin (Rabbit)，Cyclophosphamide，Fludarabine，Thiotepa
地点: United States
申办方: St. Jude Children's Research Hospital

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07270978

Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS

AI 简述这是一项Ib期试验，研究CD33 FPBMC用于微小残留病阳性的急性髓系白血病或骨髓增生异常综合征患者。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndromes；Myelodysplastic/Myeloproliferative Neoplasm
干预: CD33 FPBMC
地点: United States
申办方: University of Virginia

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07283094 / NCI-2026-03401

FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究FHD-286联合低剂量地西他滨和维奈克拉用于急性髓系白血病，在美国开展。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndrome；Refractory Acute Myeloid Leukemia (AML)
干预: Decitabine，Venetoclax，FHD-286
地点: United States
申办方: Montefiore Medical Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07295951

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

AI 简述这是一项I期试验，在英国开展，研究14C-Bleximenib用于急性白血病患者。

?

适用疾病: Acute Lymphoblastic Leukemia；Acute Leukemias；Acute Myeloid Leukemia
干预: 14C-bleximenib，bleximenib
地点: United Kingdom
申办方: Janssen Research & Development, LLC

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07300683

Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma

AI 简述这是一项I期试验，研究抗CCR9 CAR T细胞用于T细胞白血病/淋巴瘤。在英国开展。

?

适用疾病: T Cell Acute Lymphoblastic Leukemia；T Cell Lymphoblastic Lymphoma
干预: CARCCR9 T cells
地点: United Kingdom
申办方: University College, London

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07306832 / NCI-2026-04003

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

AI 简述这是一项I期试验，研究Pivekimab Sunirine用于复发或难治性急性髓系白血病儿童。

?

适用疾病: Acute Myeloid Leukemia；Refractory Childhood Acute Myeloid Leukemia；Recurrent Acute Myeloid Leukemia (AML)
干预: Pivekimab Sunirine
地点: United States，Australia，South Korea，Taiwan
申办方: AbbVie

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07320235 / NCI-2026-00002

Imetelstat Combinations in Relapsed AML

AI 简述这是一项I期试验，研究Imetelstat联合Azacitidine和Venetoclax用于复发性急性髓系白血病，在美国开展。

?

适用疾病: Relapsed Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)
干预: Imetelstat，Azacitidine，Venetoclax
地点: United States
申办方: Douglas Tremblay

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07347418

CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML

AI 简述这是一项I期试验，研究CD64 CAR T细胞用于复发/难治性急性髓系白血病。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Relapsed Acute Myeloid Leukemia (AML)；Myelodysplastic Syndrome
干预: CD64 CAR T Cells
地点: United States
申办方: University of Colorado, Denver

正在招募阶段未标明基因治疗

ClinicalTrials.gov NCT07371403

MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia

AI 简述这是一项试验，研究MB-CART19.1用于复发/难治急性淋巴细胞白血病，在约旦开展。

?

适用疾病: Acute Lymphoblastic Leukemia；Acute Lymphoblastic Leukemia Recurrent；Acute Lymphoblastic Leukemia Refractory
干预: MB-CART19.1
地点: Jordan
申办方: King Hussein Cancer Center

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT07374029 / NCI-2026-01258

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

AI 简述这是一项I期试验，在美国开展，研究DC/AML融合疫苗联合T细胞治疗、地西他滨和维奈托克用于急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia, in Relapse；Recurrent Acute Myeloid Leukemia (AML)
干预: DC/AML Fusion Vaccine，T-Cell Therapy，Decitabine，Venetoclax
地点: United States
申办方: David Avigan

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07384715

First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

AI 简述这是一项I期试验，研究GEN3018用于复发/难治性急性髓系白血病或高危骨髓增生异常综合征。

?

适用疾病: R/R AML；R/R HR-MDS；Acute Myeloid Leukemia
干预: GEN3018
地点: Denmark，Spain
申办方: Genmab

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov NCT07464951

CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究CART123细胞联合或不联合Ruxolitinib用于复发难治性急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia (AML)
干预: Anti-CD123 LV redirected T cells (CART123)，Ruxolitinib (JAKAVI®)
地点: United States
申办方: Stephan Grupp MD PhD

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07513129 / NCI-2026-02416

Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

AI 简述这是一项I期试验，研究Venetoclax、Dexamethasone、Bortezomib和Daratumumab用于复发/难治T细胞急性淋巴细胞白血病。

?

适用疾病: T-cell Acute Lymphoblastic Leukemia；Lymphoma；Recurrent T Acute Lymphoblastic Leukemia
干预: Venetoclax，Dexamethasone，Bortezomib，Daratumumab
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT07532525 / NCI-2026-00885

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

AI 简述这是一项I期试验，研究来那度胺用于CAR-T细胞治疗后复发或难治性CD19+ B细胞白血病或淋巴瘤。

?

适用疾病: Recurrent B Acute Lymphoblastic Leukemia；Recurrent B-Cell Non-Hodgkin Lymphoma；Refractory B Acute Lymphoblastic Leukemia
干预: Biospecimen Collection，Pomalidomide
地点: United States
申办方: University of Michigan Rogel Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07556757

A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia

AI 简述一项I期试验，研究CD-19 t-haNK用于B细胞急性淋巴细胞白血病。

?

适用疾病: B-ALL；Leukemia
干预: CD19 t-haNK
地点: South Africa
申办方: ImmunityBio, Inc.

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov NCT07565220

Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies

AI 简述这是一项1期试验，研究基于Thiotepa的预处理方案用于血液恶性肿瘤的异基因干细胞移植，在美国开展。

?

适用疾病: Acute Lymphocytic Leukemia (ALL)；Acute Myeloid Leukemia (AML)；Acute Leukemia
干预: Thiotepa，Fludarabine，Busulfan，PBSC infusion
地点: United States
申办方: Sawa Ito, MD

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07566585 / NCI-2026-03567

Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation

AI 简述这是一项I期试验，研究BSB-2002用于NPM1突变复发或难治急性髓系白血病。

?

适用疾病: AML - Acute Myeloid Leukemia；AML With Mutated NPM1；AML, Adult Recurrent
干预: SOC+ BSB-2002，SOC+BSB-2002
地点: United States
申办方: BlueSphere Bio, Inc

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07586618

First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.

AI 简述这是一项I期试验，在美国开展，首次在人体中研究新药4A10用于复发难治性急性淋巴细胞白血病或淋巴母细胞淋巴瘤。

?

适用疾病: Lymphoblastic Lymphoma；Acute Lymphoblastic Leukemia ALL
干预: 4A10
地点: United States
申办方: Allterum Therapeutics, Inc

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07661095 / NCI-2026-04791

A Study of CRD3874-SI in People With Leukemia

AI 简述这是一项I期试验，研究CRD3874-SI用于急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；AML；Refractory Acute Myeloid Leukemia
干预: CRD3874-SI
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2

NCI NCT03922724 / NCI-2019-02842

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

AI 简述这是一项II期试验，研究异基因造血细胞移植用于外周T细胞淋巴瘤，在美国开展。

?

适用疾病: Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified；Refractory Anaplastic Large Cell Lymphoma；Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 1, Phase 2

NCI NCT05531786 / NCI-2022-07729

Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

AI 简述这是一项I/II期试验，研究Pacritinib用于难治性慢性移植物抗宿主病。

?

适用疾病: Hematopoietic and Lymphoid System Neoplasm；Chronic Graft Versus Host Disease
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 1

NCI NCT05535764 / NCI-2022-07832

Pegylated Interferon Alfa-2a for the Treatment of Primary and Secondary Myelofibrosis following an Allogeneic Hematopoietic Cell Transplantation, ATIOM Trial

AI 简述这是一项I期试验，研究聚乙二醇干扰素α-2a用于移植后骨髓纤维化。

?

适用疾病: Secondary Myelofibrosis；Primary Myelofibrosis
干预: 未列出
地点: United States
申办方: Huntsman Cancer Institute/University of Utah

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06892223

Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation

AI 简述这是一项II期试验，研究Monalizumab用于接受单倍体移植的AML或MDS患者，在意大利开展。

?

适用疾病: Acute Myeloid Leukaemia；MDS (Myelodysplastic Syndrome)；MPN (Myeloproliferative Neoplasms)
干预: Monalizumab (anti-NKG2A monoclonal antibody)
地点: Italy
申办方: Istituto Clinico Humanitas

即将招募 Phase 3 药物

ClinicalTrials.gov NCT05876832

A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)

AI 简述这是一项III期试验，比较XY0206与挽救化疗用于FLT3-ITD突变复发或难治性急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia With FLT3/ITD Mutation
干预: XY0206，Salvage Chemotherapy
地点: 未列出
申办方: Shijiazhuang Yiling Pharmaceutical Co. Ltd

即将招募 Phase 2, Phase 3 生物制剂药物放疗

ClinicalTrials.gov NCT07157514

Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML

AI 简述这是一项II/III期试验，研究131I-apamistamab联合氟达拉滨、环磷酰胺等用于异基因移植治疗复发/难治性急性髓系白血病。

?

适用疾病: Acute Leukemia；Myeloid Leukemia；Acute Myelogenous Leukemia
干预: 131I-apamistamab，Fludarabine，Cyclophosphamide，Total Body Irradiation (TBI)
地点: 未列出
申办方: Actinium Pharmaceuticals

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07223190

A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia

AI 简述这是一项III期试验，比较皮下与静脉注射博纳吐单抗治疗B细胞前体急性淋巴细胞白血病。

?

适用疾病: Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia
干预: Blinatumomab，Blinatumomab，HyperCVAD
地点: 未列出
申办方: Amgen

即将招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT07264010

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

AI 简述这是一项II/III期试验，研究Sorafenib联合Venetoclax用于MRD阳性急性髓系白血病。

?

适用疾病: Acute Myeloid Leukaemia (AML)；Measurable Residual Disease (MRD)
干预: Sorafenib (SORA)，Venetoclax (VEN)
地点: 未列出
申办方: Nanfang Hospital, Southern Medical University

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07296445

A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)

AI 简述这是一项III期试验，比较口服三氧化二砷与静脉注射三氧化二砷用于急性早幼粒细胞白血病。

?

适用疾病: Acute Promyelocytic Leukemia (APL)；Acute Promyelocytic Leukaemia；Acute Promyelocytic Leukemia With PML-RARA
干预: Oral ATO，IV Arsenic Trioxide，all-trans retinoic acid (ATRA)
地点: 未列出
申办方: SDK Therapeutics, Inc.

即将招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT07425808

FLT3-ITD Targeted Therapy in Fit AML Patients

AI 简述这是一项II/III期试验，比较Gilteritinib等靶向治疗与标准治疗用于FLT3-ITD阳性AML。

?

适用疾病: AML (Acute Myeloid Leukemia)
干预: Gilteritinib，Venetoclax，Azacitidine (AZA)，Local standard of care (SOC)
地点: 未列出
申办方: European Organisation for Research and Treatment of Cancer - EORTC

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07516093

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

AI 简述这是一项III期试验，比较NX-5948与Pirtobrutinib用于复发/难治性CLL/SLL。

?

适用疾病: B-cell Lymphoma；Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma
干预: NX-5948，Pirtobrutinib
地点: 未列出
申办方: Nurix Therapeutics, Inc.

即将招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT07581002

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

AI 简述这是一项II/III期试验，研究Pivekimab Sunirine联合Venetoclax和Azacitidine用于急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia
干预: Pivekimab Sunirine，Venetoclax，Azacitidine，Matching Placebo for PVEK
地点: 未列出
申办方: AbbVie

即将招募 Phase 2, Phase 3 生物制剂药物

ClinicalTrials.gov NCT07623187

A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy

AI 简述这是一项II/III期试验，研究IPN60340联合阿扎胞苷和Venetoclax用于新诊断急性髓系白血病。

?

适用疾病: Acute Myeloid Leukaemia (AML)；Acute Myeloid Leukaemia
干预: IPN60340 + azacitidine + venetoclax，Placebo + azacitidine + venetoclax
地点: 未列出
申办方: Ipsen

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07476729

International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

AI 简述这是一项III期试验，研究Inotuzumab ozogamicin和Blinatumomab用于儿童复发B细胞急性淋巴细胞白血病。

?

适用疾病: B-Cell Acute Lymphoblastic Leukaemia
干预: Inotuzumab ozogamicin (INO)，Blinatumomab
地点: Austria，Belgium，Czechia，Denmark 等 16 个
申办方: Charite University, Berlin, Germany

暂时不招募 Phase 1

NCI NCT02117336 / NCI-2014-01869

Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

AI 简述这是一项1期试验，研究复发/难治性慢性淋巴细胞白血病和小淋巴细胞淋巴瘤，在美国开展。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Refractory Chronic Lymphocytic Leukemia (CLL)；Recurrent Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: Piramal Enterprises Limited

暂时不招募 Phase 2

NCI NCT02250937 / NCI-2014-02324

Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate before Donor Stem Cell Transplant in Treating Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome

AI 简述这是一项II期试验，研究Venetoclax和序贯Busulfan、Cladribine、Fludarabine在移植前用于急性髓系白血病或骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia (AML)；Myelodysplastic Syndrome
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 1

NCI NCT02333162 / NCI-2014-02469

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients with Relapsed Hematologic Cancers Undergoing a Second or above Donor Stem Cell Transplant

AI 简述这是一项I期试验，研究调整照射与Fludarabine、Melphalan用于复发性血液癌症接受干细胞移植的患者。

?

适用疾病: Recurrent Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes；Recurrent Hematopoietic and Lymphoid Cell Neoplasm；Myelodysplastic Syndrome
干预: 未列出
地点: United States
申办方: University of Chicago Comprehensive Cancer Center

暂时不招募 Phase 1

NCI NCT02530034 / NCI-2015-02131

Hu8F4 in Treating Patients with Advanced Hematologic Malignancies

AI 简述这是一项I期试验，研究Hu8F4用于晚期血液恶性肿瘤，包括高危MDS、复发AML等。

?

适用疾病: High Risk Myelodysplastic Syndrome；Recurrent Acute Myeloid Leukemia (AML)；Recurrent Chronic Myelomonocytic Leukemia
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 2

NCI NCT02629809 / NCI-2016-00016

Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients with Chronic Lymphocytic Leukemia

AI 简述这是一项II期试验，研究伊布替尼联合氟达拉滨、环磷酰胺和奥妥珠单抗用于慢性淋巴细胞白血病。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 2

NCI NCT02756897 / NCI-2016-00797

Venetoclax and Ibrutinib in Treating Patients with Chronic or Small Lymphocytic Leukemia

AI 简述这是一项II期试验，研究Venetoclax和Ibrutinib用于慢性或小淋巴细胞白血病。

?

适用疾病: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma；Refractory Chronic Lymphocytic Leukemia (CLL)；Recurrent Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 1

NCI NCT03132454 / NCI-2018-01194

Palbociclib and Sorafenib, Decitabine, Dexamethasone or Venetoclax in Treating Patients with Recurrent or Refractory Leukemia

AI 简述这是一项I期试验，研究Palbociclib联合Sorafenib、地西他滨、地塞米松或Venetoclax用于复发难治性白血病，在美国开展。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Refractory Acute Lymphoblastic Leukemia (ALL)；Recurrent Acute Lymphoblastic Leukemia
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 1

NCI NCT03816319 / NCI-2019-00238

TAK-243 in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes with Increased Blasts

AI 简述这是一项I期试验，研究TAK-243用于复发或难治性急性髓系白血病或伴原始细胞增多的骨髓增生异常综合征。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Refractory Myelodysplastic Syndrome；Recurrent Myelodysplastic Syndrome
干预: 未列出
地点: United States，Canada
申办方: University Health Network Princess Margaret Cancer Center LAO

暂时不招募 Phase 1

NCI NCT04301076 / NCI-2020-01535

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (“EPOCH”) for Adult T-Cell Leukemia-Lymphoma (ATLL)

AI 简述这是一项I期试验，研究来那度胺联合EPOCH化疗用于成人T细胞白血病淋巴瘤。

?

适用疾病: Adult T-Cell Leukemia/Lymphoma；Acute Adult T-Cell Leukemia/Lymphoma；HTLV-1 Infection
干预: 未列出
地点: United States
申办方: Yale University Cancer Center LAO

暂时不招募 Phase 1, Phase 2

NCI NCT04278768 / NCI-2020-03930

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

AI 简述这是一项I/II期试验，研究CA-4948单药用于急性髓系白血病或骨髓增生异常综合征。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Refractory Myelodysplastic Syndrome；Recurrent Myelodysplastic Syndrome
干预: 未列出
地点: United States
申办方: Curis

暂时不招募 Phase 1

NCI NCT04996030 / NCI-2021-10925

A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia

AI 简述这是一项I期试验，研究口服SY-2101用于急性早幼粒细胞白血病。

?

适用疾病: Acute Promyelocytic Leukemia with PML-RARA
干预: 未列出
地点: United States
申办方: Syros Pharmaceuticals

暂时不招募 Phase 1, Phase 2

NCI NCT05168904 / NCI-2022-00831

A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)

AI 简述这是一项I/II期试验，研究Fadraciclib用于白血病或骨髓增生异常综合征，在美国开展。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Acute Myeloid Leukemia (AML)；Myelodysplastic Syndrome
干预: 未列出
地点: United States
申办方: Cyclacel Pharmaceuticals, Inc.

暂时不招募 Phase 1

NCI NCT05400122 / NCI-2022-07858

Universal Donor Natural Killer Cells in Combination with Aldesleukin and Vactosertib for the Treatment of Patients with Locally Advanced or Metastatic Colorectal, Gastric and Esophageal Cancers and Relapsed or Refractory Hematologic Cancers

AI 简述这是一项I期试验，研究通用供者NK细胞联合Aldesleukin和Vactosertib用于局部晚期或转移性结直肠癌、胃癌、食管癌及血液肿瘤。

?

适用疾病: Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Case Comprehensive Cancer Center

暂时不招募 Phase 2

NCI NCT05761171 / NCI-2023-00503

A Study of Revumenib in Combination with Chemotherapy for Patients Diagnosed with Relapsed or Refractory Leukemia

AI 简述这是一项II期试验，研究Revumenib联合化疗用于复发或难治性白血病。在美国、加拿大开展。

?

适用疾病: Refractory Acute Lymphoblastic Leukemia (ALL)；Recurrent Acute Lymphoblastic Leukemia；Recurrent Mixed Phenotype Acute Leukemia
干预: 未列出
地点: United States，Canada
申办方: Children's Oncology Group

暂时不招募 Phase 2

NCI NCT05955261 / NCI-2023-04138

Venetoclax in Combination with Conventional Chemotherapy for the Treatment of Pediatric Patients with Acute Myeloid Leukemia

AI 简述这是一项II期试验，研究Venetoclax联合常规化疗用于儿童急性髓系白血病。

?

适用疾病: Childhood Myeloid Sarcoma；Myelodysplastic Syndrome；Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: Saint Jude Children's Research Hospital

暂时不招募 Phase 1

NCI NCT05377827 / NCI-2023-08553

Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Treating Patients with CD7+ Hematologic Cancers

AI 简述这是一项I期试验，研究抗CD7异体CAR-T细胞（WU-CART-007）用于CD7阳性血液肿瘤。

?

适用疾病: Recurrent Mycosis Fungoides and Sezary Syndrome；Refractory Acute Myeloid Leukemia (AML)；Refractory Mycosis Fungoides and Sezary Syndrome
干预: 未列出
地点: United States
申办方: Siteman Cancer Center at Washington University

暂时不招募 Phase 1

NCI NCT06514261 / NCI-2024-04616

Testing the Combination of an Anti-Cancer Drug, Iadademstat, with Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

AI 简述这是一项I期试验，研究Iadademstat联合维奈克拉和阿扎胞苷用于急性髓系白血病，在美国开展。

?

适用疾病: Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: UPMC Hillman Cancer Center LAO

暂时不招募 Phase 1

NCI NCT06802523 / NCI-2025-00575

Testing the Combination of Targeted Radiotherapy with Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults with Newly Diagnosed Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究靶向放疗联合Venetoclax和ASTX-727用于新诊断急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: Yale University Cancer Center LAO

暂时不招募 Phase 1

NCI NCT07285668 / NCI-2025-09022

TCRαβ+ and CD19+ Depleted Donor Lymphocyte Infusion after Donor Stem Cell Transplant for the Prevention of Relapse in Patients with High-Risk Blood Cancers

AI 简述这是一项I期试验，研究TCRαβ+和CD19+去除的供体淋巴细胞输注用于预防血液癌症复发。

?

适用疾病: Refractory Lymphoma；Recurrent Lymphoma；Refractory Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: University of Wisconsin Carbone Cancer Center - University Hospital

即将招募 Phase 1 生物制剂药物

ClinicalTrials.gov NCT05662904

Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML

AI 简述这是一项I期试验，研究CRISPR编辑的干细胞联合Gemtuzumab Ozogamicin用于复发/难治性AML。

?

适用疾病: Relapsed/Refractory Acute Myeloid Leukemia (AML)
干预: Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion，Gemtuzumab Ozogamicin
地点: Germany
申办方: German Cancer Research Center

即将招募 EARLY / Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT05779930 / NCI-2026-04623

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL

AI 简述这是一项早期I期试验，研究CD19 CAR-T细胞用于复发/难治性CD19阳性急性淋巴细胞白血病和非霍奇金淋巴瘤。在美国开展。

?

适用疾病: Acute Lymphoblastic Leukemia, in Relapse；Non-Hodgkin's Lymphoma, Relapsed；Non-Hodgkin's Lymphoma Refractory
干预: CD19 specific Chimeric Antigen Receptor T Cell
地点: United States
申办方: Nationwide Children's Hospital

即将招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06345027 / NCI-2026-03669

Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)

AI 简述这是一项I期试验，研究CAR-T靶向CD70用于复发难治性急性髓系白血病、B细胞白血病、T细胞白血病。

?

适用疾病: Leukemia, Myeloid, Acute；Leukemia, B-cell；Leukemia, T-Cell
干预: Treatment Arm A
地点: United States
申办方: Baylor College of Medicine

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07166549

Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)

AI 简述这是一项I期试验，在Switzerland开展，研究双特异性CAR T细胞用于B细胞恶性肿瘤。

?

适用疾病: B Cell Malignancies；B-cell Leukemia；B Cell Lymphoma
干预: Experimental Intervention
地点: Switzerland
申办方: University Hospital, Basel, Switzerland

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07225439

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

AI 简述这是一项I期试验，研究Rituximab联合Tafasitamab及异体NK细胞用于复发/难治性B细胞非霍奇金淋巴瘤。

?

适用疾病: Non Hodgkin Lymphoma；B-cell Non Hodgkin Lymphoma；Diffuse Large B Cell Lymphoma
干预: Allogeneic NK cells，Rituximab，Tafasitamab，Interleukin-2
地点: United States
申办方: Paolo Caimi, MD

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07283640

A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia

AI 简述这是一项I期试验，研究Blinatumomab联合Revumenib用于KMT2A重排急性淋巴细胞白血病。

?

适用疾病: Blinatumomab；Revumenib；Lymphoblastic Leukemia
干预: Revumenib，Blinatumomab
地点: United States
申办方: M.D. Anderson Cancer Center

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07355335

Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML

AI 简述这是一项I期试验，在美国研究Ziftomenib联合Mezigdomide用于复发/难治性AML（KMT2A重排或NPM1突变）。

?

适用疾病: KMT2A-rearranged；NPM1-mutant Refractory or Relapsed AML
干预: Ziftomenib，Mezigdomide
地点: United States
申办方: Massachusetts General Hospital

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07392814

Study With Tocilizumab in Combination With Venetoclax and Azacitidine Chemotherapy in Patients With Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究托珠单抗联合Venetoclax和阿扎胞苷用于急性髓系白血病。在法国开展。

?

适用疾病: Leukemia Acute Myeloid - AML
干预: increase dose of tocilizumab
地点: France
申办方: Nantes University Hospital

即将招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07411586 / NCI-2026-01058

Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究Olutasidenib联合Ziftomenib用于NPM1和IDH1共突变急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Biphenotypic Leukemia
干预: Ziftomenib，Olutasidenib
地点: United States
申办方: M.D. Anderson Cancer Center

即将招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07439211 / NCI-2026-03015

Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究Eganelisib联合Azacitidine和Venetoclax用于急性髓系白血病。

?

适用疾病: Leukemia, Myeloid；Leukemia；Acute Myeloid Leukemia
干预: Eganelisib，Azacitidine，Venetoclax
地点: United States
申办方: Jacqueline Garcia, MD

即将招募阶段未标明药物手术/操作

ClinicalTrials.gov NCT07443592

Treatment for Ph-negative ALL for Adults up to 65 Years

AI 简述这是一项试验，研究儿童型化疗加或不加Blinatumomab用于Ph-急性淋巴细胞白血病，在西班牙开展。

?

适用疾病: Acute Lymphoblastic Leukemia
干预: Pediatric-type of chemotherapy (+blinatumomab for B-cell precursor ALL)，Transplantation
地点: Spain
申办方: PETHEMA Foundation

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07511062

Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML

AI 简述这是一项I期试验，研究Axatilimab联合Decitabine/Venetoclax用于TP53突变急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；TP53 Gene Mutation
干预: Decitabine，Venetoclax，Axatilimab
地点: United States
申办方: Northside Hospital, Inc.

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07518654

Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma

AI 简述这是一项I期试验，研究ThINKK过继免疫疗法用于儿童白血病或神经母细胞瘤，在加拿大开展。

?

适用疾病: Leukaemia (Acute Lymphoblastic)；Leukaemia (Acute Myeloid)；Neuroblastoma
干预: Therapeutic Inducers of Natural Killer Killing (ThINKK)
地点: Canada
申办方: Michel Duval

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07549464

Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia

AI 简述这是一项1期试验，研究PLM-102用于复发/难治性急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia
干预: PLM-102
地点: United States
申办方: M.D. Anderson Cancer Center

即将招募 Phase 1 生物制剂药物

ClinicalTrials.gov NCT07572136

Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)

AI 简述这是一项I期试验，研究TSLPR-CART细胞用于复发/难治CRLF2-R/TSLPR过表达B细胞急性淋巴细胞白血病。

?

适用疾病: B-All；Acute Lymphoblastic Leukemia
干预: TSLPR-CART，Cyclophosphamide，Fludarabine
地点: United States
申办方: National Cancer Institute (NCI)

即将招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07573111

Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation

AI 简述这是一项I期试验，研究QUAIL-100用于接受造血干细胞移植的高危血液恶性肿瘤儿童及年轻成人。

?

适用疾病: Acute Leukemia；Myelodysplastic Syndrome
干预: QUAIL-100
地点: United States
申办方: Laguna Biotherapeutics, Inc.

即将招募 Phase 1 药物手术/操作

ClinicalTrials.gov NCT07583303

BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

AI 简述这是一项I期试验，研究BSB-2002用于复发或难治性NPM1突变急性髓系白血病。

?

适用疾病: Recurrent Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia
干预: Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy，Cyclophosphamide
地点: United States
申办方: City of Hope Medical Center

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07614022

A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)

AI 简述这是一项I期试验，研究LP-118联合其他药物用于新诊断的BCR::ABL1阳性急性淋巴细胞白血病，在美国开展。

?

适用疾病: Philadelphia Positive Acute Lymphoblastic Leukemia
干预: LP-118
地点: United States
申办方: Wake Forest University Health Sciences

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07617363

ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS

AI 简述这是一项I期试验，研究ATRN-119联合地西他滨用于TP53突变急性髓系白血病或高危骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia；High-risk Myelodysplastic Syndrome
干预: ATRN-119，Decitabine
地点: United States
申办方: Washington University School of Medicine

即将招募 Phase 1 药物手术/操作

ClinicalTrials.gov NCT07645469

FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究FH-WT1-E50 TCR T细胞联合阿扎胞苷用于急性髓系白血病，在美国开展。

?

适用疾病: Acute Myeloid Leukemia
干预: Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells，Azacitidine，Biospecimen Collection，Bone Marrow Aspiration
地点: United States
申办方: Fred Hutchinson Cancer Center

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07674823

Phase 1 Study Of KITE-753 in R/R B-Cell ALL

AI 简述这是一项1期试验，在美国研究KITE-753用于复发难治B细胞急性淋巴细胞白血病。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia
干预: KITE-753
地点: United States
申办方: M.D. Anderson Cancer Center

即将招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07679919

BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies

AI 简述这是一项I期试验，研究BAFF CAR-T细胞用于难治性血液恶性肿瘤。在美国开展。

?

适用疾病: Non-Hodgkin Lymphoma；Chronic Lymphocytic Leukemia；Hairy Cell Leukemia
干预: LMY-922
地点: United States
申办方: Luminary Therapeutics

即将招募阶段未标明手术/操作

ClinicalTrials.gov NCT07691047

Reassessment of the Risk of Hemolytic Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With a Regimen Containing Venetoclax

AI 简述这是一项试验，通过CT扫描评估含Venetoclax方案治疗慢性淋巴细胞白血病患者溶血综合征的风险，在法国开展。

?

适用疾病: Chronic Lymphoid Leukemia
干预: Cervical, Thoracic, Abdominal, and Pelvic CT Scan
地点: France
申办方: Private Hospital of Confluent, France

即将招募 Phase 4 药物

ClinicalTrials.gov NCT04790045

Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens

AI 简述这是一项IV期试验，研究Venetoclax方案治疗CLL后的淋巴结微环境变化。

?

适用疾病: Chronic Lymphocytic Leukemia
干预: Venetoclax
地点: 未列出
申办方: Paolo Ghia

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05055791

A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies

AI 简述这是一项I/II期试验，研究SYHX1903用于复发难治血液系统恶性肿瘤。

?

适用疾病: Acute Myeloid Leukemia；Lymphoma；Multiple Myeloma
干预: SYHX1903
地点: 未列出
申办方: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

即将招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov NCT05319249

Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia

AI 简述这是一项I/II期试验，研究自然杀伤细胞联合Talazoparib用于急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia
干预: NK cells，Talazoparib 1 MG [Talzenna]
地点: 未列出
申办方: German Cancer Research Center

即将招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT05554419

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

AI 简述这是一项II期试验，研究联合治疗用于初始治疗后持续低水平急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome；Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm
干预: Azacitidine，Bone Marrow Aspiration and Biopsy，Cytarabine，Echocardiography Test
地点: 未列出
申办方: National Cancer Institute (NCI)

即将招募 Phase 2 药物

ClinicalTrials.gov NCT05628623

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment

AI 简述这是一项II期试验，研究联合治疗用于初始治疗后持续低水平急性髓系白血病。

?

适用疾病: Leukemia, Myeloid, Acute
干预: Cytarabine，Venetoclax，CPX-351，Azacitidine
地点: 未列出
申办方: Eastern Cooperative Oncology Group

即将招募 Phase 1 药物

ClinicalTrials.gov NCT06252584

Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients

AI 简述这是一项I期试验，研究多肽疫苗联合XS15用于成人急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia, Adult
干预: Vaccines, Peptide
地点: 未列出
申办方: University Hospital Tuebingen

即将招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT06333509

Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL

AI 简述这是一项I/II期试验，研究CT071用于复发/难治性多发性骨髓瘤或原发性浆细胞白血病。

?

适用疾病: Multiple Myeloma；Primary Plasma Cell Leukemia
干预: CT071
地点: 未列出
申办方: CARsgen Therapeutics Co., Ltd.

即将招募阶段未标明药物

ClinicalTrials.gov NCT06385808

Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML

AI 简述这是一项试验，研究MTBF预处理方案用于挽救性异基因造血干细胞移植治疗复发/难治性急性髓系白血病。

?

适用疾病: Relapse Leukemia；Refractory Acute Myeloid Leukemia；Conditioning
干预: MTBF regimen
地点: 未列出
申办方: First Affiliated Hospital Xi'an Jiaotong University

即将招募 Phase 1 药物

ClinicalTrials.gov NCT06463327

ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML

AI 简述这是一项I期试验，研究TCB008用于复发难治性急性髓系白血病或骨髓增生异常综合征。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndromes
干预: TCB008
地点: 未列出
申办方: TC Biopharm

即将招募 Phase 2 联合产品

ClinicalTrials.gov NCT06602323

TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia.

AI 简述这是一项II期试验，研究TMLI/Fludarabine/Melphalan预处理用于异基因移植治疗高危骨髓增生异常综合征或急性髓系白血病。

?

适用疾病: Myelodysplastic Syndromes；Acute Myeloid Leukemia
干预: TMLI/Flu/Mel
地点: 未列出
申办方: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06667973

Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia

AI 简述这是一项II期试验，研究Gilteritinib联合FLAI方案用于FLT3阳性急性髓系白血病诱导治疗。

?

适用疾病: Acute Myeloid Leukemia；FLT3 Gene Mutation；Adult AML
干预: Gilteritinib
地点: 未列出
申办方: Gruppo Italiano Malattie EMatologiche dell'Adulto

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06930105

Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL

AI 简述这是一项II期试验，研究低强度化疗联合短程Blinatumomab用于Ph- B-ALL成人患者。

?

适用疾病: Acute Lymphoid Leukemia (ALL)
干预: Blinatumomab plus Reduced-dose Chemotherapy
地点: 未列出
申办方: Xianmin Song, MD

即将招募 Phase 2 药物手术/操作放疗

ClinicalTrials.gov NCT06954987

Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

AI 简述这是一项II期试验，研究维奈托克联合造血干细胞移植用于急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia
干预: Allogeneic Hematopoietic Stem Cell Transplantation，Biospecimen Collection，Bone Marrow Biopsy，Busulfan
地点: 未列出
申办方: National Cancer Institute (NCI)

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06979076

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL

AI 简述这是一项I/II期试验，研究选择性PKC-β抑制剂MS-553用于复发难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤。

?

适用疾病: CLL (Chronic Lymphocytic Leukemia)；SLL (Small Lymphocytic Lymphoma)
干预: MS-553, DS1，MS-553, DS2
地点: 未列出
申办方: MingSight Pharmaceuticals, Inc

即将招募阶段未标明生物制剂

ClinicalTrials.gov NCT07008872

CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia

AI 简述这是一项试验，研究CD7 CAR-T细胞疗法用于CD7阳性复发/难治T细胞淋巴瘤/急性白血病。

?

适用疾病: CD7+ Lymphoma；CD7+ Acute Leukemia
干预: CD7 CART
地点: 未列出
申办方: Qi deng

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07107204

A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

AI 简述这是一项I/II期试验，研究BT02用于复发难治血液恶性肿瘤（白血病、淋巴瘤等）。

?

适用疾病: Relapsed or Refractory Hematologic Malignancies；Leukemia；Lymphoma
干预: BT02
地点: 未列出
申办方: Biotroy Therapeutics

即将招募 Phase 1 生物制剂药物

ClinicalTrials.gov NCT07120607

Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia

AI 简述这是一项I期试验，研究异体CD7 CAR γδ T细胞用于复发/难治性白血病。

?

适用疾病: Leukemia
干预: CD7 CAR-γδT cell（QH106），Fludarabine (FLU)，Cyclophosphamide (CTX)
地点: 未列出
申办方: Anhui Provincial Hospital

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07131085

QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS)

AI 简述这是一项I期试验，研究QH101细胞疗法用于复发/难治性AML和MDS。

?

适用疾病: MDS；AML
干预: Allogeneic TCR-enhanced γδ T cell(QH101)，Fludarabine (FLU)，Cyclophosphamide (CTX)
地点: 未列出
申办方: Anhui Provincial Hospital

即将招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT07153497

Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

AI 简述这是一项II期试验，研究Olutasidenib联合ASTX727和Venetoclax用于急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Myelodysplastic Syndrome
干预: Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy，Decitabine and Cedazuridine
地点: 未列出
申办方: National Cancer Institute (NCI)

即将招募 Phase 1, Phase 2 器械药物

ClinicalTrials.gov NCT07175415

HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

AI 简述这是一项I/II期试验，研究Capivasertib联合Venetoclax和地塞米松用于复发难治儿童血液肿瘤。

?

适用疾病: Acute Lymphoblastic Leukemia；Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent；Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
干预: Capivasertib，Venetoclax，Dexamethasone，Intrathecal chemotherapy
地点: 未列出
申办方: Princess Maxima Center for Pediatric Oncology

即将招募 Phase 2 生物制剂

ClinicalTrials.gov NCT07244380

Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.

AI 简述这是一项2期试验，研究S101自体抗CD7 CAR-T细胞用于复发难治T淋巴母细胞白血病/淋巴瘤。

?

适用疾病: T Lymphoblastic Leukemia/Lymphoma
干预: Autologous CD7-targeting CAR T cells
地点: 未列出
申办方: Hebei Senlang Biotechnology Inc., Ltd.

即将招募阶段未标明药物

ClinicalTrials.gov NCT07245251

To Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of STR-P004

AI 简述这是一项早期试验，研究STR-P004用于急性淋巴细胞白血病。

?

适用疾病: Acute Lymphobkastic Leukemia
干预: STR-P004
地点: 未列出
申办方: Starna Therapeutics

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07303660

A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients

AI 简述这是一项I期试验，研究Lonitoclax联合Azacitidine用于急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia
干预: ZE50-0134，Azacitidine Days 1-7，ZE 50-0134
地点: 未列出
申办方: Lomond Therapeutics Holdings, Inc.

即将招募 EARLY / Phase 1 生物制剂

ClinicalTrials.gov NCT07335094

A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy

AI 简述这是一项早期I期试验，研究人源化CD19 CAR-T细胞联合TLR2用于初治B细胞急性淋巴细胞白血病/淋巴瘤。

?

适用疾病: B Lymphoblastic Leukemia/Lymphoma
干预: humanized CD19 CAR-T Cells with TLR2
地点: 未列出
申办方: Zhujiang Hospital

即将招募 EARLY / Phase 1 生物制剂

ClinicalTrials.gov NCT07336875

Clinical Study of Novel CAR-ITNK Cells Targeting CD70 and CLL1 for Refractory/Relapsed AML

AI 简述这是一项早期I期试验，研究靶向CD70和CLL1的CAR-ITNK细胞用于复发/难治AML。

?

适用疾病: R/R AML
干预: CAR-ITNK Cells targeting CD70 and CLL1
地点: 未列出
申办方: Tongji Hospital

即将招募 EARLY / Phase 1 生物制剂

ClinicalTrials.gov NCT07338357

Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML

AI 简述这是一项早期I期试验，研究CLL-1 CAR-T用于儿童复发/难治性急性髓系白血病。

?

适用疾病: AML (Acute Myeloid Leukemia)；CAR-T
干预: CAR-T
地点: 未列出
申办方: First Affiliated Hospital of Guangxi Medical University

即将招募阶段未标明药物

ClinicalTrials.gov NCT07371533

Clinical Study of Recombinant Anti-CD19m-CD3 Antibody Injection (A-319)

AI 简述这是一项试验，研究A-319用于急性淋巴细胞白血病。

?

适用疾病: Acute Lymphocytic Leukemia
干预: Treatment with A319
地点: 未列出
申办方: Shanxi Bethune Hospital

即将招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07383233

CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant Lymphoma

AI 简述这是一项I期试验，研究CD19/BAFF-R体内CAR-T细胞疗法用于复发/难治性B细胞急性白血病或恶性淋巴瘤。

?

适用疾病: Lymphoma；CAR T Cell Therapy；Acute Leukemia
干预: CD19/BAFF-R in vivo CAR-T cell intravenous infusion
地点: 未列出
申办方: Qi deng

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07387926

Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

AI 简述这是一项I/II期试验，研究Asciminib用于儿童和年轻成人复发/难治性Ph阳性或Ph样急性淋巴细胞白血病。

?

适用疾病: Acute Lymphoblastic Leukemia；Leukemia, Lymphoblastic, Acute, Philadelphia-Positive；Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
干预: Asciminib Adult formulation，Asciminib Pediatric formulation，Dexamethasone，Vincristine
地点: 未列出
申办方: Novartis Pharmaceuticals

即将招募阶段未标明生物制剂

ClinicalTrials.gov NCT07412405

This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R

AI 简述这是一项试验，研究自体抗CD19 CAR-T细胞（ARI-0001）用于复发/难治性CD19+血液恶性肿瘤。

?

适用疾病: Adult B-cell Acute Lymphoblastic Leukemia；Follicular Lymphoma (FL)；Mantle Cell Lymphoma (MCL)
干预: ARI-0001 T cells with anti-CD19 chimeric antigen receptor (CAR-T)
地点: 未列出
申办方: GUSTAVO SALGUERO

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07423104

A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia

AI 简述这是一项II期试验，研究CAV方案（克拉屈滨、低剂量阿糖胞苷、维奈克拉）用于复发/难治或继发性急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia (AML)
干预: CAV
地点: 未列出
申办方: University of Rochester

即将招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07432100

Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究通用型CLL1 CAR-T细胞用于复发/难治性急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia；Chimeric Antigen Receptor T-cell；Universal CLL1 CAR-T
干预: universal CLL1 CAR-T cells
地点: 未列出
申办方: Mingfeng Zhao

即将招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT07437950

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

AI 简述这是一项II期试验，比较Venetoclax不同疗程用于老年新诊断急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia
干预: Biospecimen Collection，Bone Marrow Aspiration，Decitabine and Cedazuridine，Venetoclax
地点: 未列出
申办方: National Cancer Institute (NCI)

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07520006

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

AI 简述这是一项I/II期试验，研究NX-5948联合其他药物用于B细胞恶性肿瘤。

?

适用疾病: B-cell Lymphoma；Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma
干预: NX-5948，venetoclax，rituximab，obinutuzumab
地点: 未列出
申办方: Nurix Therapeutics, Inc.

即将招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07538713

Functionally Optimized CD33 CAR-T Cell Therapy Targeting Recurrent/Refractory Acute Myeloid Leukemia

AI 简述这是一项I期试验，研究功能优化CD33 CAR-T细胞用于复发/难治急性髓系白血病。

?

适用疾病: CAR T Cell Therapy；CD33 Positive Acute Myelogenous Leukemia
干预: Functionally optimized CD33 CAR-T
地点: 未列出
申办方: Qi deng

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07598110

FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML

AI 简述这是一项II期试验，研究氟达拉滨联合曲奥舒凡预处理方案用于老年或体弱急性髓系白血病。

?

适用疾病: Acute Myeloid Leukemia
干预: fludarabine and treosulfan
地点: 未列出
申办方: Institut Paoli-Calmettes

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07624799

Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).

AI 简述这是一项II期试验，研究固定疗程的pirtobrutinib联合短程免疫化疗用于初治慢性淋巴细胞白血病。

?

适用疾病: CLL (Chronic Lymphocytic Leukemia)
干预: Pirtobrutinib，Fludarabine，Cyclophosphamide，Obinutuzumab
地点: 未列出
申办方: French Innovative Leukemia Organisation

即将招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov NCT07636564

Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment

AI 简述这是一项II期试验，研究Blinatumomab联合或不联合Revumenib用于特定基因改变的B细胞急性淋巴细胞白血病。

?

适用疾病: Acute Leukemia of Ambiguous Lineage；B Acute Lymphoblastic Leukemia；B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
干预: Biospecimen Collection，Blinatumomab，Bone Marrow Aspiration，Bone Marrow Biopsy
地点: 未列出
申办方: SWOG Cancer Research Network

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07642453

VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia.

AI 简述这是一项II期试验，比较VA-CAG两周与三周方案用于新诊断急性髓系白血病诱导缓解。

?

适用疾病: Acute Myeloid Leukemia (AML)
干预: Venetoclax,Azacitidine,Arubicin,Cytarabine,G-CSF.
地点: 未列出
申办方: Hematology department of the 920th hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07643636

Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML

AI 简述这是一项II期试验，研究西达本胺、维奈克拉、阿扎胞苷和高三尖杉酯碱用于高危适合化疗的急性髓系白血病。

?

适用疾病: AML (Acute Myeloid Leukemia)
干预: Chidamide (Chi)+VAH
地点: 未列出
申办方: Dongguan People's Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07686107

Phase 2 Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML."

AI 简述这是一项II期试验，研究Revumenib联合FLA化疗用于复发或难治性NUP98重排急性髓系白血病儿童。

?

适用疾病: Leukemia, Myeloid, Acute
干预: Revumenib，Fludarabine，Cytarabine (Ara-C)，Methotrexate (IT)
地点: 未列出
申办方: Therapeutic Advances in Childhood Leukemia Consortium

即将招募 Phase 2 药物

ClinicalTrials.gov NCT05944211

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leukemia

AI 简述这是一项II期试验，研究海曲泊帕用于急性髓系白血病化疗所致血小板减少。

?

适用疾病: Chemotherapy-Induced Thrombocytopenia
干预: Hetrombopag Olamine
地点: 未列出
申办方: RenJi Hospital

即将招募 EARLY / Phase 1 生物制剂

ClinicalTrials.gov NCT06879262

Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL

AI 简述这是一项早期I期试验，研究新型TLR2嵌合抗原受体T细胞（靶向CD19和CD22）用于复发/难治性B细胞急性淋巴细胞白血病和NHL。

?

适用疾病: R/R NHL
干预: CAR1922T2 T cells（Targeting CD19 and CD22 with CAR-T cells）
地点: 未列出
申办方: Tongji Hospital

即将招募阶段未标明手术/操作

ClinicalTrials.gov NCT07451743

Are Clinical Outcomes Unchanged by ALL Fixation at 0° or 30° of Knee Flexion in Combined ACL-ALL Reconstruction? Despite Numerous Technical Descriptions of Anterolateral Procedures, There is Limited Knowledge Regarding the Effect of Knee Flexion Angle During Graft Fixation.

AI 简述这是一项试验，研究前交叉韧带断裂修复时膝关节屈曲角度对临床结局的影响。

?

适用疾病: Anterior Cruciate Ligament Rupture
干预: anterolateral ligament reconstruction
地点: 未列出
申办方: ASL Lecce

术语	中文意思	对找临床试验有什么用
AML	急性髓系白血病。	海外 AML 试验常按 FLT3、IDH、TP53、既往治疗等拆分。
ALL	急性淋巴细胞白血病。	可以找 B-ALL、T-ALL、CAR-T、bispecific antibody 等方向。
CLL	慢性淋巴细胞白血病。	常见方向包括 BTK inhibitor、BCL2 inhibitor、复发难治等。
CML	慢性髓性白血病，常与 BCR-ABL 融合相关。	可以找 BCR-ABL、TKI resistant、T315I 等相关试验。
MRD	微小残留病灶，表示治疗后仍可检测到少量病变细胞。	部分试验会要求 MRD 阳性或以 MRD 作为观察指标。
Relapsed / refractory	复发或难治。	很多白血病新药和细胞治疗试验会限定 R/R 患者。

Recruiting	正在招募，可能仍可申请参加。
Not yet recruiting	尚未开始招募，可关注后续开放时间。
Active, not recruiting	试验仍在进行，但通常不再招新患者。
Completed	试验已经完成。
Terminated	试验提前终止。
Unknown	公开页面上的状态不明确或未及时更新。

白血病

当前同步到的治疗类试验